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Importance: Thyroid hormones play a key role in modulating myocardial contractility and 
vascular function. Subclinical hypothyroidism is associated with worse cardiovascular 
outcomes, in those without cardiovascular disease, and a poor prognosis in patients with acute 
myocardial infarction.  
Objective: To evaluate the effect of levothyroxine treatment on left ventricular function, 
markers of vascular function and patient reported outcomes in patients with acute myocardial 
infarction and subclinical hypothyroidism.  
Hypotheses: Levothyroxine treatment will improve left ventricular function as a primary 
outcome measure.  Furthermore, levothyroxine treatment will decrease thrombus burden, 
improve clot kinetics, platelet reactivity and endothelial function as well as patient reported 
outcomes.   
Design, Setting, and Participants: A double blind, randomized clinical trial conducted in six 
hospitals in the United Kingdom. Patients with acute myocardial infarction including ST-
segment elevation and non-ST-segment elevation were recruited between February 2015 and 
December 2016 with the last participant being followed up in December 2017. 
Interventions: Levothyroxine treatment (n=46) commencing at 25 mcg titrated to aim for 
serum thyrotropin levels between 0.4 and 2.5 mU/L or identical placebo (n=49), both provided 
in capsule form, once daily for 52 weeks. 
Main outcomes and measures: The primary outcome measure was left ventricular ejection 
fraction at 52 weeks, assessed by magnetic resonance imaging, adjusted for age, sex, type of 
acute myocardial infarction, affected coronary artery territory and baseline left ventricular 
ejection fraction. Secondary outcomes were surrogate markers of vascular function and patient 
reported outcome measures of health status, health-related quality of life, and depression.   
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Results: Among the 95 participants randomized, the primary outcome measurements at 52 
weeks were available in 85 (89.5%) patients. The mean left ventricular ejection fraction at 
baseline and at 52 weeks was 51.3% and 53.8% in the levothyroxine group compared to 54.0% 
and 56.1% in the placebo group; adjusted difference in groups (95% confidence interval) of 
0.76% (-0.93% to 2.46%), p=0.37. Levothyroxine treatment did not significantly decrease 
thrombus burden, improve clot kinetics, decrease platelet reactivity or improve endothelial 
function.  Furthermore, patient reported outcomes were not significantly different between both 
groups at the study end. There were 15 (33.3%) and 18 (36.7%) cardiovascular adverse events 
in the levothyroxine and placebo groups, respectively.  
Conclusions and relevance: In this preliminary study involving patients with subclinical 
hypothyroidism and acute myocardial infarction, treatment with low dose levothyroxine, 
compared to placebo, did not significantly improve left ventricular ejection fraction, markers 
of vascular function and patient reported outcomes after 52 weeks. These findings do not 
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1 Chapter: Background and Introduction 
1.1 Basic principles of thyroid hormone action on the cardiovascular system 
1.1.1 Background 
Acute myocardial infarction (AMI) and its related complications represent a major public 
health problem. Despite improvements in reperfusion therapy the 2020 World Health 
Organisation projections view the high incidence of post-ischaemic heart failure as the most 
important cause of morbidity and mortality (Kitakaze, 2010).  Over the years improvements in 
coronary reperfusion, first by thrombolysis and later by angioplasty, have significantly 
improved outcomes in patients with AMI (Keeley et al., 2003).  Limitation of infarct size extent 
and recovery of dysfunctional contractile segments are the key elements for preventing post-
ischaemic left ventricular remodelling.  Despite improvements in coronary perfusion, many 
patients go on to develop heart failure due to pathological ventricular remodelling.  In addition 
to research into new reperfusion strategies, a new perspective involves studying mechanisms 
by which myocytes can self-protect at times of stress which can prevent irreversible cell death.  
Such mechanisms include preventing myocyte apoptosis, preserving mitochondria, targeting 
survival pathways such protein kinase B (PKB) and protein kinase C (PKC) as well as 
promoting angiogenesis (Kitakaze, 2010; Nicolini et al., 2013).  
In this regard, thyroid hormones (TH) are increasingly being recognised as significant players 
both in the pathogenesis of and the recovery and repair after an AMI.  The role of TH in 
aggravating cardiovascular disease is recognised, given that TH receptors are present in both 
the myocardium and vascular endothelial tissues thereby allowing changes in circulating TH 
concentrations to modulate end organ activity.  This involves regulating genes which encode 
key proteins involved in myocardial contractility such as the myosin heavy chain, and the 
sarcoplasmic reticulum calcium pump as well as activating key survival pathways which will 
be explored in more detail. It is likely that interventional trials investigating the role of thyroid 
hormones in ameliorating post AMI complications will be performed in the coming few years 
(Pantos et al., 2009b; Pantos et al., 2010).  Low TH in different cardiac states has traditionally 
been thought as an adaptive process, which lowers energy demands.  However it is also likely 
that low TH levels in heart disease states is due to a permissive state, which favours cardiac 
failure.  This is shown by the presence of low TH in states such as AMI, heart failure and post 
coronary artery bypass grafting (CABG) being associated with a worse prognosis (Hamilton et 
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al., 1990; Novitzky et al., 1996; Friberg et al., 2001; Lymvaios et al., 2011).  Furthermore, 
experimental studies have demonstrated that abnormal cardiac remodelling, angiogenesis, gene 
expression and systolic functional changes in low TH states are reversible with TH 
supplementation (Pantos et al., 2008a; Forini et al., 2011). 
Even subclinical hypothyroidism (SCH) is associated with worse cardiovascular outcomes 
(Parle et al., 2001; Walsh et al., 2005).   From a clinical perspective ‘subclinical’ denotes the 
presence of disease without manifest symptoms and suggests the presence of either mild or 
early disease.  SCH has been associated with increased cardiovascular morbidity and mortality, 
especially in younger individuals (Imaizumi et al., 2004; Kvetny et al., 2004).  However, the 
clinical significance of SCH and mild thyroid overactivity (subclinical hyperthyroidism) is 
uncertain. The absence of high-quality clinical trials has adversely impacted on optimal 
protocols for diagnostic testing and created uncertainty regarding the appropriateness of 
treating the mildly abnormal serum thyroid test. Furthermore, thyroid function tests are 
commonly checked by health professionals: one in four people in the United Kingdom have 
their thyroid function assessed annually (Allahabadia et al., 2009). Frequent testing therefore 
can lead to detection of incidentally abnormal thyroid function parameters and, in the absence 
of high quality evidence either for or against treatment, lead to confusion as to the best 
evidence-based management of subclinical thyroid diseases.   
Another challenge in the diagnosis of SCH includes the variation of the median TSH and 
reference ranges with age and time of day with the latter related to the circadian variation of 
TSH, which current TSH reference ranges do not account for.  Normal TSH reference ranges 
are based according to the 2.5th and 97.5th percentiles of the distribution in the tested population.  
The National Health and Nutrition Examination Survey (NHANES) study showed the 97.5th 
percentile to be 3.5 mU/L in 20-30 year olds and 7.5 mU/L in those above the age of 80 whereas 
Vadiveloo et al in the TEARS Study assessed thyroid function tests retrospectively in over 
150000 subjects without thyroid disease and found the 97.5th median TSH centile to increase 
from 3.98, in subjects 30-40 years of age, to 5.94 in those above 90 (Hollowell et al., 2002; 
Vadiveloo et al., 2013).  Another retrospective laboratory database interrogation of TSH data 
from more than 19,000 outpatient visits concluded that the prevalence of SCH reduced from 
14.1% to 7.9% and that of SHyper increased from 6.8% to 7.9% between 7-8am and 2-3pm, 
respectively (Andersen et al., 2015).  This shows there are clear confounders in relation to the 
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normal TSH reference range and therefore any decision on treating an individual should not be 
according to one TSH value above the normal range. 
 
1.1.2 Historical perspective 
The association between thyroid dysfunction and cardiovascular disease (CVD) is not new. In 
1878 William Greenfield, decades before thyroid function tests became available, described 
the autopsy findings of a middle-aged woman with myxoedema as having “much serous 
effusion in the pericardium…….the heart was large……the arteries were everywhere 
thickened, the larger ones atheromatous” (Ord, 1878).  Soon after, clinical and autopsy 
accounts describing atherosclerosis in myxoedema patients were beginning to be reported (T, 
1883; TM, 1888).  It soon became apparent that the clinical condition of myxoedema was 
linked to a poorly functioning thyroid gland. However, the diagnosis of myxoedema (a severe 
form of hypothyroidism) was based purely on clinical grounds and, in the absence of modern 
thyroid function assays, milder and less clinically apparent forms of the disease would have 
been missed. In 1891, George Murray, injected sheep thyroid hormone extract subcutaneously 
to a patient with clinical features of myxoedema with dramatic effect.  Over the subsequent 30 
years Murray switched to oral thyroid extract collected from a pool of sheep - the glands being 
obtained from an abattoir. It took many years (1949) before commercial production of 
thyroxine was available but, even then, for many years, tablets of desiccated thyroid extract 
were the mainstay of replacement (Slater, 2011).  This new therapeutic agent was shown in 
clinical trials of myxoedema patients to have positive effects in reducing high cholesterol levels 
(Barnes, 1959) and improving cardiovascular morbidity (Barnes, 1973) and mortality (Kountz, 
1950). From 1965 onwards, the first generation of radio-immunoassays to estimate serum 
Thyroid Stimulating Hormone (TSH) with limited functional sensitivity were developed 
(Carole Spencer Thyroid Disease Manager). In 1967, Belgian researchers, in a case-control 
study of 25 inadequately-treated hypothyroid autopsies matched to 50 age and gender-matched 
controls, reported that the presence and severity of coronary artery disease was more common 
in the hypothyroid patients (96%) than in controls (60%) and that left ventricular hypertrophy 
and dilatation was more frequent in the hypothyroid group. In 1977, Tunbridge et al performed 
the first cross-sectional cohort study in Whickham, North-East England, and concluded there 
was no association between SCH and presence of CVD however, a follow up of the population 
cohort over 20 years found SCH to be associated with increased cardiovascular events and 
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mortality with subsequent treatment with levothyroxine improving such outcomes  (Tunbridge 
et al., 1977b; Razvi et al., 2010).   
These initial data led investigators to consider using TH analogues in euthyroid individuals at 
high CV risk with the aim to reduce the deleterious effects of thyroxine excess while preserving 
its recognised beneficial effects on CV risk factors ('The coronary drug project. Findings 
leading to further modifications of its protocol with respect to dextrothyroxine. The coronary 
drug project research group,' 1972; Brenta et al., 2007).  The results of a trial of Dextro-
thyroxine, a low-activity dextro-isomer of thyroxine in male AMI survivors, conversely, 
curbed the enthusiasm for using TH therapy in patients with CVD. This trial showed increased 
arrhythmias and higher mortality in the treated group probably due to contamination with levo-
thyroxine (Stamler, 1977) and the supra-physiological doses of Dextro-thyroxine (more than 
double the normal endogenous thyroxine production) (Pingitore et al., 2012).  Another trial 
using a TH analogue diiodothyropropionic acid (DITPA) in heart failure patients showed 
higher heart rate and symptoms suggestive of hyperthyroidism (Brenta et al., 2007; Goldman 
et al., 2009).  It is worth noting that both studies used TH analogues rather than native THs. 
The results of these early trials prejudiced clinicians and curbed enthusiasm of researchers as 
well as pharmaceutical companies in developing and researching the use of TH and its 
analogues at therapeutic doses in patients with CVD. More recently, studies using a liver-
selective TH receptor agonist eprotirome in patients with resistant and familial 
hypercholesterolemia, respectively, showed a beneficial impact on lipids but haven’t 
progressed to large –scale phase III studies due to concerns over liver and cartilage injury 
(Sjouke et al., 2014).  
 
1.1.3 Cellular activity of thyroid hormones 
Thyroid function is regulated by the hypothalamic-pituitary-thyroid axis via a classic endocrine 
negative feedback mechanism (Figure 1-1).  Thyrotropin releasing hormone (TRH) is secreted 
by the hypothalamus, and stimulates the anterior pituitary to produce TSH - which in turn 
drives the thyroid gland to release TH.  TH have a negative feedback effect on the 
hypothalamus and pituitary. TSH has a log-linear relationship with T4 levels meaning that even 
mild changes in TH concentrations lead to large changes in TSH. Thus, serum TSH is a robust 





Figure 1-1  Hypothalamic-pituitary-thyroid axis 
TRH released by the hypothalamus causes TSH release from the pituitary gland leading to TH 
release from the thyroid gland in the form of T4 and T3.  These have a negative feedback effect 
on both the hypothalamus and pituitary gland. 
 
The thyroid gland secretes two main iodinated hormones, thyroxine (T4) and triiodothyronine 
(T3).  Both molecules can generate biological activity in responsive tissues, however, T3 is 
considered the biologically active hormone that elicits its effect by binding to the thyroid 
hormone receptor (TR) (Klein and Danzi, 2007).  The affinity of TR is approximately 10 times 
higher for T3 than for T4 and thus makes T3 very potent (Sandler et al., 2004).  Less than 20% 
of circulating T3 is secreted by the thyroid gland whereas the bulk is produced in extra-
thyroidal tissues from T4, by a process of deiodination in which T4 is converted to T3 by a 
process of deiodinising a single iodine atom, leading to the potent thyroid hormone receptor-
mediated effects of T3. The metabolism of TH is regulated by three selenocysteine enzymes 
called deiodinases (Gereben et al., 2008). Two deiodinase pathways [deiodinase 1 (D1) and 
deiodinase 2 (D2)] lead to extra-thyroidal T3 production.  D1 is active mostly in the liver and 
the kidney and is thought to contribute 15 – 20% of total circulating T3.  D2 activity is located 
in brown adipose tissue, pituitary gland, brain and the heart and is responsible for the majority 
(two thirds) of T3 production (Croteau et al., 1996; Salvatore et al., 1996).  The third deiodinase 
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(D3) catabolises both T4 and T3 to inactive products, leading to termination of thyroid hormone 
action.  Increased D3 activity has been shown to decrease T3 and cause a local hypothyroid 
state in cardiomyocytes (Pol et al., 2011).  Therefore the effect of intracellular T3 on TR defines 
the thyroid status of an organism and is dependent on circulating (serum) thyroid hormone 
levels, as well as intracellular tissue levels regulated by deiodinasing enzymes.   
TH have a broad range of effects, particularly on the heart, but also on the cardiovascular 
system in general (Figure 1-2).  TH influence cardiac status in 3 ways: 1) the direct effect of 
T3 on cardiac myocytes by binding to nuclear receptors which influences gene expression 2) 
effects of T3 on the sympathetic nervous system 3) effects of T3 on the peripheral circulation 
which determines cardiovascular haemodynamics, cardiac filling and systolic contractility.  T3 
activity in the cardiomyocyte regulates genes that encode proteins related to myocardial 
contractility such as the myosin heavy chain, sarcoplasmic reticulum calcium pump and 
phospholamban (He et al., 1997; Kaasik et al., 1997; Holt et al., 1999).  TH receptors are not 
membrane bound, but located in the intracellular compartment. Within the cardiac myocyte, 
T3 binds to thyroid nuclear receptors (TRs), which in turn bind to thyroid hormone response 
elements (TREs) of the regulated genes to induce transcription.  The two main thyroid receptors 
are TRα, which is highly expressed in cardiac myocytes, and TRβ.  Thyroid receptors are 
unique in that they can bind to TREs in the absence of TH and therefore repress transcription 
and regulate specific genes.  Therefore different key proteins within the myocyte are dependent 
on the availability of TH (Brent, 1994).  Proteins which are TH dependent include alpha-
myosin heavy chain (αMHC), sarcoplasmic reticulum proteins such as calcium-activated 
ATPase (SERCA), and Na+/K+-ATPase whereas proteins which are negatively regulated by 
TH include β-Myosin heavy chain (βMHC) and phospholamban.  The two myosin heavy chains 
form an important component of the cardiac myocyte contractile apparatus whereas both 
SERCA and its inhibitor phospholamban regulate the release and reuptake of calcium from the 
sarcoplasmic reticulum.  SERCA pumps calcium out of and back into the sarcoplasmic 
reticulum during contractility and relaxation of the cardiac myofilaments respectively.  This 
efficient calcium release and reuptake from the sarcoplasmic reticulum is essential for efficient 
cardiomyocyte function. (Ojamaa et al., 1996; Fazio et al., 2004; Kranias and Hajjar, 2012).  
Therefore cardiac contractility is not only dependent on myosin heavy chains but also calcium 
handling by SERCA and its inhibitor phospholamban.    
TH influence cardiac chronotropy by both genomic and non-genomic effects on components 
of the adrenergic-receptor complex as well as sodium, potassium and calcium channels. This 
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manifests as tachycardia and increased risk of atrial fibrillation (AF) in hyperthyroid states, 
whereas bradycardia and reduced cardiac contractility are the main clinical features of 
hypothyroidism. The genomic effects include encoding for the αMHC and SERCA which are 
positively regulated by T3 whereas βMHC and phospholamban are negatively regulated.  Other 
important cardiac genes regulated by TH include TR protein themselves and the 
sodium/calcium ion (Na+/Ca2+) exchanger. 
The non-genomic effects on the cardiac myocyte and systemic vasculature are usually receptor 
independent, largely occur on the plasma membrane and are identified by their rapid rate of 
action compared to the genomic effects which have longer to take effect.  These include 
activation of sodium, potassium and calcium membrane ion channels, effects on the 
mitochondrial membrane and involvement in signalling pathways of the cardiac myocyte and 
vascular smooth muscle.  One signalling pathway is the P13K/AKT pathway, which causes 
endothelial nitric oxide (NO) production and a subsequent reduction in the systemic vascular 
resistance (SVR) (Kuzman et al., 2005).  In addition, TH also significantly affect cardiac 
mitochondrial function (Marin-Garcia, 2010) and changes in their circulating levels may lead 
















Figure 1-2 The effect of TH on the cardiomyocyte.  
Schematic representation of the effect of thyroid hormones T4 and T3 on the cardiomyocyte 
via genomic and non-genomic actions. T3 enters the cardiomyocyte directly as well as being 
produced by the conversion of T4 by D2. T3 binds to thyroid nuclear receptors (TRs) which in 
turn bind to thyroid hormone response elements (TREs) of the regulated genes to induce 
transcription. Proteins which are TH dependent include alpha-myosin heavy chain (αMHC), 
sarcoplasmic reticulum proteins such as calcium-activated ATPase (SERCA) whereas proteins 
which are negatively regulated include β-Myosin heavy chain (βMHC) and phospholamban. 
D3 breaks down both T4 and T3.  From: Jabbar et al, Nat Rev Cardiol. 2017 Jan;14(1):39-55 












1.1.4 Thyroid hormone effects on cardiovascular haemodynamics 
TH has an inotropic effect on the heart by direct action on beta adrenoreceptors and increasing 
αMHC, which forms a key component of the myocyte contractile function (Pantos et al., 2007a; 
Pantos et al., 2010).  TH also effects systolic function by regulating the amount of calcium 
available within the sarcoplasmic reticulum for systolic contraction (Dillmann, 1990).  These 
effects are genomic and take time to take effect.  TH effects diastolic function by increasing 
the expression of SERCA within the sarcoplasmic reticulum which subsequently leads to 
reuptake of calcium during diastole leading to improved ventricular relaxation (Klein and 
Danzi, 2007).   TH also decreases systemic vascular resistance (SVR) by causing smooth 
muscle relaxation within the arterioles by increasing calcium reuptake via SERCA, inhibiting 
phospholamban and increasing tissue metabolism and thermogenesis (Kiss et al., 1994; Carr 
and Kranias, 2002).  This decrease in SVR with the direct inotropic effects leads to an increase 
in cardiac output (Figure 1-3).  The renin-angiotensin system plays a key role in the 
haemodynamic effects by TH.  An initial decrease in the SVR by TH leads to decreased 
perfusion within the kidneys which leads to increased renin and aldosterone levels.  This leads 
to an increase in the blood volume and hence cardiac preload which is another explanation for 
an increase in cardiac output by TH (Klein and Ojamaa, 2001; Klein and Danzi, 2007). 
TH also have a regulatory effect on blood pressure. Hyperthyroidism causes a hyperdynamic 
circulation characterised by an increase in cardiac contractility and heart rate, increased preload 
and a decrease in SVR with the overall result increasing the cardiac output by 5-300%.  
Although hyperthyroidism can increase systolic blood pressure, the net effect is variable 
depending on the increased cardiac output versus the decreased systemic vascular resistance 
(Ching et al., 1996; Danzi and Klein, 2003). The relationship between subclinical 
hyperthyroidism and blood pressure is less clear with most observational studies including a 
meta-analysis showing no link (Volzke et al., 2006; Volzke et al., 2009; Cai et al., 2011).  
Hypothyroidism is associated with bradycardia, a decreased cardiac output, diastolic 
hypertension and a narrowed pulse pressure. This is due to impaired vascular smooth muscle 
relaxation which causes an increase in SVR and therefore an isolated rise in the diastolic blood 
pressure which can reverse after TH replacement (Streeten et al., 1988; Dernellis and 
Panaretou, 2002; Taddei et al., 2003).  With overt hypothyroidism and SCH, the increase in 
SVR combined with impaired diastolic relaxation of the smooth muscles and ventricles 
increases the afterload.  It is this diastolic impairment combined with a low heart rate that 
impairs ventricular filling and therefore results in a low cardiac output (Brenta et al., 2003; 
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Ripoli et al., 2005).  Hypothyroidism can also lead to myocardial fibrosis, by stimulating 
fibroblasts as well as leading to progressive systolic dysfunction and a reduction in myocardial 
blood flow due to a loss of arterioles as has previously been demonstrated in animal studies 




Figure 1-3 Effect of TH on cardiovascular haemodynamics. 
TH increases cardiac output by affecting thermogenesis, blood volume, vascular resistance, 
cardiac contractility and heart rate. From: Klein et al, N Engl J Med. 2001; 344(7):501-9 (Klein 



















1.1.5 Overt and subclinical hypothyroidism 
Overt hypothyroidism is prevalent in 0.2 to 2% of non-pregnant adults (Tunbridge et al., 1977a; 
Canaris et al., 2000) and, by definition, is diagnosed when serum TSH is elevated (usually 
more than 10 mU/L) and circulating TH (FT4) is low. Overt hypothyroidism has several cardiac 
manifestations including a reduction in cardiac output and cardiac contractility, a decrease in 
heart rate, and an increase in peripheral vascular resistance (Klein and Danzi, 2007).  There are 
also significant changes in modifiable atherosclerotic risk factors, including 
hypercholesterolemia, diastolic hypertension, increased carotid intimal media thickness, and 
reduced endothelial derived relaxation factor (nitric oxide), which accompany overt 
hypothyroidism. All these clinical features are reversible with TH replacement.  
SCH is diagnosed in the presence of serum TH within their reference range with raised serum 
TSH concentrations and can be mild (TSH > 4.0 or 4.5 but <10mU/L) or severe (>10mU/L).  
However, there is a lack of consensus on the “normal” upper range of TSH leading to 
controversy on both definition and clinical significance of SCH (Hamilton et al., 2008). The 
common causes of hypothyroidism and SCH are outlined in Table 1-1. The prevalence of SCH 
ranges between 4–20% of the adult population (Biondi and Cooper, 2008). The wide range is 
a result of differences in age, sex, body-mass index, race, dietary iodine intake, and the cut-off 
concentrations of serum TSH that are used to define the condition. The prevalence of raised 
serum TSH concentrations is higher in white than in black populations, supporting a genetic 
effect on TSH secretion (Hollowell et al., 2002).  It is estimated that at least 10% of older 












Cause Hypothyroidism and SCH 
Autoimmune disease Hashimoto’s autoimmune thyroiditis, TSH-
receptor blocking antibodies 
Structural disease Thyroid damage due to thyroidectomy or 
radiation damage (radioactive iodine therapy 
or external radiotherapy of head and neck) 
Release of preformed 
thyroid hormones 
Post thyroiditis state in those with underlying 
thyroid disease 
Pituitary disease Secondary hypothyroidism due to TSH 
deficiency 
Drugs Lithium, amiodarone, tyrosine kinase 
inhibitors and interferon therapy. 
             Table 1-1 Common causes of hypothyroidism and SCH. 
 
SCH can impair relaxation of vascular smooth muscle cells, inducing increases in systemic 
vascular resistance and arterial stiffness, as well as changes in endothelial function by reduction 
of nitric oxide availability, without apparent clinical significance (Owen et al., 2007).  
Population studies support these findings with the Whickham Survey cohort revealing higher 
systolic and diastolic blood pressures and total cholesterol concentrations in subclinical 
hypothyroidism than in euthyroid controls (Razvi et al., 2010) and the EPIC-Norfolk study 
reporting that in spite of the worse cardiovascular risk profile seen in SCH subjects, coronary 
heart disease and all-cause mortality did not increase across 10·6 years of follow-up (Boekholdt 
et al., 2010).  There is conflicting evidence from population studies about the association of 
SCH, with increased risk of cardiovascular disease and mortality in some prospective 
population-based cohort studies (Walsh et al., 2005; Razvi et al., 2010; McQuade et al., 2011) 
which hasn’t been confirmed in others (Rodondi et al., 2005; Boekholdt et al., 2010).  Patient-
level meta-analysis of several prospective cohort studies providing 542,494 person-years of 
follow-up showed that SCH is associated with a higher risk of CV events and mortality in 
people with higher serum TSH levels particularly in those with TSH levels greater than 10 
mU/L (Rodondi et al., 2010).   
There is evidence from observational studies to suggest a link between SCH and adverse 
cardiovascular outcomes. There are however no randomised clinical trials of TH treatment of 
SCH to determine whether improvements in cardiovascular events accrue.  Small intervention 
trials of levothyroxine in SCH using surrogate markers have shown improvement in left 
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ventricular function, vascular endothelial function and atherogenic lipid particles (Biondi and 
Cooper, 2008; Cooper and Biondi, 2012).  Several other studies have shown similar results 
(Biondi et al., 1999; Monzani et al., 2001; Ripoli et al., 2005).  In an observational study of 
3093 patients with a raised serum TSH treated in primary care, those under 70 years of age 
who were treated with levothyroxine had fewer cardiovascular events than those who weren’t 
treated (Razvi et al., 2012).  However, in individuals over the age of 70 years (n=1642), there 
was no benefit to levothyroxine detected (Razvi et al., 2012).  Recently, a small before-after 
trial in SCH patients showed improvement in cardiac mitochondrial function with 
levothyroxine treatment (Madathil et al., 2015).  This study provides a novel sub-cellular level 
insight into the action of TH in cardiac tissue (Figure 1-4).  
 
 
Figure 1-4 Cardiac 31P spectra from SCH and euthyroid controls 
Sample cardiac 31P spectra from a SCH patient (A) before and (B) after LT4 treatment 
demonstrating PCr/ATP ratios that improve with treatment and are comparable to (C) euthyroid 
control. PCr/ATP is a marker of mitochondrial function. (Adapted with permission from the 





SCH is associated with CV risk factors which will be explored in more detail (Table 1-2). As 
there is lack of evidence from prospective randomised controlled trials in SCH, international 
guidelines have suggested that treatment should only be considered in those with more severe 
disease (serum TSH > 10 mU/L), symptoms of hypothyroidism or individuals younger than 70 
years old particularly if they also have other CV risk factors (Pearce et al., 2013). 
 
 
 Hypothyroidism and SCH 
Lipids Higher total and LDL cholesterol 
Hypertension Diastolic hypertension 
Thrombogenicity Unclear 
Endothelial dysfunction  Impaired endothelium-dependent vasodilatation 
and arterial stiffness 
Cardiac structure and 
function 
LV systolic and diastolic dysfunction 

















1.2 Potential mechanisms linking thyroid dysfunction with CV disease    
1.2.1 Thyroid hormones and hyperlipidaemia  
Thyroid hormones are involved in lipid metabolism.  The association between hypothyroidism 
and hypercholesterolemia and elevated low-density lipids (LDLs) has been known for many 
years with some estimates showing a link present in up to 90% of cases (Duntas, 2002; Klein 
and Danzi, 2007).  Hypothyroidism is also associated with increased oxidation of LDL which 
leads to an increase in atherogenesis which can reverse with thyroxine treatment (Costantini et 
al., 1998; Diekman et al., 1998).  Lipoprotein (a) is known to be more atherogenic that other 
lipoproteins and has been shown to increase in overt hypothyroidism and subsequently 
decreases with TH treatment (Martinez-Triguero et al., 1998; Tzotzas et al., 2000).   
Elevated levels of lipids are also evident in patients with SCH suggesting an increased risk for 
atherosclerosis; however evidence remains controversial based on different population based 
studies.  In some studies such as the Whickham Survey and National Health and Nutritional 
Examination Survey (NHANES) III, there was no link between SCH and hyperlipidaemia 
whereas other studies showed a link as well as a relative increase in serum lipids with an 
increase in serum TSH in SCH (Tunbridge et al., 1977a; Hueston and Pearson, 2004; Asvold 
et al., 2007).  In other studies, such as those by Bauer et al, there was a relative increase in LDL 
and cholesterol levels with an increase in serum TSH in SCH in the older age group (Bauer et 
al., 1998; Kanaya et al., 2002).  Furthermore, other population-based studies have shown that 
SCH not only increases lipid levels but is strongly associated with atherosclerosis (Hak et al., 
2000; Kvetny et al., 2004).   
The causes of hyperlipidaemia in an underactive thyroid state is due to a decrease in LDL 
receptors, which reduces the clearance of cholesterol from the liver, and decreased activity of 
the enzyme cholesterol 7α-hydroxylase which is usually activated by thyroid hormones in 
breaking down cholesterol (Pandak et al., 1997; Duntas, 2002).  Randomised placebo-
controlled trials have shown differences in whether thyroxine treatment has a beneficial effect 
on LDL and cholesterol levels.  Some of these trials have shown a beneficial effect (Caraccio 
et al., 2002; Monzani et al., 2004; Razvi et al., 2007), whereas others have not (Jaeschke et al., 
1996; Kong et al., 2002).  Such differences in all these studies are probably due to different 
population groups, varying severity of hypothyroidism, the presence of thyroid antibodies, the 
dose of thyroxine and the age group of the participants.  A Cochrane review of the literature 
including 6 RCTs concluded that thyroxine treatment of SCH had a trend towards improving 
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LDL levels greater than 155mg/dL in a subgroup analysis although there were no overall 
effects in reducing total cholesterol, high density lipids (HDLs) and low density lipids (LDLs) 
in the interventional groups (Villar et al., 2007). 
 
1.2.2 The role of vascular function in cardiovascular disease 
The vascular endothelium is an organ with secretory and synthesising functions.  It is semi- 
permeable with different receptors which regulates the flow of molecular substances through 
the body.   The endothelium has a multifactorial role in vascular haemostasis by maintaining 
the balance between vasodilation and vasoconstriction, inhibiting smooth muscle cell 
proliferation and regulating thrombogenesis and fibrinolysis (Davignon and Ganz, 2004).  A 
disturbance is this function leads to endothelial dysfunction, marked by modifications in the 
secretory function of the endothelium and transformation to a thrombogenic medium, which 
causes arterial wall disease.  Endothelial dysfunction is a marker of atherosclerosis preceding 
plaque formation and is associated with traditional risk factors such as, hypertension, 
hypercholesterolemia, diabetes, stress and diseases marked by systemic inflammation (Gokce 
et al., 2002). 
Vascular tone is determined by the production of vasodilators and vasoconstrictors.  
Vasodilators include nitric oxide (NO), prostacyclin, bradykinin and endothelium-derived 
relaxing factor (EDRF).  All these vasodilators inhibit platelet aggregation whereas bradykinin 
also stimulates the production of tissue plasminogen activator (t-PA) which breaks down 
thrombus, indicating a role in fibrinolysis.  Vasoconstrictors produced by the endothelium 
include endothelin and angiotensin II which promote smooth muscle proliferation therefore 
contributing to plaque formation.  Endothelial dysfunction disrupts the balance between 
vasodilators and vasoconstrictors leading to atherosclerosis by increasing platelet aggregation, 
leukocyte adhesion and smooth muscle proliferation (Levine et al., 1995; Davignon and Ganz, 
2004). 
The progression of fatty deposits to atheromatous plaques within the endothelium is dependent 
on continuous insults which can either be endogenous such as hypercholesterolemia and 
hypertension or exogenous such as smoking (Chien, 2003).  In response to such insults, the 
endothelium expresses vascular cell adhesion molecule-1 (VCAM-1) and P-selectin which are 
adhesion molecules for leucocytes aiding in self repair (Linton and Fazio, 2003).  Continuous 
insults cause these adhesion molecules to be overexpressed causing increased leucocyte 
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attachment (Figure 1-5).  Overtime the leucocytes undergo transformation to tissue 
macrophages within the tunica media and lead to the release of various mediators and cytokines 
which act on the endothelial receptors to impair the secretory and regeneration mechanisms 
within the endothelium.  The macrophages cause transformation of lipoproteins into foam cells 
which leads to enlargement of the atheromatous plaque (Libby, 1995).   
 
 
Figure 1-5  Endothelial dysfunction leading to plaque formation. 
Endothelial function is impaired by cardiovascular risk factors and systemic cytokines.  
Cardiovascular insults over a prolonged period lead to adhesion molecule expression which 
attracts leukocytes.  These leukocytes transform to tissue marcophages in the tunica media and 
release cytokines leading to lipid transformation.  From: Ganz et al, Eur Heart J. 
2013;34(27):2025-7 (Ganz and Hsue, 2013).   
 
Given the link between cardiac risk factors and endothelial dysfunction, the use of endothelial 
function has been used to predict clinical outcomes related to atherosclerosis.  In one study of 
patients with mild CAD followed up for 28 months, significant coronary artery endothelial 
dysfunction resulted in increased cardiac events whereas no events occurred in patients with 
mild endothelial dysfunction (Suwaidi et al., 2000).  One problem with this study was the 
majority of cardiac events were driven by the need for revascularisation rather than MI 
therefore representing a softer end point however; the study still did show the importance of 
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measuring endothelial function with regard to cardiac status.  In another study of 281 patients 
followed up over 4.5 years, endothelium dependent and independent vasodilation was assessed 
using venous occlusion plethysmography, which measured blood flow responses, with 
impaired vasodilator responses predicting cardiovascular events during follow up (Heitzer et 
al., 2001). 
 
1.2.3 Thyroid hormones and vascular function 
Overt and SCH are associated with diastolic hypertension and impaired vascular function. The 
causes of hypertension in these patients are numerous.  Firstly, there is an increase in systemic 
vascular resistance due to a lack of the vasodilatory effects of TH on the smooth muscle cells 
of blood vessels.  Other causes include endothelial dysfunction, as well as increased arterial 
stiffness (Danzi and Klein, 2003; Biondi and Cooper, 2008).  Some studies have shown an 
isolated elevation of systolic blood pressure in hypothyroidism (Saito et al., 1983; Fommei and 
Iervasi, 2002), of which one study used ambulatory blood pressure measurements and showed 
a significantly elevated systolic blood pressure readings in hypothyroid patients (Fommei and 
Iervasi, 2002).  The Tromso study showed a significant positive relationship between TSH and 
both systolic and diastolic blood pressure (Iqbal et al., 2006).  Studies have also shown a 
relationship between SCH and hypertension.  Two community-based studies concluded that 
subjects with SCH had a significantly higher systolic blood pressure (SBP) than euthyroid 
subjects (adjusted for age, sex and body mass index)(Duan et al., 2009; Liu et al., 2010).  In 
a further smaller study which compared 57 women with SCH to 34 healthy controls, mean 
diastolic blood pressure was increased in SCH patients (Luboshitzky et al., 2002).  These 
studies are further supported by a meta-analysis which showed SCH to be associated with 
increased systolic and diastolic pressures (Cai et al., 2011). 
Central arterial stiffening increases cardiac afterload and is an important determinant of all-
cause mortality as well as being a precursor for atherosclerosis.  Pulse wave velocity, a measure 
of arterial stiffness, is an accurate means by which a relationship between cardiac risk factors 
and arterial stiffness can be sought (Amar et al., 2001).  Two studies have shown central arterial 
stiffness, as measured by pulse wave velocity, to be higher in hypothyroid patients compared 
to controls with levothyroxine therapy fully reversing stiffness and improving vascular 
function (Dernellis and Panaretou, 2002; Obuobie et al., 2002).  Three other studies have 
shown arterial stiffness to increase in SCH patients with and without autoimmune thyroiditis 
and this subsequently decreases post thyroxine therapy (Nagasaki et al., 2006; Nagasaki et al., 
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2007; Nagasaki et al., 2009).  These studies demonstrate that treating underactive thyroid 
disease improves cardiovascular risk profile as measured non-invasively.   
Flow-mediated dilatation (FMD) is a non-invasive test to measure endothelium function and 
refers to the dilatation of the brachial artery in response to an increase in blood flow after a 
period of reactive hyperamia, in which the brachial artery is occluded. It is dependent on the 
effects of NO on the vascular endothelium. The principle of reactive hyperaemia involves 
occluding the brachial artery and measuring a change in blood vessel diameter by ultrasound 
post occlusion.  Healthy vasculature responds to NO resulting in an increased vessel diameter 
post occlusion. Flow mediated endothelium dependent vasodilation has been compared in 
hypothyroid and SCH patients with FMD decreasing with a subsequent increase in TSH and 
reduced thyroid function (Lekakis et al., 1997).  This finding is further supported by two 
randomised placebo controlled trials (RCTs) which showed thyroxine treatment to improve 
endothelial function in SCH patients (Taddei et al., 2003; Razvi et al., 2007).  The RCT by 
Razvi et al showed thyroxine to reduce LDL levels, improve the quality of life and improve 
endothelial function as measured by FMD in SCH patients (Razvi et al., 2007). 
Intima-media-thickness (IMT) as measured by ultrasonography of different arteries such as the 
carotid artery has been associated with atherosclerosis and CAD (Bots et al., 1997; Mannami 
et al., 1997).  The thickening of the intima-media of an artery not only indicates regional 
changes but also generalised atherosclerosis and IMT is a non-invasive method for assessing 
early atherosclerosis and providing an end point to assess the effects of intervention (Allan et 
al., 1997; O'Leary and Polak, 2002).  Increased IMT is considered to be an early marker for 
systemic atherosclerosis and CAD in both overt and SCH subjects and thyroxine therapy has 
shown to improve IMT.  In SCH, a positive correlation between TSH and intima-media 
thickness has been found on regression analysis independent of other variables (Monzani et al., 
2004).   
Numerous factors are likely to cause vascular dysfunction and elevated blood pressures in 
patients with an underactive thyroid state.  The role of hyperlipidaemia in low thyroid states is 
one cause due to its role in atherosclerosis and arterial stiffening as well causing inflammation 
(Dart et al., 1991; Taddei et al., 2003). The deposition of fatty deposits with the endothelium 
results in the expression of vascular adhesion molecules which starts the process of 
atherosclerosis.  Such adhesion molecules such as E-selectin and P-selectin are also 
increasingly expressed in patients with Hashimoto’s thyroiditis, suggesting there is a close 
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interplay between autoimmune thyroid antibodies and inflammation (Marazuela et al., 1995).  
Further evidence shows that in patients with SCH associated with autoimmunity, the 
improvement in endothelial dysfunction is far less than would be expected in such patients who 
had SCH alone (Taddei et al., 2003).  Other studies have also shown the role autoantibodies in 
inflammation when investigating endothelial and vascular function in patients with SCH with 
autoantibodies (Cikim et al., 2004; Kvetny et al., 2004; Taddei et al., 2006; Turemen et al., 
2011).  In one such study by Taddei et al, patients with SCH had higher CRP and interleukin 
levels compared to those who were euthyroid and administering an anti-inflammatory agent in 
the form of indomethacin significantly improved the vasodilatory response to acetylcholine 
(Taddei et al., 2006).  In the Rotterdam study, the prevalence of arterial disease, aortic 
calcification and MI was not only increased in patients with SCH but the strongest association 
was observed in those patients with SCH and positive thyroid auto-antibodies (Hak et al., 
2000). 
Finally, TH have beneficial effects on the endothelial cell through the TRα1 and TRβ.  
Activation of TRα1 increases coronary blood flow as well as decreasing coronary resistance 
and improving cardiac contractility in ischaemia–reperfusion injury (Suarez et al., 2014). 
Activating TRα1 also causes vascular myocyte relaxation by increasing the production of nitric 
oxide in endothelial and vascular smooth muscle cells through the activation of nitric oxide 
synthase and the important signalling pathway PI3K/AKT (Carrillo-Sepulveda et al., 2010).  
Activation of TRβ by TH activates the mitogen-activated protein kinase (MAPK) pathway 
inducing angiogenesis (Suarez, 2010). This leads to the transcription of several proangiogenic 
genes, such as vascular endothelial growth factor (VEGF) (Cheng et al., 2010), angiopoietin 
(Cheng et al., 2010) and basic fibroblast growth factor (bFGF) (Tomanek et al., 1998a).  
  
1.2.4 Assessing endothelial dysfunction 
A key process in endothelial dysfunction is impaired NO bioavailability leading to decreased 
vasodilation.  Endothelial dysfunction is assessed using both invasive and non-invasive 
methods.  Invasive methods include the infusion of acetylcholine into the coronary artery which 
promotes vasodilation if the endothelium is intact whereas on the contrary, vasoconstriction 
occurs in the presence of atherosclerosis due to the direct constricting effects of acetylcholine.  
Infusing agents such as nitroglycerine on the other hand test vasodilation independent of the 
endothelium; however these tests are limited by their invasive nature.  
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Because endothelial dysfunction is a systemic process affecting different vascular beds, non-
invasive tests for endothelial function have been developed which are thought to be a better 
representation of coronary vascular function by assessing the peripheral vasculature.  These 
tests are dependent on the physiological stimulation of NO produced post-ischaemic 
hyperaemia and include FMD, finger plethysmography and EndoPAT.  FMD is the most 
common method for assessing endothelial function and involves ultrasonography of the 
brachial artery and assessing changes in luminal diameter following transient ischaemia for 5 
minutes using a pneumatic cuff around the forearm.  On cuff deflation, there is an increase in 
the volume of blood flow which increases shear stress and activates NO leading to vasodilation.  
Therefore FMD measures the percentage change in diameter of the brachial artery (Charakida 
et al., 2010).  Despite its frequent use, there are certain problems with the use of FMD.  This 
includes careful operator training due to significant operator variability which includes probe 
positioning.  Importantly environmental factors need to be controlled as FMD is influenced by 
room temperature, medications, use of caffeine as well as recent infection.  Furthermore, the 
literature shows variations in mean FMD when measurements are taken in similar populations 
for different studies (Bots et al., 2005).   
EndoPAT is a non-invasive test which uses a peripheral arterial tone (PAT) signal for non-
invasively measuring arterial tone in the peripheral arterial beds.  The PAT signal is measured 
from the fingertip by recording peripheral arterial volume changes using a pneumatic probe 
with a plethysmographic cuff (Figure 1-6).  It quantifies changes in endothelium mediated 
arterial tone by occluding the brachial artery for 5 minutes and then measuring reactive 
hyperaemia manifested by an increase in the PAT signal amplitude.  By using one arm for the 
experiment and the other arm as a control, EndoPAT can account for general systemic changes 
that occur during the test and corrects for this when giving a final reactive hyperaemia index 
(RHI) score.  A significant advantage of using EndoPAT is that it is both operator and 
interpreter independent as the procedure involves very few variables that are interoperator 
dependent.  Selamet et al demonstrated excellent reproducibility in 30 adolescents who had 
their test repeated within seven days.  A further study confirmed EndoPAT to be more 
reproducible when compared to FMD even though FMD was measured by an experienced 





Figure 1-6  EndoPAT test procedure. 
One arm is used as the experiment arm and the other arm as a control.  An increase in the 




1.2.5 Thyroid hormones and thrombosis 
Alterations in coagulation parameters in SCH might play a role in the potential development 
of atherosclerosis.  In one study comparing women with SCH with euthyroid controls, factor 
VII activity and the factor VII activity:factor VII antigen ratio were significantly increased in 
women with SCH, whereas no differences in vWF or other haemostatic factors were observed 
(Muller et al., 2001).  In another similar study, decreased antithrombin III activity and 
increased levels of fibrinogen, factor VII and plasminogen activator inhibitor antigen were 
found in SCH patients which may explain a hypercoagulable state (Canturk et al., 2003).  This 
is further supported in a study by Guldiken et al who found the global fibrinolytic activity, such 
as tissue plasminogen activator, to be lower in SCH subjects than in controls (Guldiken et al., 
2005).  These studies demonstrate how TH may act on both the coagulation and fibrinolytic 
pathways leading to decreased thrombus formation.  A recent study using the Badimon 
chamber, a model which simulates ex vivo coronary artery blood flow through a diseased 
artery, has shown the thrombus area in patients with SCH 7-10 days post non-ST elevation 
myocardial infarction to be larger than in euthyroid patients despite the use of dual antiplatelets 
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in the form of aspirin and clopidogrel (Figure 1-7) (Viswanathan et al., 2014a).  This may also 
help explain the increased adverse outcomes in SCH patients post AMI as such a state is likely 
to be more thrombogenic.   
The mean platelet volume (MPV) which reflects platelet size has shown to be associated with 
cardiovascular risk (Endler et al., 2002; Chu et al., 2010).  In one retrospective analysis, 
patients with SCH had a higher MPV than euthyroid subjects and there was a positive 
correlation between TSH and MPV which could explain thrombotic risk (Kim et al., 2013).  
This could suggest another reason for increased thrombogenesis in SCH however more 
research is needed with regard to this.  The Tromso Study on the other hand did not show a 
significant difference in coagulation markers between SCH and euthyroid subjects (Jorde et 
al., 2006).  Other studies have also not shown a difference in homocysteine levels between 
SCH and euthyroid subjects (Deicher and Vierhapper, 2002; Christ-Crain et al., 2003).  
Minimal research has been undertaken to assess the effect of TH replacement therapy on 
haemostasis and thrombus burden.  In one study, SCH subjects exhibited a prothrombotic state 
as shown by increased levels of factor VII, plasminogen activator inhibitor antigen and lower 
d-dimer levels compared to healthy controls which fully reversed with 6 months of thyroxine 
therapy (Lupoli et al., 2015).  These findings are supported by a further study which showed 
the same findings in SCH patients treated with thyroxine (Canturk et al., 2003). In another 
smaller study, although SCH subjects exhibited a prothrombotic state as shown by increased 
levels of antithrombin III, fibrinogen and homocysteine, 6 months of thyroxine therapy had no 
effect on coagulation although it was unclear how many patients attained euthyroidism post-






Figure 1-7 Difference in thrombus burden between SCH and euthyroid patients. 
The Badimon chamber assesses ex-vivo thrombus burden. SCH patients post MI, on dual 
antiplatelets, have a higher thrombus burden in comparison to euthyroid patients.  This may 
explain the higher cardiovascular risk in SCH.  From: Viawanathan et al, J Clin Endocrinol 
Metab. 2014 Jun;99(6) (Viswanathan et al., 2014a). 
 
 
Studies assessing coagulability in hypothyroidism have produced conflicting results with some 
studies showing hypercoagulability whereas other studies demonstrated increased fibrinolysis.  
Erem et al found a hypofibrinolytic state in patients with hypothyroidism as shown by increased 
levels of fibrinogen and plasminogen activator inhibitor (Erem et al., 2003).  In other studies 
serum thyroxine levels were inversely related to fibrinogen and d-dimer levels in patients with 
hypothyroidism leading to a hypercoagulable state (Chadarevian et al., 1998; Chadarevian et 
al., 1999).  Studies have also found elevated homocysteine levels in hypothyroidism with 
Christ-Crain et al showing elevated levels of CRP and homocysteine in patients with 
hypothyroidism which did not reverse with thyroxine therapy whereas Catargi et al found  
homocysteine levels to increase with a subsequent increase in TSH levels, and total 
homocysteine levels in hypothyroid patients were higher compared to controls (Catargi et al., 
1999; Morris et al., 2001; Christ-Crain et al., 2003). 
Hypothyroidism has also been associated with increased fibrinolysis with studies showing 
reduced von Willebrand factor antigen which effects primary haemostasis and increases the 
bleeding time (Nitu-Whalley and Lee, 1999; Michiels et al., 2001; Gullu et al., 2005).  In one 
study comparing moderate and severely hypothyroid patients with euthyroid controls, patients 
with moderate hypothyroidism had decreased fibrinolytic activity and were more susceptible 
to clot formation whereas patients with severe hypothyroidism had increased fibrinolysis and 
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lower tissue plasminogen activator antigen (Chadarevian et al., 2001).  A systematic review 
taking into account the main studies looking at coagulation and fibrinolysis showed patients 
with hypothyroidism to have an increased risk of bleeding (Squizzato et al., 2007).  However, 
the authors state that no high quality study with regard to the effects of hypothyroidism on 
coagulation was identified.  Furthermore, subjects in the studies did not have the same degree 
of thyroid dysfunction with many studies including subjects with subclinical thyroid disease.  
Finally, in some studies thyroid function tests were not repeated at the time of coagulation tests 
(Squizzato et al., 2007). 
In summary, there is considerable heterogeneity in all these studies making it difficult to 
ascertain the impact of an underactive thyroid state on the coagulation pathway.  Studies have 
demonstrated that TH deficiency can alter the coagulation pathway but more research is needed 
by having higher quality studies with robust methodologies which include a larger number of 
participants, the type of tested TH, TH measurements at similar intervals as coagulation tests 
and including subjects with the same degree of thyroid dysfunction.  At present, one can 
conclude the likely increased risk of AMI in SCH subjects may be due to a prothrombotic 
effect, however more robust studies are needed relating to SCH and thrombogenesis. 
 
1.2.6 Thyroid hormones and cardiac function 
Overt hypothyroidism can cause left ventricular diastolic dysfunction by reducing the activity 
of SERCA and this subsequently leads to reduced reuptake of calcium during diastole leading 
to impaired ventricular relaxation (Tielens et al., 2000; Virtanen et al., 2001).  This impairs left 
ventricular filling during diastole.  Similar findings also occur in SCH patients as shown from 
imaging studies using doppler echocardiography and radionuclide ventriculography to 
compare SCH patients with euthyroid controls.  These studies have demonstrated an increase 
in the peak A wave velocity, a decrease in early diastolic mitral flow velocity/late diastolic 
mitral flow velocity ratio (E: A) and mitral acceleration and deceleration times (Figure 1-8, 
Table 1-3) which are important measures of diastolic function (Biondi et al., 1999; Monzani et 
al., 2001; Brenta et al., 2003; Aghini-Lombardi et al., 2006).  Other impaired parameters in 
these studies include a more prolonged isovolumetric relaxation time (IRT) and impaired peak 
filling rate during diastole.  Biondi et al, Yazici et al and Aghini-Lombardi et al have all shown 
a significant reduction in early diastolic mitral flow velocity/late diastolic mitral flow velocity 
ratio (E: A) in SCH subjects in comparison to controls with the use of Doppler 
echocardiography (Biondi et al., 1999; Yazici et al., 2004; Aghini-Lombardi et al., 2006).  In 
26 
 
other studies diastolic dysfunction has been demonstrated at both rest and exercise as well as  
systolic dysfunction on exertion with thyroxine therapy normalising such parameters (Biondi 
et al., 1999; Biondi et al., 2002; Brenta et al., 2003).  Diastolic heart failure has implications 
in hypothyroid and SCH patients due to the high prevalence in the elderly and that it likely 




Figure 1-8 Diastolic function is derived by doppler echocardiography which measures the 
inflow velocity across the mitral valve into the left ventricle during relaxation. 
The E wave represents peak velocity in early diastole whereas the A represents peak velocity 
in late diastole due to atrial contraction.  The E velocity should be greater than A velocity with 
a ratio >1.  In diastolic dysfunction, the ventricle can become stiff which impairs ventricular 
filling therefore increasing the back pressure as it fills leading to a decrease in the E velocity 






















1999   26  
36 ± 
12  8.6 ± 4.8  
↑ A, ↓ 
E/A, ↑ 
IRT  Doppler echo  
Di Bello, 
2000  16  
32 ± 
12  5.3 ± 1.9  
↑ A, ↔ 
E/A, ↑ 
IRT  Doppler echo  
Monzani, 
2001  20  
33 ± 
12  5.4 ± 2.4  
↔ E/A, ↑ 
A, ↑ IRT  Doppler echo  
Vitale, 
2002   20  
38 ± 
12  10.6 ± 4.05  
↔ E/A, ↑ 
IRT  Doppler echo  
Brenta, 
2003  10  
50 ± 




2004  45  
40 ± 
7.9  8.41 ± 2.1  
↑ A, ↑ 
IRT, ↓ 
E/A  Doppler echo  
Aghini-
Lombardi, 
2006   24  
35 ± 
6.2  5.3 ± 1.1  
↑ A, ↑ 
IRT, ↓ 
E/A  Doppler echo  
 
Table 1-3 Table to demonstrate studies which have compared SCH and euthyroid subjects with 
regard to LV function. 
The studies demonstrate that SCH causes a decrease in E:A, a prolonged isovolumetric 
relaxation time and an increase in the total peak filling rate which are important measures of 









Even in euthyroidism, subjects with lower TH levels have impaired cardiac function whereas 
an increase in thyroid hormone is associated with enhanced ventricular contraction and 
relaxation indicating that variations in TH within the reference range can effect cardiac function 
(Roef et al., 2013).  Cardiac MRI (CMR) is considered the gold standard test for accurately 
assessing LV volumes and function.  In one robust study, CMR was used in otherwise healthy 
SCH patients to assess cardiac volumes and function with the results demonstrating a reduced 
end diastolic volume (EDV), a reduced ejection fraction of 5% and an increase in SVR in SCH 
subjects compared to controls.  Repeat CMR post thyroxine showed normalisation of these 
parameters which were similar to controls (Ripoli et al., 2005).   
In summary, the current evidence demonstrates diastolic dysfunction to be the most frequent 
cardiac abnormality in SCH in a clinical setting due to impaired ventricular filling and 
relaxation although the number of participants in these studies were small. Although these 
studies have not yielded conclusive results with regard to systolic function, a robust study using 
cardiac MRI has demonstrated systolic dysfunction which reversed with thyroxine therapy.  
Overall an underactive thyroid state is a risk factor for heart failure by causing diastolic 
dysfunction and increasing the SVR.   
 
 
1.2.7 Assessing cardiovascular function and scar size 
Cardiovascular magnetic resonance imaging (CMR) is the gold standard method for assessing 
ejection fraction since this modality achieves superior image quality.  It is non-invasive, avoids 
exposure to radiation and is the most reproducible method for quantifying left ventricle (LV) 
volumes and hence ejection fraction. (Hudsmith et al., 2005).  Volumetric measurements of 
the LV cavity is dependent on a time-volume relation of the LV cavity and this is obtained by 
a series of breath held short-axis planes whilst in the scanner.   
Late gadolinium enhancement (LGE) CMR is the most accurate modality for scar detection 
post AMI due to its high spatial resolution which can detect even subendocardial infarctions 
(Wagner et al., 2003).  Gadolinium contrast given to patients during CMR accumulates in the 
extracellular spaces of both healthy and diseased myocardium to exhibit enhancement.  The 
rate of gadolinium uptake, accumulation and washout is influenced by diseased myocardium 
post MI leading to increased enhancement, due to accumulation and delayed washout, in 
comparison to healthy myocardium in which the gadolinium is washed out after a specific time 
period.  The relative contrast in healthy and diseased myocardium is dependent on when 
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imaging occurs post gadolinium administration.  Up to 3 minutes post administration, 
gadolinium resides in the blood pool and healthy myocardium.  After approximately 10 
minutes, the gadolinium is washed out from the normal tissues but is retained in diseased tissue 
post MI leading to late enhancement on T1-weighted imaging (Figure 1-9).  This is due to 





Figure 1-9  The detection of scar by the use of LGE on CMR.  Myocardial cell necrosis post 
AMI increases the extracellular space leading to a delay in the gadolinium washout at 10 

















1.3 Experimental studies involving TH 
1.3.1 Thyroid hormones and cardioprotection 
Post myocardial infarction cardioprotection is a new therapeutic target for pharmacological 
intervention in both the acute and chronic phase of AMI when post-ischaemic heart failure 
develops. The main goal of cardioprotection is to reduce or limit myocardial damage in order 
to avoid impairment of left ventricular function. Furthermore, the additional goal is to limit the 
progression toward irreversible HF syndrome. Myocardial damage in AMI is caused by two 
main processes: ischaemic damage due to the abrupt occlusion of the coronary vascular system 
and damage caused by revascularisation leading to reperfusion injury. Cardioprotection is a 
complex phenomenon involving the stimulation of cell growth, neo-angiogenesis, metabolic 
adaptation, and maintenance of mitochondrial integrity is a new emerging aspect. In this post 
myocardial infarction cardioprotection scenario, the emerging role of TH in influencing 
different molecular, tissue, and cellular mechanisms requires further exploration, particularly 
as data accumulates with regards to its regenerative properties (Columbano et al., 2006; Naqvi 
et al., 2014). The targets of TH cardioprotective effects are the limitation of infarct extent, 
mainly involving the border zone, and the limitation of the LV post-ischemic remodelling 
process, involving both the border and the remote zone through the antifibrotic and pro-
angiogenetic effects.  LV remodelling involves changes in cardiomyocytes, extracellular 
matrix, and microcirculation affecting the infarct region, AMI border zone, and remote regions 
(Gerdes et al., 1992; Dixon and Spinale, 2010).  This causes thinning of the infarct area, infarct 
expansion at the site of the necrotic border zone, and hypertrophy and fibrosis of the remote 
zone (Pfeffer, 1995).  The net result of this process is progressive LV dilatation, its functional 
impairment, and the progression to heart failure.  
 
1.3.2 Thyroid hormones and the foetal genotype 
Cardiac remodelling is the stress response of the heart to myocardial ischaemia, metabolic 
changes and changes in mechanical loading to restore the function of the heart.  Haemodynamic 
overload leads to cardiac dilatation which in the short term helps to maintain cardiac output 
and blood flow (Pantos et al., 2010). Therefore remodelling involves changes in 
cardiomyocytes, the vasculature and the extracellular matrix.  A key feature of this process is 
activation of the foetal gene program in which the myocardium has characteristics similar to 
the foetal heart in regard to genetic expression, isoform switches of proteins, and energy 
consumption in which glucose is metabolised over fatty acids (Taegtmeyer et al., 2010).  
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The experimental setting has shown how α-myosin heavy chain (αMHC) and SERCA decrease 
post AMI whereas β-myosin heavy chain (βMHC) increases as in the foetal genotype (Pantos 
et al., 2007a; Henderson et al., 2009).  In experimental studies, TH supplementation reverses 
these changes and improves myocardial function by increasing αMHC which is the main 
contractile protein (Chang et al., 1997; Ojamaa et al., 2000; Pantos et al., 2007a; Henderson et 
al., 2009).  The reasons for why there is a change in myocyte expression to the foetal mode 
post AMI is not clear although we do know TH deficiency has a large part to play.  Ojamaa et 
al have shown T3 to be low up to 4 weeks post AMI whereas another study showed that T3 
remained low for up to 8 weeks post AMI (Ojamaa et al., 2000; Olivares et al., 2007).  
Furthermore, TH is low during the foetal stage of development and subsequently increases in 
the post-natal period leading to maturation of the myocardium with transcriptional gene 
changes which cause alterations in metabolism, myocyte shape and cellular function (Pantos 
et al., 2008b).  Rajabi et al have shown that a low T3 in the injured myocardium could be a 
benefit in conserving energy after an AMI however this is also considered to be a maladaptive 
state in the long term, if not reversed, which has poor prognostic benefits (Rajabi et al., 2007).  
The different mechanisms by which a low TH state effects the heart will be discussed in detail 
below. 
 
1.3.3 Thyroid hormones and LV function 
Suppression of TH post AMI causes calcium overload within cells which contributes to 
reperfusion injury and hence LV impairment (Krause et al., 1989).  Although TH levels 
decrease in rats post AMI, supplementation of TH post AMI has shown beneficial effects on 
LV function. TH administered for 2 weeks after an AMI was shown to attenuate remodelling 
and improve LV function in the viable myocardium (Pantos et al., 2007a), whereas TH 
administered for 13 weeks post AMI was found to increase LV function, improve LV systolic 
and diastolic diameters and improve myocyte geometry (Pantos et al., 2008a).  Even 
administration of a high dose of TH 13 weeks after AMI showed TH to partially reverse cardiac 
dysfunction in rats with an old MI by changing cardiac geometry and myosin expression, 
indicating how myocyte remodelling can take place over a long period with the potential of 
reversal of pathological remodelling to physiological (Pantos et al., 2009b).  Chen et al, 
Henderson et al and Forini et al have also shown similar beneficial effects of TH on LV 
function in experimental studies post MI (Henderson et al., 2009; Forini et al., 2011; Chen et 
al., 2013).  Although the doses of TH in some of these studies were higher than optimal, 
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Henderson et al used a dose that was physiological and found an improvement in both systolic 
and diastolic function (Henderson et al., 2009).  TH has also been shown to limit the extent of 
infarct size and apoptosis in the border area of the infarcted tissue leading to an improvement 
in LV function (Chen et al., 2008; Kalofoutis et al., 2010).  This limitation of infarct extension 
is through the activation of the cellular pro-survival pathways PI3K/Akt and PKC and 
suppression of the p38 MAPK pathway, which reduces myocyte apoptosis (programmed cell 
death), as shown experimentally in rodent models of AMI treated with T3 (Rybin and 
Steinberg, 1996; Kuzman et al., 2005; Pantos et al., 2009a).  
 
 
Figure 1-10 Mechanisms of TH cardioprotection 
TH activates pro-survival signalling pathways (non-genomically) which has a benefit post MI.  
TH also regulate myocyte contractile proteins (direct genomic action) and upregulate 
cardioprotective molecules via mitochondrial biogenesis (non-genomic action). 
 
These studies in the experimental setting show how LV function not only improves due to the 
inotropic effects and anti-apoptotic of TH non-genomically but also genomically due to an 
increase expression of αMHC, SERCA and inhibition of phospholamban.  This is supported by 
a study by Pantos et al in which T3 treated cells expressed 51% αMHC and 49% βMHC 
compared to non-treated cells which expressed 100% βMHC (Pantos et al., 2007b).  In another 
study by Forini et al, human atrial cardiomyocytes cultured with and without T3 demonstrated 
how T3 deprived cardiomyocytes had larger dimensions and altered morphology resembling 
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impairments observed in heart failure.  One of the key findings was a reduction in SERCA 
which resulted in poor calcium handling and this is well known to cause myocardial 
impairment as shown by studies in which reuptake of calcium during diastole leads to impaired 
ventricular relaxation (Forini et al., 2001).   
 
1.3.4 Thyroid hormones and myocyte shape and geometry 
Compensatory mechanisms are activated post AMI to try to restore cardiac function but 
sustained activation in the long term can also lead to cardiac failure.  Cardiac function 
deteriorates due to myocyte changes in the viable, non-ischaemic myocardium.  A key aspect 
of maladaptive cardiac remodelling is myocytes becoming large and spherical which causes an 
increase in wall stress and a decline in LV function (Sehgal and Drazner, 2007).  Wall stress is 
increased with an increase in myocyte diameter and subsequently decreases with an increase 
in wall thickness.  Therefore progression to dilated failure has been show to occur with 
increased myocyte diameter without an increase in myocyte width and thickness, which 
therefore reduces the cross sectional area (Gerdes et al., 1992; Gerdes and Iervasi, 2010).  
TH has been shown to alter myocyte size and diameter.  In hypertensive rats with heart failure, 
TH reduced LV stress by decreasing the ratio of LV diameter to wall thickness indicating that 
physiological remodelling entails reducing the myocyte major diameter and increasing the 
minor diameter (Thomas et al., 2005).  In rats with an old MI, TH changed myocyte geometry 
from a spherical shape to a more elliptical shape leading to an increase in ejection fraction (EF) 
(Pantos et al., 2008a; Pantos et al., 2009b).  The beneficial effects of TH on cardiac geometry 
immediately after an AMI have also been investigated.  Myocytes from the non-infarcted 
myocardium showed increased lengthening and TH treatment increased the cross sectional area 
by increasing myocyte thickness which lead to an increase in LV function (Chen et al., 2013).  
This provides more evidence on how TH therapy can prevent pathological remodelling post 
AMI.  TH has been shown to effect myocyte shape and geometry by activating survival 
pathways such as the ERK signalling pathway (Pantos et al., 2007b; Mourouzis et al., 2012).  
This is shown by the administration of PD98059 (an inhibitor of ERK signalling) which 




1.3.5 Thyroid hormone effects on angiogenesis and mitochondrial function 
Small arterioles within the myocardium are important for oxygen delivery and therefore 
myocardial function.  A reduction in myocardial arterioles and blood flow has been 
demonstrated in dilated cardiomyopathy, hypothyroidism and neonatal hypothyroidism (Heron 
and Rakusan, 1996; Khalife et al., 2005; Tang et al., 2005; Liu et al., 2009).  In 
cardiomyopathic hamsters with SCH, coronary blood flow was shown to be impaired which 
contributed to a reduction in LV function and myocyte loss.  Such changes were fully reversed 
with TH treatment (Khalife et al., 2005).  TH has been shown to induce arteriolar growth in 
hypertrophy secondary to hyperthyroidism (Tomanek et al., 1995; Tomanek et al., 1998b), and 
to prevent the loss of arterioles during induction of hyperthyroidism (Liu et al., 2008).  In a MI 
setting, TH increase arteriolar length and density which helps oxygen delivery to the injured 
myocardium (Forini et al., 2011; Chen et al., 2013).   
TH can induce angiogenesis via the integrin receptor αVβ3 which leads to activation of the 
ERK 1 and 2 pathway. This leads to the transcription of different angiogenic genes such as 
vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and 
angiopoietin (Mousa et al., 2005; Mousa et al., 2006).  Another proangiogenetic effect of TH 
is via the interaction of TH with TRβ receptor leading to hypoxia-inducible factor 1 alpha (HIF-
1α) expression which is an important factor in cell proliferation and promoting vascular growth 
(Eckle et al., 2008).  Furthermore, TH also has non genomic angiogenic effects by causing 
coronary smooth muscle cell relaxation via TRα receptors and this represents another likely 
mechanism for increasing coronary artery blood flow by decreasing coronary vascular tone 
(Taddei et al., 2003).   
Mitochondrial dysfunction plays a key role in the development of heart failure post MI (Ide et 
al., 1999; Ikeuchi et al., 2005).  T3 administration has been shown to rescue mitochondrial 
function and therefore prevent cardiac remodelling as well as reduce myocyte apoptosis in a 
post ischemic rat model (Forini et al., 2011; Nicolini et al., 2013).  The cardioprotective 
mechanisms of T3 on mitochondria is through generating an antioxidant response and 
controlling the calcium flux into the myocardium which prevents the development of heart 
failure. The beneficial effect of thyroid hormones through SERCA activation has to be weighed 
against actions on mitochondrial oxygen demand, because SERCA is one of the most sensitive 
enzymes to ATP depletion. Therefore, mitochondrial dysfunction during ischaemia–
reperfusion could undermine calcium removal by SERCA and affect myocyte function (Willis 
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et al., 2015).  T3 also activates important pathways such as the mitochondrial ATP-sensitive K 
channels (mitoKATP) pathway, peroxisome proliferator-activated receptor gamma  
coactivator1-alpha, and the mitochondrial transcription factor A.  This results in an increased 
expression of factors involved in mitochondrial DNA transcription such as HIF-1α and 
mitochondrial transcription factor A (mtTFA).   An overexpression of mtTFA has shown to 
increase mitochondrial DNA and inhibit LV remodelling post AMI whereas a reduction in 
mtTFA causes mitochondrial dysfunction and attenuates cardiac failure (Wang et al., 1999; 
Ikeuchi et al., 2005).  By targeting the expression of mtTFA, mitochondrial DNA and 
mitochondrial electron transport system can be restored which reduces myocardial oxidative 
stress.  The mitoKATP pathway is also an important pathway for myocardial protection with 
T3 being shown to protect myocytes against oxidative stress (Ardehali et al., 2005; Forini et 
al., 2011) (Figure 1-11).  One study has shown T3 induced cardiprotection via the mitoKATP 
pathway in cardiomycoytes exposed to hydrogen peroxide (Forini et al., 2011).  Therefore the 
mitoKATP pathway could be a key target for preventing cardiomyocyte cell death secondary 
to oxidative stress. 
The TH system has multiple roles in maintaining mitochondrial integrity. Thyroid hormones 
are critical regulators of tumour suppressor protein p53 a protein that accumulates within the 
myocardium in the acute phase of MI leading to apoptosis (Figure 1-11). Experimental studies 
have shown that the intracellular increase in p53 in cardiomyocytes is more pronounced in rats 
developing low T3 syndrome early after AMI than in those without low T3 syndrome (Forini 
et al., 2014).  Early T3 administration blunts the increase of p53 levels in the AMI border zone 
after ischaemia–reperfusion, and this effect is associated with preserved mitochondrial 
function, decreased apoptosis, and reduced extent of necrosis (premature cell death) in the 






Figure 1-11 Main mechanisms of mitochondrial preservation and cardiomyocyte protection. 
Ischaemic reperfusion (IR) causes myocyte injury by decreasing ATP, increasing intracellular 
calcium and reactive oxygen species.  This insult is further enhanced by p53 and low T3 which 
leads to mitochondrial dependent apoptosis.  Increasing TH levels leads to 1) opening of the 
protective mitoKATP channel 2) increasing mitochondrial biogenesis via mtTFA which leads 
to mitochondrial DNA transcription 3) reducing p53 levels post ischaemic reperfusion injury 
by inhibiting miRNA involved in production. From: Pingitore et al, Cardioprotection and 
thyroid hormones. Heart Fail Rev. 2016;21(4):391-9 (Pingitore et al., 2016). 
  
 
1.3.6 Thyroid hormones and apoptosis 
Controlling survival signalling pathways which prevent myocyte apoptosis and preserve 
myocytes can reduce the severity of heart failure (Figure 1-12).  The AKT/PKB pathway is an 
important survival signalling pathway which reduces apoptosis in hypoxia and ischaemia 
reperfusion to improve cardiomyocyte function (Matsui et al., 1999; Fujio et al., 2000; Matsui 
et al., 2001).  Furthermore T3 administration activates the PKB pathway in serum starved 
myocytes to protect against cell death as well as activating the pathway in the area affected by 
myocardial infarction to reduce apoptosis (Kuzman et al., 2005; Chen et al., 2008).  The AKT 
pathway is also important for physiological hypertrophy.  Hypertrophy of surviving 
cardiomyocytes is an integral part in cardiac remodelling.  Cardiac hypertrophy develops as a 
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result of different signalling pathways which should be targeted in order to prevent pathological 
hypertrophy which is associated with changes in extracellular matrix composition, myocardial 
fibrosis and impaired capillary growth (Walsh, 2006; Nicolini et al., 2013).  TH activates 
PI3K/AKT (phosphatidylinositol 3′ kinase/protein kinase B) and 2 GSK3β (glycogen synthase 
kinase 3 beta) which have a role in normal physiological hypertrophy by reducing fibrosis, 
increasing vascular growth and activating genes which code for key regulatory proteins 
(DeBosch et al., 2006; Maillet et al., 2013).   
TH also has an important role in ischaemic reperfusion injury with the administration of T3 
during the reperfusion period reducing myocyte apoptosis via the PKB pathway resulting in 
cardioprotection (Pantos et al., 2009a).  TH can also protect against ischaemia-reperfusion via 
heat shock proteins.  Heat shock protein 27 (HSP27) is an important cytoskeletal protein which 
becomes increasingly expressed, secondary to TH, in the cytoskeleton during ischaemic stress 
and therefore increasing tolerance to ischaemia (Pantos et al., 2003a) whereas heat shock 
protein 70 (HSP70) expression is associated with decreased p38 MAPK activation in an 









Figure 1-12 The translational effect of thyroid hormones on cardioprotection: from 

















1.4 Clinical studies involving thyroid hormones and cardiovascular disease 
1.4.1 Clinical outcomes of SCH in cardiovascular disease 
A number of observational studies have shown individuals with subclinical hypothyroidism to 
have an increased risk for cardiovascular disease (Hak et al., 2000; Imaizumi et al., 2004; 
Walsh et al., 2005; Iervasi et al., 2007).  The Whickham Survey evaluated cardiovascular 
events in a population cohort over 20 years and found SCH to be associated with increased 
cardiovascular events and mortality and subsequent treatment of SCH with levothyroxine 
improved such outcomes (Razvi et al., 2010).  Walsh et al showed SCH to be a strong 
independent risk factor for coronary heart disease whereas Hak et al in the Rotterdam Study 
demonstrated those with SCH were more likely to have a myocardial infarction and 
calcification of the aorta (Hak et al., 2000; Walsh et al., 2005).  These findings are supported 
by a meta-analysis which shows the association of SCH with an increased risk of coronary 
heart disease (Rodondi et al., 2006).  
Not all prospective cohort studies have shown a link between SCH and cardiovascular disease 
(Rodondi et al., 2005; Cappola et al., 2006).  This is likely due to such studies including a 
population age group whom were significantly older and above the age of 65 whereas other 
studies which did show a significant difference included a younger age group.  Age variation 
and cardiovascular risk in SCH is supported by a study in Denmark which showed the risk to 
be only significant in those people less than 50 (Kvetny et al., 2004).  Furthermore, a 
retrospective study of patients from the United Kingdom General Practitioner Research 
Database showed that treatment of SCH with levothyroxine in healthy individuals was 
associated with fewer IHD events in younger individuals but this was not evident in older 
people (Razvi et al., 2012).  This further supports the view of SCH being a risk factor in the 
younger age group.  A patient-level meta-analysis by Rodondi et al of 55,287 participants from 
11 prospective cohort studies showed SCH to be associated with coronary heart disease and 
mortality in those with higher TSH levels>10 whereas a mild increase in TSH was not 
associated with CHD (Rodondi et al., 2010).   
Studies relating to heart failure and SCH have shown such patients to be more likely 
hospitalised and have a worse prognosis in comparison to euthyroid patients (Iacoviello et al., 
2008; Rodondi et al., 2008; Silva-Tinoco et al., 2011).  The Health, Aging, Body Composition 
population-based study showed elderly patients with a TSH>7 to have an increased risk of 
developing CCF in comparison to euthyroid individuals (Rodondi et al., 2005).  In an analysis 
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of more than 3000 participants aged 65 years or more without heart failure at baseline, who 
were followed up for 12 years in the Cardiovascular Health Study, showed that SCH subjects 
treated with levothyroxine had a 72% reduction in heart failure events and furthermore, a TSH 
above 10mu/L was associated with a higher risk for heart failure (Rodondi et al., 2008).  This 
is supported by the Prosper Study which was a prospective cohort study assessing the link 
between SCH and heart failure.  Prosper showed subjects with SCH were more likely to be 
hospitalised for heart failure and once again heart failure was higher in subjects with TSH 
greater than 10 (Nanchen et al., 2012).  Previous observational studies have also shown SCH 
to be associated with worse cardiovascular outcomes including mortality in patients with acute 
cardiovascular disease (Iervasi et al., 2007; Rodondi et al., 2010; McQuade et al., 2011; 
Molinaro et al., 2012; Rhee et al., 2017; Seo et al., 2018). 
In summary, despite known cardiovascular risks of SCH, there is not enough evidence for 
treating all patients at present due to current data being from observational studies or from 
small interventional trials with cardiac risk factor change as outcomes.  For this reason 
randomised controlled trials are needed to evaluate the benefits of treating SCH in reducing 
cardiovascular risk.  In the meantime, it may be beneficial to treat SCH patients who are at high 
risk of cardiovascular disease or those that may have evidence of cardiac impairment on 
imaging.  Current data suggests treatment of SCH is likely to be more beneficial in younger 
patients than the elderly however more studies are needed to ascertain the risks or benefits of 
thyroxine treatment in the elderly with SCH.  Further studies are needed to assess the outcomes 
of patients with SCH post myocardial infarction. 
 
1.4.2 Low thyroid hormones in myocardial infarction and the role of inflammation 
Within hours of an acute illness, the changes in thyroid hormone levels are referred to as non-
thyroidal illness (NTI).  The most common abnormality is a reduction in T3 whereas in unwell 
patients T4 also decreases.  Both a low T4 and T3, which are sustained, are associated with a 
worse prognosis in NTI (Fliers et al., 2015). A reduction in TH levels post MI may be 
considered beneficial by lowering oxygen consumption and energy requirements in the injured 
myocardium however; the net effect on the heart may still be detrimental due to the role of TH 
in LV remodelling post MI. A decrease in TH levels post myocardial infarction is related to 
increased cytokine expression, decreased expression of deiodinase 1 enzyme (D1) and 
increased expression of deiodinase 3 enzyme (D3).  Three studies in patients post AMI showed 
both interleukin-6 (IL-6) and interleukin-10 (IL-10) to increase post AMI which correlated 
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significantly with low TH levels (Kimura et al., 2000; Nishino et al., 2000; Kimur et al., 2001).  
Kimur et al showed how subjects post AMI had lower TH levels in comparison to healthy 
controls whereas the levels of IL-6 and IL-10 were significantly higher and correlated with low 
FT3 levels (Kimur et al., 2001).  In a study by Kimura et al, all patients post AMI had an 
elevated IL-6 and low concentrations of TH, compared to controls, and the mechanism of 
action was via glycoprotein (gp) 120 receptors (Kimura et al., 2000).  Cytokines such as IL-1 
and IL-6 decrease TH by inhibiting D1 activity and competing for receptor coactivators leading 
to decrease conversion of T4 to T3 (Yu and Koenig, 2000).   TNFα is also upregulated in AMI 
and has been shown to increase IL-6 in ischaemia-reperfusion and in the viable border area of 
the myocardium further supporting the role of cytokines in decreasing TH (Hirschl et al., 1996).  
This decrease in TH is considered to be protective by decreasing energy consumption as has 
previously been discussed but can be maladaptive in the long term if not reversed.   
TH signalling can also be impaired post AMI due to an increase in D3 activity.   A study by 
Wassen et al, in a rat model of right ventricular (RV) failure and hypertrophy, demonstrated 
how D3 activity was increased in the overloaded RV with no change in the normal functioning 
LV.  Furthermore D3 activity was increased in the RV of rats with heart failure compared to 
those with hypertrophy alone (Wassen et al., 2002). The largest clinical study assessing the 
relationship between increased D3 activity and low TH levels in pathological states was 
conducted in intensive care patients by Peeters et al who showed such changes to occur locally 
within the heart and at the systemic level (Peeters et al., 2003). These studies show how 
markers of inflammation and deiodinase enzymes make the heart hypothyroid post myocardial 
infarction by reducing the availability of T3.   
 
1.4.3 Clinical studies investigating thyroid hormones in AMI 
Experimental studies have shown enough evidence of how a low TH which does not reverse in 
cardiac disease is maladaptive rather than adaptive and can lead to a reduction in LV function 
post AMI.  In comparison to other organs, the heart is unique and more susceptible to a 
reduction in TH in the circulation as cardiomyocytes have reduced ability in converting T4 to 
T3 (Klein and Danzi, 2007; Gerdes and Iervasi, 2010).  Therefore even mild changes in 
circulating TH can make the heart relatively hypothyroid at times when TH will be required to 
repair the myocardium.  This may explain the high mortality amongst patients who have SCH 
and cardiovascular disease (Rodondi et al., 2010; Molinaro et al., 2012), low T3 and heart 
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failure (Hamilton et al., 1990; Pingitore et al., 2005) and in patients with low T3 who are 
undergoing CABG (Holland et al., 1991; Cerillo et al., 2014).  
Previous observational studies have shown SCH to be associated with worse outcomes 
including mortality in patients admitted with cardiovascular disease including AMI (Iervasi et 
al., 2007; Rodondi et al., 2010; Molinaro et al., 2012; Seo et al., 2018).  Iervasi and colleagues 
found cardiac patients with SCH (6.7% of the total cohort) and low circulating T3 levels 
(29.2%) to have a higher risk of cardiovascular and all-cause mortality than euthyroid 
individuals within a large cohort of patients admitted with cardiac events (Iervasi et al., 2007).  
SCH after admission for an acute cardiac problem has been associated with an up to 3.6 fold 
increase in cardiac mortality and a 2.3 fold increase in overall death (Molinaro et al., 2012).  In 
another study of AMI patients followed for 3.5 years post coronary intervention, patients with 
SCH had a worse outcome including mortality; with TSH being a very strong predictor for all-
cause mortality (Seo et al., 2018).  A prospective study by Friberg et al showed T3 levels to 
rapidly decline within a week after an AMI whereas in another study by Friberg, in-hospital 
and post discharge mortality was higher in patients with the most suppressed TH levels post 
AMI (Friberg et al., 2001; Friberg et al., 2002).  In a study by Zhang et al, 501 patients had 
TFTs measured post AMI with 171 patients having a low T3.  During a 1 year follow-up, 
patients with low FT3 had a higher mortality in comparison to euthyroid patients indicating 
how low TH levels post AMI are predictor of short-term and long-term poor prognoses (Zhang 
et al., 2012). A further study showed a low T3 in up to 20% of patients below the age of 75 
with an AMI and such patients were shown to have a lower survival rate despite percutaneous 
coronary intervention, further supporting the role of TH in myocardial recovery (Lazzeri et al., 
2012).  Two further studies have shown a higher mortality in patients with a low T3 post AMI 
in comparison to euthyroid patients (Pavlou et al., 2002; Iervasi et al., 2003).  In Iervasi’s 
study, 173 of the 573 consecutive cardiac patients had a low T3 compared to 400 patients with 
normal thyroid function.  At 1 year, 25 deaths occurred in the low T3 group compared to 12 in 
the euthyroid group with low TH levels being the biggest predictor of mortality on multivariate 
analysis.  Furthermore TH were lower in patients developing heart failure and progressing to 
death post AMI (Iervasi et al., 2003).  Imaging studies have shown how a low T3 post AMI is 
associated with a worse cardiac function (Ceremuzynski et al., 2004; Lymvaios et al., 2011).  
In one study, the 48 hour post percutaneous coronary intervention LV function strongly 
correlated with serum TH whereas at 6 months an improvement in LV function correlated with 
an improvement in TH levels (Lymvaios et al., 2011).  Low TH has also been shown to 
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correlate with the severity of coronary artery disease on angiography as well as cardiac 
mortality indicating that a reduction in TH is not only associated with a worse outcome post 
MI but may also be a risk factor for ischaemic heart disease as has previously been discussed 
(Auer et al., 2003; Coceani et al., 2009).  In the study by Coceani et al, patients with suspected 
coronary artery disease (CAD) who were having angiography had their TH measured to see if 
there was a relationship with disease burden on angiography (Coceani et al., 2009).  The study 
showed individuals with CAD on angiography to have lower T3 levels in comparison to those 
who did not have CAD, with free T3 being a significant predictor of CAD using multivariate 
logistic regression.   The level of T3 was not statistically significant between patients who had 
single and multi-vessel disease (Coceani et al., 2009).  From all these studies it is difficult to 
illicit whether low TH levels contribute to disease progression or are a consequence of disease 
severity.  Factors favouring the former view include T3 being the active form of thyroid 
hormone and therefore a low T3 state could be a risk factor for CAD as are both hypothyroidism 
and subclinical hypothyroidism which are known to be associated endothelial dysfunction, 
hyperlipidaemia, cardiac dysfunction and thrombosis.  Unfortunately, the relationship between 
a low T3 state and such parameters has not been assessed previously as in both hypothyroidism 
and subclinical hypothyroidism.  This is further supported by an improvement in cardiovascular 
risk factors with thyroid therapy in patients with SCH.  These studies demonstrate how TH 
may also be used as a risk stratifier in patients with an AMI due to its correlation with disease 
burden on angiography, LV impairment on imaging as well as long-term mortality. 
There are limitations with all these studies.  Firstly, the timing of T3, T4 and TSH is not stated 
in most of these studies with such measurements taken only once.  Therefore these studies 
cannot account for variations in thyroid function over a period of time from an AMI.  For this 
reason we do not know whether a change in TH was due to sick euthyroid syndrome, in which 
TH levels normalise after a short time period, or due to a maladaptive response?  It is very 
likely that TH levels would have normalised days after an MI in some patients recruited to 
these studies.  Furthermore, AMI and CAD are not clearly specified in these studies making it 
difficult to ascertain if subjects were stable CAD patients or patients with chest pain and 
unstable symptoms characterised by troponin and ECG changes.  Therefore, there is always 
potential for selection bias and heterogeneity in all these studies.  In summary, despite 
acknowledging worse outcomes in patients with AMI who have supressed TH, current studies 
at present are either observational, retrospective or prospective studies.  For this reason 
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randomised controlled studies are necessary to investigate whether TH replacement can 
improve myocardial function and improve mortality outcomes in a clinical setting. 
 
1.4.4 Thyroid hormones and heart failure 
SCH and low T3 syndrome are the more frequent metabolic TH alterations in HF (Silva-Tinoco 
et al., 2011).  In particular low T3 syndrome occurs in almost 20-30 % of HF patients (Passino 
et al., 2009).  Low T3 syndrome and SCH have been associated with a worse prognosis in HF 
(Iervasi et al., 2003; Iervasi et al., 2007; Iacoviello et al., 2008).   
Studies have been conducted to assess the relationship between low TH and heart failure.  In 
one study, 21% patients with dilated cardiomyopathy had a low T3 which was associated with 
worse cardiac function on echocardiography.  All patients with a Ft3/ft4 ratio less than 1.7 had 
worse cardiac function, increased mortality or subsequently needed a shock from cardiac arrest 
whereas this was not the case with a ratio greater than 1.7 (Kozdag et al., 2005).  In a 
prospective study by Opasich et al the prevalence of low T3 in patients with severe heart failure 
being considered for heart transplantation was 18%.  Low T3 correlated with NYHA class as 
shown by 31% of patients in NYHA class 3 and 4 having low T3 compared to 7% in class 1 
and 2.  Furthermore, mortality was higher in patients with low T3 in comparison to euthyroid 
subjects, 48% v 21% (Opasich et al., 1996).  This is supported by another study assessing the 
relationship between T3 and mortality in patients with both ischaemic and non-ischaemic 
dilated cardiomyopathy admitted to hospital.  In such patients ejection fraction (EF) and T3 
were the only dependent factors associated with mortality (Pingitore et al., 2005).   In another 
study looking at ambulatory patients with heart failure with an ejection fraction (EF) of less 
than 35, the prevalence of patients with a low T3 was 34% which correlated with a worse 
NYHA class and disease severity (Ascheim and Hryniewicz, 2002).    
Similar results have been sought for studies evaluating the prognostic role of SCH in heart 
failure.  In stable heart failure patients followed up for 1-2 years, serum TSH was considered a 
stronger variable than T3 in heart failure progression as measured by echocardiography and B 
natriuretic peptide (BNP).  Even slight changes in TSH resulted in worse outcomes as shown 
in subjects with heart failure progression who had an average TSH of 4.8 compared to 2.2 in 
those who remained stable (Iacoviello et al., 2008).  The Health, Aging, Body Composition 
population-based study also showed that elderly patients with a TSH>7 had an increased risk 
of developing heart failure in comparison to euthyroid individuals (Rodondi et al., 2005).  
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Iervasi et al in a retrospective study assessed the effects of subclinical thyroid disease on 
cardiac outcomes in patients who had known cardiac disease.  The study showed that survival 
rates and overall death was higher in subclinical thyroid disease and low T3 syndrome 
compared to euthryroidism (Iervasi et al., 2007).    
Although these studies have shown the association between a low thyroid state and a worse 
prognosis in patients with heart disease, there are limitations to take into account.  Firstly, in 
many of these studies thyroid function tests were performed only once making it difficult to 
ascertain how many of these patients had sick euthyroid syndrome and how many patients with 
mild hypothyroidism may have progressed to overt hypothyroidism which needed treating.  
Other limitations include exclusion of patients with acute cardiac states such as myocardial 
infarction which itself increases mortality risk.  With some of these studies being retrospective, 
there is the potential for selection bias and misclassification of the causes of death based on 
death certificates which may not have been cardiac.  Finally, there is no differentiation to the 
different cardiac states in the studies meaning more serious cardiac disorders were likely 
associated with a low thyroid state and that disease severity rather than thyroid state resulted 
in worse outcomes in some patients. 
 
1.4.5 Thyroid hormone therapy in heart failure 
Studies have also examined the effects of TH therapy in heart failure.  Moruzzi and colleagues 
investigated both the short and medium term effects of levothyroxine therapy in a small sample 
of patients with dilated cardiomyopathy.  Giving short-term levothyroxine improved LVEF, 
improved cardiac exercise ability, decreased diastolic dimensions and SVR without causing 
adverse side effects.  Both the cardiac and exercise ability of patients were increased without 
changes in adrenergic support (Moruzzi et al., 1994).  In another study, similar changes were 
observed with medium-term levothyroxine therapy over a period of 3 months with an increase 
in EF% and cardiac output, a decrease in ventricular diastolic dimensions and SVR, and an 
enhance response of cardiac output and heart rate to a dolbutamine infusion.  Surprisingly 
despite the levels of thyroxine increasing, patients did not show symptoms or features of 
hyperthyroidism as shown by the findings (Moruzzi et al., 1996).  Pingitore et al showed a low 
T3 to be associated with a higher mortality in patients with dilated cardiomyopathy and 
therefore the short term effects of TH replacement in patients with low T3 and dilated 
cardiomyopathy were investigated in this randomised, placebo-controlled study. TH 
replacement improved ventricular performance as shown by an increase in stroke volume and 
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there were no side effects such as arrhythmias or haemodynamic compromise.  Furthermore, 
the neuroendocrine profile significantly improved with a reduction in aldosterone, BNP and 
IL-6 levels (Pingitore et al., 2005; Pingitore et al., 2008).  In a prospective study by Hamilton 
et al, low T3 was an increased predictor of mortality in patients with CCF.  The 1 year survival 
in subjects with a normal T3/reverse T3 ratio of 100% compared to 37% in those with low ratio 
(Hamilton et al., 1990).  In a second study, the safety and haemodynamic effects of intravenous 
triiodothyronine was assessed in patients with congestive cardiac failure.  Triiodothyronine 
was well tolerated with no adverse effects such as arrhythmias or ischaemia.  Cardiac output 























2 Chapter: Hypothesis and aims 
2.1 Hypothesis 
Treating SCH with levothyroxine following an AMI improves left ventricular systolic function, 
thrombus area, endothelial function, health status, quality of life and is safe. 
 
2.2 Aims 
There is enough evidence to state that even minor changes in TH concentration may impact 
adversely on the cardiovascular system.  SCH affects both endothelial function and cardiac 
function in healthy individuals and is likely to be prothrombotic.  Furthermore, several 
observational studies have demonstrated that SCH in high-risk patients is associated with worse 
cardiovascular outcomes.  This apparent increased risk could be due to the fact that both the 
pathogenesis of atherosclerosis, and recovery and myocardial-repair after AMI are influenced 
by TH levels. Much research on SCH and cardiovascular disease has focussed on large 
population studies and there is no RCT to date investigating the effect of thyroid hormone 
therapy in patients post AMI, when repair and recovery of myocytes is essential to prevent 
pathological remodelling.   
This study was therefore designed with the following aims in mind: 
1. To perform a prospective longitudinal observational study to investigate the prevalence of 
thyroid dysfunction in patients presenting with AMI and its association with troponin levels. 
2. To assess the association between thyroid dysfunction post AMI and long term mortality. 
3. To perform a double-blind placebo-controlled trial of levothyroxine treatment in 
patients with SCH post AMI, in an adequately powered sample to detect a significant 
difference on left ventricular systolic function with LT4 versus placebo. 
4. To determine the effect of LT4 therapy on endothelial function, platelet dependent 
thrombus, viscoelastic properties of thrombus and platelet reactivity in SCH post AMI. 








3 Chapter: Methods 
3.1 General methods 
3.1.1 Study design 
The study was divided into two parts ThyrAMI 1 and ThyrAMI 2 
ThyrAMI 1 - This was a prospective longitudinal observational study of patients with AMI 
(both ST-elevation AMI and non-ST-elevation AMI) that were followed up to study the 
association between thyroid status at the time of AMI (within 24 hours of diagnosis) with long-
term mortality. 
ThyrAMI 2 - This study was a double blinded, randomised placebo-controlled trial of 
levothyroxine of 12 months duration in patients with SCH (serum TSH persistently 4.01 to 
10.0 mU/l, normal FT4) starting within 21 days following AMI. The day of AMI was the date 
of diagnosis or the date of admission to hospital, whichever was later. 
 
3.1.2 Primary outcome measure 
ThyrAMI 1 - The primary outcomes were the prevalence of thyroid dysfunction in patients 
presenting with AMI and the association between thyroid status at the time of AMI (within 24 
hours of diagnosis) with markers of severity of AMI and subsequent all-cause mortality. 
ThyrAMI 2 - The primary outcome measure was a change in LV ejection fraction as assessed 
by magnetic resonance imaging.   
 
3.1.3 Secondary outcome measure ThyrAMI 2 
I. Left ventricular systolic and end diastolic volumes and myocardial viability assessed 
by cardiac MR imaging. 
II. Thrombus burden measured by the Badimon chamber, a highly reproducible clinical ex 
vivo model of thrombosis that mimics flow conditions within the coronary circulation 
of man.  
III. Efficiency and quality of ex vivo thrombus formation utilising Thromboelastography 
(TEG™), a noninvasive measure. Quantitative measures include clotting time 
parameters, clot strength and clot lysis were also measured.  These parameters have 
been validated as highly correlated with longer-term cardiac outcomes in several 
conditions of risk.  
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IV. Endothelial function assessed by measuring peripheral arterial tone using a validated 
tool, EndoPAT™. Endothelial function assessment using the EndoPAT™ has been 
shown to have a high degree of correlation with coronary artery endothelial function, 
the severity and extent of coronary artery disease, and traditional cardiovascular risk 
factors and is useful in predicting future cardiovascular events.  
V. Platelet reactivity: The reactivity (inhibition) of platelets to anti-platelet agents such as 
aspirin, clopidogrel, prasugrel and ticagrelor were quantified by the point-of-care 
monitor VerifyNow™ (Accumetrics, CA, USA).  
VI. Safety assessments: The safety of levothyroxine therapy in post-AMI patients was 
assessed at each study visit by enquiry of symptoms by New York Heart Assessment 
(NYHA) category classification, ECG recording for rhythm disturbance and adverse 
and serious adverse events during the course of the study.  
 
3.1.4 Participant population 
ThyrAMI 1 
I. Inclusion criteria 
1. Adult males and females (aged 18 years or older). 
2. Acute myocardial infarction diagnosed in the preceding 24 hours (defined as chest 
pain with dynamic ECG changes or increased troponin enzymes (at least a fourfold 
increase above the local laboratory reference range). 
3. Participants in other research studies were eligible for inclusion as this is an 
observational study. 
II. Exclusion criteria 
1. Patients who were unable to provide informed consent. 
2. Those with advanced malignancy (who were unlikely to survive for more than 
6 months in the opinion of local investigator). 
3. Those on medications that can affect thyroid function such as amiodarone, 
lithium, carbimazole and propylthiouracil. Patients on levothyroxine will be 








I. Inclusion criteria: 
1. Males and females aged between above the age of 18. 
2. Serum TSH ≥4.01 mU/L with normal free thyroxine levels (9 to 25 pmol/L) on 
two occasions with at least one TSH result between 4.01 to 10.00 mU/L (on day 
of admission for AMI and 7 to 10 days after AMI). 
3. Acute myocardial infarction diagnosed on admission to hospital (chest pain with 
dynamic ECG changes or increase troponin enzymes (at least a fourfold increase 
above the laboratory reference range). 
II. Exclusion criteria: 
1. Patients on medications that affect thyroid function (levothyroxine, 
carbimazole, propylthiouracil, amiodarone, lithium). 
2. Patients who were unable to provide written informed consent. 
3. Patients with advanced malignancy (who, in the opinion of the investigator, are 
unlikely to survive for more than 6 months). 
4. Patients with sustained ventricular tachycardia requiring treatment that occurs 
>24 hrs after myocardial reperfusion/revascularisation. 
5. Patients who had contra-indications to MR scanning (cardiac pacemaker, 
metallic heart valves, cochlear implants, coronary artery stents incompatible 
with MR scanning, etcetera). 
6. Patients who were unlikely or unwilling, in the opinion of the investigator, to 
attend for study-specific visits. 
7. Participants whose serum TSH is >10.0 on both occasions or <4.0 on either 
occasion. 
8. Patients who are already participating in another interventional study. 
 
3.1.5 Screening and recruitment, consent, and biochemical analysis 
i. Screening and recruitment 
Eligible participants were identified from the cardiology units of acute hospitals in the North 
of England (Gateshead, Newcastle, Sunderland, North Tyneside, Leeds and Middlesbrough).  
The Freeman Hospital in Newcastle was the biggest site for recruitment to the study.  All 
individuals who met the study inclusion and exclusion criteria for ThyrAMI 1 had their thyroid 
function checked, after informed consent was obtained, within 24 hours of diagnosis of AMI.  
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A 24 hour timeframe post AMI was used to prevent the influence of sick euthyroidism on 
thyroid function, which usually takes place with maximal changes between 24 and 36 hours 
(Friberg et al., 2002). Other blood tests, routinely performed post AMI such as total cholesterol, 
troponin T/troponin I and serum creatinine were also evaluated on admission. A troponin was 
repeated in all patients within 12 hours (median 6, range 3 – 12 hours) as per local clinical 
practice. Other variables measured on admission including demographic details, clinical 
features, and coronary angiographic findings and ischaemia time for STEMI patients.   
Of those patients that had TSH and FT4 levels within inclusion range were provided with a 
participant information sheet for ThyrAMI 2.  Furthermore, these individuals were invited to 
have a repeat thyroid blood test 7 to 10 days after the day of AMI (Figure 3-1).  The day of 
AMI was the date of diagnosis or the date of admission to the hospital, whichever was later.  
Those individuals who had a TSH and FT4 levels within the inclusion range on the second 
occasion were asked to participate in ThyrAMI 2 and sign the consent form.  Those who did 
not attend for their second visit blood test were contacted to enquire whether they are still 
interested in participating.  Ethical approval was granted by the UK National Research Ethics 
Service (Ref: 14/NE/0151).  The study was conducted as per the guidelines outlined in the 
Helsinki Declaration, and patients had the right to refuse to take part in the study and 
furthermore could withdraw anytime without giving a reason. 
Once a participant had thyroid blood results that were within the desired range for inclusion in 
the study on two occasions and had consented to participate in the RCT, the study team 
arranged a convenient date and time for the baseline tests and randomisation to the treatment 








Figure 3-1 Flow chart representing ThyrAMI 1 observational study and identification of 
potential cohort for the interventional trial ThyrAMI 2. 
 
 
ii. Consent procedures 
All informed consent discussions were undertaken with an opportunity for participants 
to ask any questions. Following receipt of information about the study (that is, provision 
of the patient information sheets), participants were given reasonable time to decide 
whether or not they wanted to participate.  Those wishing to take part provided written 
informed consent by signing and dating the study consent form and initialling the 
relevant sections, which was witnessed and dated by myself.   
The original signed consent form was retained in the Investigator Site File, with a copy 
in the relevant clinical notes and a copy provided to the participant.  The participant 
consented to their GP being informed of their participation in the study.  The right to 
refuse to participate without giving reasons was respected.  The information sheet and 
consent form for the study were available only in English. Participants who lacked 





Informed consent and first 
blood tests for TFTs
If TSH >4.0 mU/L and FT4 
9 to 25 pmol/L, blood tests 
were repeated in 7-10 days  
If repeat TSH >4.0 mU/L 
and FT4 9 to 25 pmol/L, 
then participant was 
candidate for ThyrAMI 2 
If both TSH >10 mU/L, or 
repeat TSH ≤4.0 then 
excluded from ThyrAMI 2
If TSH ≤4.0 mU/L, then 




iii. Biochemical analysis 
Biochemistry: Serum TSH, FT4 FT3, high sensitive (hs) troponin T, troponin I, total 
cholesterol, and urea and electrolytes were analysed using the Roche assay (Roche 
cobas, Roche Diagnostics UK).  At two of the sites, the same analytes were measured 
by the Advia Centaur immunoassay (Siemens Healthineers, Surrey, UK).  Reference 
ranges were as follows: TSH (0.4 - 4.0 mU/L), FT4 (9.0 - 25.0 pmol/L), FT3 (3.0 - 7.0 
pmol/L), hs troponin T (0 - 14 ng/L), hs troponin I (0-45 ng/L), creatinine (70 - 110 
mol/L), total cholesterol (0 - 4.5 mmol/L). Anti-thyroid peroxidase antibodies 
(TPOAb) were measured by the Roche immunoassay and levels below 35 mU/L were 
classed as negative. 
 
3.1.6 Study specific procedures undertaken by participants 
For patients meeting the study criteria for the RCT, a visit to the Clinical Research Facility 
(CRF) was arranged, with the tests including: the Badimon chamber, EndoPAT, VerifyNow 
and TEG.  Either on the same day or on a separate day, patients also had a visit to the Cardiac 
MRI Centre, Newcastle University, where the cardiac MRI was performed.  All these tests 
were performed within 21 days of the MI.  Each patient was randomised the previous day to 
enable the investigational medicinal product (IMP) to be collected and assigned to the 
participant. 
For the CRF tests, patients attended having fasted from midnight which included not taking 
their morning medications till the initial tests had been completed. The patients’ understanding 
of the study was checked and any final queries or questions were answered.  The baseline 
demographic data including blood pressure, height, and weight were recorded.  The first test to 
be performed was EndoPAT and this was followed by the Badimon chamber.  Prior to starting 
the chamber, patients had bloods taken for the VerifyNow, TEG and storage of the serum and 
plasma by the biochemistry laboratory for later date analysis.  Participants were then given 
breakfast.  Patients were then transferred to the MRI Centre for their cardiac MRI.  
Alternatively, some patients opted to have the scan on a separate day.  After completion of all 
baseline tests, the study medication was given to the patient with strict instructions to take one 
capsule daily on an empty stomach 30mins before breakfast.  A wallet sized card was also 
provided containing emergency contact details for both the principal investigator and myself.   
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Patients were seen for visits 2, 3, and 4 on a monthly basis during which their blood pressure 
was taken, ECG performed and changes in other medications or medication dose verified.  
Compliance to the IMP was also assessed with the number of capsules left being counted.  
Importantly, patients were asked about any adverse events with serious adverse events being 
reported to the trial manager within 24 hours (Figure 3-2).  A blood test was taken to recheck 
the thyroid level as this determined whether patients needed a slight change in dose of 
levothyroxine if they were in the active group.  The blood was taken to biochemistry 
department for analysis with the result being sent to the independent physician who confirmed 
the next dose on the Randomisation system, at the Newcastle Clinical Trials Unit.  I was 
notified by email regarding confirmation that the next bottle was ready to be issued.  A 
pharmacy script was generated from the Randomisation system to give to pharmacy who 
usually issued the bottle on the same day.  This was then delivered to the patient.  Visit 5 took 
place three months after visit 4 (6 months into the study).  All patients were seen 52 weeks 






Figure 3-2  Flow chart representing the ThyrAMI 2 RCT study 
 
 
3.1.7 Data collection and outcome assessments 
The schedule of events for ThyrAMI-2 were as follow: 
      Visit 1A (7 – 10 days post AMI) 
The following procedures and assessments and carried out at the screening visit: 
 Written informed consent 
 Physical examination: Height in cm (or participant reported if apparatus not available), 
Weight (kg), Blood pressure (mm/Hg), Pulse rate (beats/minute). 
 Venipuncture: 20mls blood (TSH, Free T4, Free T3, TPO antibodies, Total cholesterol, 
HDL, Triglycerides).  
 Clinical history: (Relevant medical history, Medication list) 
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 Questionnaires (in the order stipulated below). If patients refused to answer certain 
questions, their wishes were respected. 
 SF-12: Participant completed 
 Minnesota Living With Heart Failure Questionnaire  
 CES-D questionnaire 
 ECG (12 lead) and NYHA classification 
 Visit 1B: (day 0) 
All recruited participants underwent the following at Newcastle Magnetic Resonance Centre, 
Newcastle University. 
 Cardiac MR scanning. 
   Visit 1C: (day 0) 
The following procedures and assessments were carried out at the baseline visit: 
 Badimon chamber, TEG®, VerifyNow® and EndoPat® analyses at Clinical Research 
Facility, Royal Victoria Infirmary. 
 
   Visits 2 - 5: Follow-up (weeks 4 - 24 +/- 7 days) 
The following procedures and assessments were carried out at visits 2 – 5 at either the local 
hospital or participant’s home: 
 Venepuncture: 5mls blood (TSH, Free T4, FT3). 
 Clinical History (Adverse event, Serious adverse events, changes to concomitant 
medication) 
 Safety assessments: ECG (rhythm only), NYHA classification assessment 
 Study Medication: 
               o Assessed LT4 dose according to dose titration guidelines 
               o Prescribed study medication (prescribed by independent blinded physician) 
               o Dispensed study medication  
               o Assessed compliance. 
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   Visit 6A: Follow-up (week 52 +/- 7 days) 
All participants underwent the following at Newcastle Magnetic Resonance Centre, Newcastle 
University. 
 Cardiac MR scanning 
  Visit 6B: 
 Badimon chamber, TEG®, VerifyNow® and EndoPat® analyses at Clinical Research 
Facility, Royal Victoria Infirmary. 
   Visit 6C: 
The following procedures and assessments were be carried out at the local hospital at this visit: 
 Physical examination: Weight (kg), Blood pressure (mm/Hg), Pulse rate (beats/minute). 
 Venepuncture: 20mls blood (TSH, Free T4, Free T3, Total cholesterol, HDL, 
Triglycerides) 
 Questionnaires (in the order stipulated below).  
       o SF-12: Participant completed  
       o Minnesota Living With Heart Failure Questionnaire  
       o CES-D questionnaire  
 ECG (12 lead) and NYHA classification  
 Clinical History (Adverse event, Serious adverse events, changes to concomitant 
medication). 
 Study Medication collected (see Section 17 for further details): 
      o Assessed compliance 
      o Assessed integrity of the blind 
 At this visit the study participants were asked to contact their General Practitioner to 





   Visit 7: Telephone follow-up (week 53 +/- 7 days) 
A telephone call was arranged by a member of the local study team to the participant to enquire 




3.1.8 Investigational medicinal product 
I. Intervention and control 
This was a double-blinded RCT study in which levothyroxine and placebo were used.  
Levothyroxine is the active investigational medicinal product (IMP) and was used to 
achieve a target TSH of 0.4 to 2.5 mU/L.  The placebo served as the control.  Both the 
levothyroxine and placebo were prepared and appeared the same to ensure blinding in 
accordance with the specifications of the Medicine Health Regulatory Authority 
(MHRA).  
The study drug was sourced, assembled and packaged by Newcastle Specials 
(Pharmacy Production Unit) at The Newcastle upon Tyne Hospitals NHS Foundation 
Trust, MIA (IMP) 17136.  The LT4 used in the study was the generic Levothyroxine 
25 mcg and 50 mcg tablets (Amdipharm Mercury Ltd).  This was provided in blister 
packs. 
The double-blind was achieved by de-blistering and over-encapsulation, using a capsule 
filler of Lactose BP.  For doses that were multiples of 50 mcg, we over-encapsulated 
Levothyroxine 50 mcg tablets; for the remaining 25 mcg, 75 mcg and 125 mcg dose 
increments, we over-encapsulated Levothyroxine 25 mcg tablets.  This ensured the 
capsule size was kept as small as possible for swallowing purposes.  Capsules were re-
packaged into an appropriate bottle container (polypropylene) and labelled. 
The side effects of LT4 (25 mcg and 50 mcg) are well known and documented ('EMC 
Mercury Pharmaceuticals. http://www.medicines.org.uk/emc/medicine/27213. 
Accessed 08 Nov 2014.,' ; 'EMC Mercury Pharmaceuticals. 
http://www.medicines.org.uk/emc/medicine/22557. Accessed 08 Nov 2014,'). The total 




II. Randomisation and Blinding 
Participants were randomised using a computerised randomisation algorithm, stratified 
by type of MI (NSTEMI versus STEMI), in a 1:1 ratio to levothyroxine therapy or 
placebo (as container or bottle numbers), starting within 21 (+/− 7) days of the AMI 
(date of diagnosis or the date of admission to hospital, whichever was later).  In 
addition, investigators were unaware of allocation and were blinded to treatment 
groupings. Randomisation was administered centrally via Newcastle Clinical Trials 
Unit using a secure password-protected web-based system. 
Assignment to either the LT4 or placebo arm was blinded to the participant as well as 
study team (double-blind).  Code break envelopes were available at the pharmacy at 
each site.  Study medication was prescribed by the study team at each site using a trial-
specific prescription (documenting the required IMP pack number), and dispensed 
according to local pharmacy practice. Independent study physicians, who were 
unblinded, adjusted study drug dose as per protocol. The relevant pharmacy held a 
corresponding list allowing pharmacy staff to correlate IMP pack number with relevant 
packaged IMP dose for any particular IMP bottle, thus maintaining the double-blind. 
 
III. Administration of the study drug 
Participants were randomised to either LT4 or placebo to be taken orally once daily.  
This was discussed with the patient at the time of consent and was made clear in the 
patient information sheet.  Initial starting dose of LT4 was 25 mcg daily.  To achieve 
the desired target TSH levels in the LT4-treated group (target TSH levels 0.4 to 2.5 
mU/L), participants had their TSH levels checked every 4 weeks and concomitant dose 
of their LT4 altered by 25 mcg daily, if required.  The IMP was provided as 5 week 
supplies of LT4 or matching placebo (dispensed separately at each visit), packaged into 
appropriate individual polypropylene bottles.  The label on the bottle did not indicate 
details of the arm of the study to which the participant had been randomised.   
Study medication was be prescribed by the PI or co-investigator at each site using a 
trial-specific prescription (documenting the required IMP pack number), and dispensed 
according to local pharmacy practice.  Independent study physicians who were 
unblinded adjusted the study drug dose as per protocol. The relevant pharmacy held a 
corresponding list allowing the pharmacy staff to correlate the IMP pack number with 
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relevant packaged IMP dose for any particular IMP bottle, thus maintaining the double-
blind. 
Participants were informed of potential adverse reactions and advised to contact the 
relevant study team if required. A study-specific participant contact card was provided 
to each participant. 
Once randomised, the participant began their study medication on Day 0. 
At 4, 8, 12 and 24 weeks (+/− 7 days), serum TSH levels were checked and LT4 doses 
adjusted as follows (the next bottle of IMP was started at week 4, 8, 12, 24 +/− 7 days, 
respectively): 
LT4 group: 
TSH 0.4 to 2.5 mU/L: Continue LT4 at current dose once daily 
TSH > 2.5 mU/L: LT4 increased by 25 mcg daily 
TSH < 0.4 mU/L: LT4 reduced by 25 mcg, or if already on 25 mcg daily (the lowest 
possible dose), then recheck TFTs in 4 weeks. If TSH is ≥0.4 mU/L then continue on 
current dose. Otherwise, if TSH continues to be <0.4 mU/L on the repeat blood test, 
then the participant will be withdrawn from the study. 
Placebo group: 
Individuals in this group received a fresh bottle of IMP starting at 4, 8, 12, 24 +/− 7 
days after blood tests to maintain the double blind. 
LT4 treatment based on the above regimen continued for a total of approximately 52 
weeks at which point the final set of study specific assessments were be made (with a 
further follow-up phone call at approximately 53 weeks).  If a participant in the placebo 
arm had a TSH >10 mU/L then their TFTs were rechecked in 4 weeks.  If, the TSH was 
≤10 mU/L on the repeat test then the participant continued with the study and, if, the 
TSH continued to be >10 mU/L then the participant was withdrawn from the study.  At 
the final visit, participants on each arm of the study stopped their IMP and were referred 
back to their GP to have their thyroid function checked in 6 to 12 weeks.  The GP and 
the patient were encouraged to discuss whether there was a need to commence LT4 
therapy in these individuals based on the clinical situation.  The GP letter (sent once the 
participant was randomised) and the GP follow-up letter (sent after each participant 
61 
 
completed their IMP) outlined the suggestion to recheck TSH levels at 6 to 12 weeks 
for each participant once they have completed their IMP. 
At the end of each visit, participants were asked to return any surplus study drug in the 
original packaging to the study team, who verified and documented compliance.  All 
unused study medication and packaging was sent to the local pharmacy for 
documentation and destruction as per local policy (following appropriate reconciliation 
by the Trial Manager). Documentation of prescribing, dispensing and return of study 
medication was maintained for study records. 
 
IV. The role of the independent clinical team 
In double-blinded randomised controlled trials, participants and investigators are 
unaware of intervention assignments throughout the trial.  In the ThyrAMI 2 RCT 
where dose adjustment of the active study drug took place, it was important that an 
independent study physician and at least two third party representatives, not directly 
involved within the trial, kept accurate documentation of each participant’s 
randomisation arm, the dose of active study medication prescribed, and thyroid function 
test results during the trial. 
For each randomised participant the independent study physician or third party 
representative created and stored a prescribing record which consisted of an excel 
spreadsheet for each participant detailing the centre number, the randomisation number, 
the trial arm to which the participant has been randomised, the thyroid function test 
result for each relevant study visit and the dose of medication prescribed according to 
TSH results for those on the interventional arm.  The prescribing records were stored 
on a separate computer drive at Gateshead which was password protected with access 
restricted to only the independent study physician and third party representatives 
Thyroid function tests (TFTs) were performed at 6 visits (visit 1a, 2, 3, 4, 5, 6c).  The 
participant’s blood sample for each study visit was sent to the Pathology Department in 
the local laboratory. After processing the sample, the Pathology Departments sent the 
results electronically to a generic e-mail address: thyrami@ghnt.nhs.uk.  Access to this 
e-mail account was restricted to the independent study Physician and the Third Party 
representatives.  The independent study physician or third party representative logged 
into the e-mail address at least once daily to assess participants’ blood results.   
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At Visit 1a the randomisation system allocated a bottle number corresponding to the 
stocks of study drug held at the recruiting site.   The dose of LT4 at this visit was 25mcgs 
once daily.   The study staff at each site logged into the computer system and generated 
the site specific prescription for the study drug.  The system automatically uploaded the 
required IMP pack number.   The study staff printed out the prescription and the PI or 
delegated individual at site signed the prescription and took to the hospital Pharmacy 
for dispensation.  At Visits 2,3,4,5 the independent study physician or third party 
representative adjusted the study drug dose if necessary.   If the participant had been 
allocated to the levothyroxine arm, participants with a TSH 0.4 – 2.5 mU/L continued 
LT4 at their current dose once daily.  With a TSH > 2.5mU/L, the LT4 dose was 
increased by 25mcgs once daily and if the TSH < 0.4 mU/L, the LT4 dose was reduced 
by 25mcgs once daily.  The maximum dose of LT4 to be prescribed was 150 mcgs once 
daily. 
At Visits 4 and 5 if a participant had a TSH level < 0.4 mU/L, and the LT4 dose 
prescribed was currently 25mcgs once daily then the TFTs were checked in 4 weeks 
and the independent study physician emailed the study staff at each individual site with 
a standard e-mail.   If the TSH level subsequently raised to ≥0.4mU/L then LT4 25mcgs 
once daily was to be continued.  If the repeat TSH level remained <0.4mU/L the 
independent study physician or third party representative informed the chief 
investigator and the principal investigator at the relevant study site with a standard e-
mail.  If a participant in the placebo arm has a TSH >10 mU/L then their TFTs were 
rechecked in 4 weeks and the independent study physician emailed the study staff at 
each individual site with a standard e-mail.  If the TSH is ≤10 mU/L on the repeat test 
then the participant continued with the study and, if, the TSH continued to be >10 mU/L 
then the participant was withdrawn from the study.  The independent study physician 
or third party representative informed the chief investigator and the principal 
investigator at the relevant study site with a standard e-mail. 
The third party representative checked all blood results and allocation of study drug 
bottles and doses to the participant.  In the absence of the independent physician, the 
third party representative performed the above functions.   For the LT4 arm, if the third 
party representative had any queries in regard to the dose of LT4, advice from the CI, 
PI or research fellow were sought as long as blinding was maintained.  Advice gathered 
was recorded in the file stored by the independent study physician. 
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3.1.9 Statistical methods 
Left ventricular ejection fraction (LVEF) is considered to be the strongest predictor for adverse 
outcomes after an acute myocardial infarction (AMI). Previous randomised trials in patients 
with AMI and a significant improvement in ventricular ejection fraction demonstrated 
concurrent absolute differences in LVEF of 3 percentage points or more (Sharpe et al., 1991; 
Doughty et al., 2004).  The ThyrAMI 2 study was designed with 90% power to detect an overall 
difference of 3% in LVEF between the two groups (3% improvement in the placebo group and 
6% in the LT4 group) 12 months after AMI, at a two-sided significance level of 5%.  Using 
ANCOVA (differences in change in EF from baseline between placebo and LT4 taking into 
account variability in the baseline with correlation between baseline and follow-up of 0.75), 
we calculated that 47 patients would need to be enrolled in each group, allowing for a 10% 
drop-out. 
Statistical analyses: For baseline characteristics, categorical data are expressed as numbers and 
percentages and compared using the Chi squared test. Continuous variables are expressed as 
mean±SD and were compared using unpaired Student’s t test or ANOVA where necessary.  
Non-parametric continuous variables are expressed as median with their interquartile ranges 
(IQR) and were logarithmically transformed prior to analysis.  Multiple regression was used in 
each results chapter to assess variables that predicted each dependent variable.  Linear 
relationship between the dependent variable and other continuous predictor variables was 
assessed using scatter plots using sequential analysis of variance. Firstly, for each analysis, the 
relationship of all the main independent variables was checked with the dependent variable to 
see if there was a linear relationship prior to performing multiple regression. Multivariate 
regression analysis was then performed. Residuals were evaluated by Q-Q plots to ensure that 
they were normally distributed.  Multicollinearity was assessed by variance inflation factor and 
values above 2.5 were deemed indicative of multicollinearity. 
Predictors of thyroid dysfunction were assessed using multivariable binary logistic regression 
analysis. Missing data was dealt with by using multiple imputation method. Ten imputed 
datasets were created and pooled results were summarised.  Both troponin T and I levels are 
reflective of the severity of myocardial damage and are used to diagnose AMI, but their 
absolute values differ. Therefore, we first standardised, centred and then combined the two 
values to form a single hs-standardised Troponin (st Troponin) variable. This combined single 
variable was utilised in all analyses.   
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The relationship between thyroid parameters and all-cause mortality was evaluated using Cox 
proportional hazards multivariable analysis. Survival times were calculated from the date of 
the AMI till the date of death or date of being known to be alive. A p value of <0.05 was 
deemed as being indicative of statistical significance in all analyses. Analyses were performed 
using the statistical software package SPSS v22 (Ill, Chic, USA). 
 
3.1.10 Data handling and record keeping 
Medical information obtained at each visit was recorded in the subject’s medical notes or other 
source documentation in real time.  Data was collected and entered into a secure, validated 
clinical data management system (MACRO), by an authorised member of the research study 
team.  Data for each visit was entered by relevant local staff at each site.  The clinical data 
management system was web based; allowing access to authorised staff via password 
protection.  Data was handled, computerised and stored in accordance with the Data Protection 
Act 1998.  No participant identifiable data will leave the study site (CRFs identified participants 
by initials, date of birth and unique patient number only).  Strict confidentiality was ensured 
while dealing with patient-sensitive data in accordance with the Caldicott Guardian’s 
recommendations (applications will be made to the relevant Caldicott Guardian for use of NHS 
patient data). 
All study data was held in strict confidence by the investigators/research team.  Data and 
documents were be stored in locked cupboards.  A confidential list of trial identifiers and 
corresponding patient identifying details were held at site in a locked cupboard by the Principal 
Investigator.  The quality and retention of study data was the responsibility of the CI.  All study 
data retained in accordance with the latest Directive on GCP (2005/28/EC) and local policy. 
 
3.1.11 Compliance and withdrawal 
i. Assessment of compliance 
Compliance with study medication (IMP) was assessed and documented by the research 
team by checking and recording the number of returned capsules at each visit.   This 
allowed any issues to be addressed immediately with the participant. Compliance was 
classed to be good if between 80 to 100%.  The local pharmacy documented all unused 




ii. Withdrawal of participants 
Participants had the right to withdraw from the study at any time for any reason without 
giving a reason.  The investigator also had the right to withdraw patients from the study 
drug in the event of inter-current illness, adverse events, and serious adverse events, 
suspected unexpected serious adverse reactions, protocol violations, administrative 
reasons or other reasons. 
A participant who decided to withdraw from the study, their wishes were respected. 
These participants were asked to complete a “confirmation of withdrawal” form to 
document their decision.  However, for participants that withdrew due to reasons other 
than related to tolerance of MR scanning, they were offered the chance to have the 
primary outcome assessment (cardiac MR imaging) performed at the time of 
withdrawal.  Participants who had serum TSH <0.4 or >10.0 mU/L on two separate 
occasions at least 4 weeks apart whilst on study drug were  withdrawn from the study 






















3.2 Measuring left ventricular volumes and ejection fraction by cardiac magnetic 
resonance imaging 
3.2.1 Methods 
All CMR examinations were performed on a 3 Tesla MR scanner (Philips) at the Magnetic 
Resonance Centre at Newcastle University.  Participants were scanned supine using a 6-
channel cardiac coil and ECG gating (Philips Achieva).  Balanced steady-state free precession 
images were obtained covering the entire left ventricle (field of view (FOV) 350 x 314mm2, 
repetition time/echo time (TR/TE) = 3.9/1.9ms, turbo factor 17, flip angle (FA) 40o, slice 
thickness 7mm, 25 phases, resolution 1.37mm).  After piloting using localisation, cine images 
were acquired in the long-axis and short-axis views during breath holding in end-expiration.  
The images were acquired during breath holding to avoid image artefact whereas ECG gating 
was important to ensure image acquisition at the start of the QRS complex which marked 
ventricular contraction.  The end result is a series of short axis views across the left ventricle 
during each cardiac cycle from diastole (relaxation) to systole (contraction).   
 
3.2.2 Image analysis 
CMR image analysis was performed using the IntelliSpace software version 6.0 (Philips 
Achieva).  The Cine images open with the short axis images on the left and the long axis images 
on the right as seen in the image below (Figure 3-3).  The range of LV segmentation for analysis 
is defined by indicating the valve and apical slice on the short axis using the long axis as a 







Figure 3-3 Long-axis and short-axis views of the left ventricle 
Long-axis views are shown on the right whereas short-axis views on the left.  Moving up and 
down the slices of the ventricle in the long-axis gives a corresponding short axis view during 
the cardiac cycle from diastole to systole.  The apical slice is the last slice furthest from the 
valves whereas the basal slice is slice of the ventricle closest to the valves. 
 
Manual tracing of the endocardial and epicardial contours of the short-axis slices at end-
diastole and end-systole was performed across each slice which covered the left ventricle 
(Figure 3-4).  The basal slice was selected for end-diastole and end-systole when at least 50% 
of the blood pool was surrounded by myocardium whereas the apical slice was defined as the 
final slice in the apex showing blood volume.  This method has been approved by the Society 







Figure 3-4 Contours in diastole and systole of a single slice of the left ventricle 
The image on the left shows a short-axis view in end-diastole representing the maximum 
volume during that slice of the cardiac cycle whilst the heart relaxes whereas the right image 
shows a short-axis view in end-systole representing the minimum volume whilst the heart 
contracts. 
 
Tracing of the endocardial and epicardial contours of the short-axis views at end-diastole and 
end-systole across each slice covers the left ventricle and enables the relevant results to be 
obtained: 
• End diastolic phase (ED): The phase at the beginning of a heartbeat where the heart is 
‘at rest’, i.e. where the blood volume is at a maximum. 
• End systolic phase (ES): The phase where the heart is fully contracted, i.e. where the 
blood volume is at a minimum. 
 • End diastolic volume (VED): The amount of blood in the heart at the end diastolic 
phase; expressed in milliliters (ml). 
 • End systolic volume (VES): The amount of blood in the heart at the end systolic phase; 
in ml.  
• Stroke volume (SV): The amount of blood pumped out per heartbeat, i.e. the difference 
between the blood volume at the end diastolic phase and the end systolic phase; in ml. 
 SV = VED - VES 
• Stroke index (SI): The stroke volume relative to the body surface area; in ml/beat/m2.  
SI = SV/BSA 
• Body Surface Area (BSA): The estimated (not measured) area of the patient's body 
surface; in m2. For adults, the approximate value of BSA can be calculated using Mosteller's 
formula:  BSA = √ (Height [cm] x Weight [kg]) / 3600 
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• Ejection fraction (EF): The amount of blood pumped out per heartbeat relative to the 
blood volume at the end diastolic phase in percentages. 
 EF = (SV / VED) × 100 
• Cardiac output (CO): The amount of blood that is pumped out per minute; in liter (l). 
The heart rate is in beats per minute (bpm).  CO = (SV × HeartRate) / 1000 
 
3.2.3 Volume over time curve and diastolic function 
The final aspect of the LV function analysis involves looking at the volume over time curve of 
the left ventricle.  This shows the changes in the volume within the left ventricle over a period 
of time during which the heart contracts and relaxes during one cycle.  This is not only 
important for showing systolic function, which is the ability of the ventricle to contract, but 
also demonstrates diastolic function which the ability of the ventricle to relax and fill during 





Figure 3-5 Volume over time graph within the left ventricle   
The graph represents one cardiac cycle during systole and diastole.  The downward slope 
represents systole whereas the upward curve represents diastole when the heart relaxes and 
fills.  The volume over time curve enables early filling and late filling to be calculated which 




3.2.4 Quality control for cardiac MRI 
Prior to performing cardiac MRI analysis, inter- and intra-observer variability was assessed for 
LVEF which was the primary end point for the study.  The LVEF is derived from the end-
diastolic volumes (EDV) and end-systolic volumes (ESV).  For inter-observer variability, two 
researchers analysed 19 patient scans on separate days over a one-month period.  As shown in 
Table 3-1, the coefficient of variation for inter-observer variability was 2.62% for ejection 
fraction.  For intra-observer variability (Table 3-2), one researcher repeated the analysis for 18 
patient-scans giving a coefficient of variation of 2.20% for ejection fraction, which is within 


































1   
Researcher 
2   
Patient 
EDV 









1 256.9 183.7 29 256.7 188 27 -2 
2 226.7 154.9 32 225.5 155.5 31 -1 
3 111.7 62.5 44 110.3 61.7 44 0 
4 136.6 60.8 56 133.4 57.9 57 1 
5 137.4 53.8 61 136.2 52.6 61 0 
6 144.1 71.5 50 146.2 73 50 0 
7 185.7 97.9 47 183.2 96.9 47 0 
8 162.7 69.3 57 158.3 69.2 56 -1 
9 114.8 38.7 67 118.8 36.3 69 2 
10 93.8 27.2 71 95.1 26.5 72 1 
11 163.2 76.1 53 164.2 72.9 56 3 
12 151.5 59.3 61 138.9 40.4 71 10 
13 104.1 36.8 65 104.8 32.8 69 4 
14 155.2 69.5 58 148.8 62.9 58 0 
15 128.6 66 51 130.2 65.6 50 -1 
16 119.2 60.8 49 116.7 58.2 50 1 
17 138 56.7 59 133 54.4 59 0 
18 118.8 56.2 53 122.3 54.4 55 2 







Table 3-1  Table showing inter-observer variability for LV function analysis with a coefficient 














      Average mean difference      1.0 
      Standard deviation      2.62 





1-1   
Researcher 









(mls) ESV (mls) 
EF 
(%) 
Mean difference in 
EF 
        
1 185.7 97.9 47 186.2 98 47 0 
2 162.7 69.3 57 163.5 69 58 0 
3 114.8 38.7 67 115.5 40.2 65 -2 
4 93.8 27.2 71 95.4 29.9 69 -3 
5 163.2 76.1 53 164 77.2 53 -1 
6 151.5 59.3 61 152.1 60.4 60 -1 
7 104.1 36.8 65 100.9 36.2 64 1 
8 155.2 69.5 58 154.2 65.2 55 4 
9 128.6 66 51 126.8 61.6 51 4 
10 111 38.2 66 110.9 36.9 67 1 
11 156.3 62.6 60 153.3 63.2 59 -1 
12 185.9 108.2 42 183.5 105.7 42 3 
13 115.7 47.5 59 116 46.8 60 1 
14 152 69 54 154.4 70.8 54 -1 
15 119.2 60.8 49 115.9 59.7 49 1 
16 138 56.7 60 137.1 55 59 2 
17 118.8 56 53 117.1 54 53 2 







Table 3-2  Table showing intra-observer variability with a coefficient of variation of 2.20 which 













      Average mean difference      0.5 
      Standard deviation      1.10 
      Coefficient of variation      2.20 
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3.3 Late gadolinium enhancement (LGE) using cardiac MRI 
3.3.1 Methods 
Following completion of acquiring the Cine images, 0.2 mmol/kg of gadolinium was 
administered intravenously for LGE assessment.  LGE images were obtained ten minutes after 
injecting to allow gadolinium to enter and leave the extracellular space within the myocardium.  
The images were obtained during breath holding with a cardiac triggered 3 dimensional phase 
sensitive inversion recovery sequence (multi shot gradient echo  TR/TE = 5/2.4, FA = 15°/5°, 
acceleration factor 31, parallel imaging factor 2, 1.8mm resolution zero filled to 1.3mm).  LGE 
was only administered in patients with normal or mildly impaired renal function with an 
estimated glomerular filtration rate above 60. 
 
3.3.2 Myocardial segmentation and analysis 
The American Heart Association 17 segment model is the standardised way of the dividing the 
myocardium into 17 segments in the short axis to establish the number of segments possessing 
LGE (Cerqueira et al., 2002).  As shown in Figure 3-6, the basal, mid-cavity and apical short 
axis segments are derived from the location on the long axis of the left ventricle. Figure 1-9 
demonstrated the detection of myocardial scar on CMR.  For the analysis, both Tim Hodgson 
(senior cardiac radiographer) and myself analysed all the scans together and agreed on what 
segments had LGE.  The Phillips Intellispace software was then used to quantify LGE using 
the ‘n’-SD technique in which the endocardial and epicardial borders for the myocardial region 
of intetest (ROI) were outlined and then a normal ‘remote’ (dark) segment ROI within the 
myocardium was selected and used to define the reference signal intensity (mean and standard 
deviation, SD) (Figure 1-9).  Semi-automated thresholding to n+5SD was used as a threshold 
between normal myocardium and LGE to quantify infarct size.  This method has been approved 
by the Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force (Schulz-





Figure 3-6  17 segment representation of the LV cavity 
The diagram shows the basal, mid-cavity and apical segments in the short axis corresponding 
to the respective long axis view.  The number of segments showing LGE were verified between 




















3.4 Badimon Chamber to assess thrombus burden 
3.4.1 Principles of the Badimon chamber 
The Badimon chamber is an ex vivo model of thrombosis which assesses thrombus formation 
on a substrate which has undergone deep arterial injury.  The chamber has previously been 
used in studies to assess the effect of anti-thrombotic and antiplatelet agents on thrombus 
formation (Balasubramaniam et al., 2014; Viswanathan et al., 2014b).  The main advantage of 
using the chamber is that it mimics physiological blood flow conditions of the coronary artery 
and has been shown to be highly reproducible when assessed within and between days reducing 
inter- and intra-observer variability (Lucking et al., 2010).  The chamber has previously been 
used in our laboratory and has demonstrated higher thrombus burden in NSTEMI patients with 
SCH compared to those with euthyroidism (Viswanathan et al., 2014a). 
The generation of thrombus in the chamber depends on two principles: 
1) A substrate which is highly thrombogenic, similar to a diseased coronary artery to 
which platelets are likely to bind. 
2) Shear stress which induces platelet activation 
Freshly slaughtered pig aortas were the source of substrate in the Badimon chamber.  The 
endothelium was surgically removed to expose the tunica medium, which is rich in collagen, 
and this permitted platelet aggregation in a manner similar to a diseased coronary vessel which 
undergoes changes prior to a MI.  Platelet activation occurs under high shear stress at sites 
where there are narrowing within the blood vessel secondary to atheromatous plaques.  This is 
due to the normal laminar blood flow being disrupted at narrowings which encourages blood 
flow under high shear stress.  Therefore, reducing the luminal diameter within the chamber 
increases the shear stress causing a subsequent increase in the velocity of blood flow and 










Figure 3-7 A cross sectional image of an aorta segment.   
Removing the endothelium and tunica intima exposes the underlying media which is highly 
thrombogenic and rich in collagen  
 
3.4.2 Set up the Badimon chamber 
The Badimon chamber consists of: 
1) one low shear stress plexi glass chamber 
2) two high shear stress plexi glass chambers 
3) three plexi glass over chambers with a screw in which each plexi glass chamber is 
placed and secured 
4) four plastic connectors 
5) a plexi glass container into which all the plexi glass over chambers are placed in line 
with each other 
Each of three plexi glass chambers consist of an upper lid unit and a lower core unit which are 
secured together with the substrate in between (Figure 3-8).  The substrate is held in place by 
the pressure of the upper lid onto the lower core unit. The lower core unit has cylindrical 
channels which have a dimension of 1mm*25mm in the two high shear chambers and 
2mm*25mm in the low shear stress chamber.  The purpose of these channels is to allow direct 
contact of the substrate with the flowing blood.  The over chamber with a screw holds together 
the upper lid and lower core unit securely with substrate in between.  All three chambers are 
connected together by plastic connectors which connect to the channels in the lower core unit.  
77 
 
In the study the 3 chambers were arranged in the following order: low shear chamber → first 
high shear chamber →second high shear chamber.  The rheological conditions in the first 
chamber (low shear) simulate those of patent coronary arteries whereas the second and third 
chambers (high shear) simulate a stenosed coronary artery.  The whole assembly was kept 




                                    
 
                                                          
Figure 3-8 Set up of the plexi glass chambers.   
Each chamber consists of a lower core unit into which the aortic substrate is placed (A).  The 
upper lid is placed on top of the lower core unit with the substrate in between (B and C).  The 
unit is then placed in an over chamber with a screw which ensures that the units are held 
securely.  There are three chambers in total (2 high shear stress and 1 low shear stress).   
 
Aortas from freshly slaughtered pigs were obtained from a local abattoir.  Each aorta was 
surgically dissected into numerous segments measuring 15mm*35mm.  The thin endothelial 
layer was stripped off to expose the underlying tunica media, which was rich in collagen, and 
excess tunica adventitia was also removed to ensure fitting into the chamber.  The aortas were 
thoroughly inspected with a magnification glass to ensure there was no damage to the tunica 
media as well as to remove any dissection flaps which could predispose to excess to thrombus 
formation.  They were then stored in a 0.01M phosphate buffer solution at minus 80 degree 
Celsius.   One day before the chamber study, the aorta segments were placed into a fridge at 5 
78 
 
degress Celcius to enable thawing.  The segments were once again examined for any damage 
or flaps and only aortas without dissection flaps were used for each chamber study.   
The chamber was kept at a temperature of 37 degrees Celcius to mimic body temperature.  A 
peristaltic pump was used to draw blood from a large vein in the antecubital fossa via tygon 
tubing through the three perfusion chambers (Figure 3-9).  14.0 tygon tubing (Cole Palmer, IL, 
USA) was used to connect the distal end of the chamber to a peristaltic pump (Masterflex, 
model 7013) which ensured the flow was 10ml/min.  Tygon tubing was used to connect the 
proximal end of the chamber to one port of a 3 way tap (Alaris, MFX2280E, Cardinal Health 
Inc, Rolle, Switzerland) which was subsequently connected to a cannula in the cubital fossa of 
the subject’s right arm via further tubing.  The final port of the 3-way tap was used to flush and 
prime the system 0.01M buffer solution prior to starting the experiment to ensure there was a 
continuous flow within the system without air bubbles.  The venous blood was then allowed to 
flow into the system for 5 minutes after which further buffer solution was again passed through 
the chamber for 30 seconds to remove blood which had not attached to the substrate.  
It was important that the connectors of the Badimon chamber were non-thrombogenic and 
sustained the expected shear rates.  Tygon tubing which satisfied these conditions was used.   
0.01M phosphate buffer solution (PBS) was prepared from PBS in concentrate powder form 
(Cole-Palmer inc, MA, USA).  Deiodinased water was used to reconstitute the powder to 







Figure 3-9 Setup and principles of the Badimon chamber. 
Blood from the antecubital fossa flows through the chamber at 10mls/min due to the peristaltic 
pump drawing blood.  The chamber was kept at temperature of 37 degrees Celsius.  The blood 
flowed through the chamber via the tygon tubing.  Upon entering the low shear unit the blood 
came into direct contact with the overlying aortic substrate and then continuously flowed into 
the subsequent 2 high shear units before being discarded.  
 
3.4.3 Histopathology methods 
Aorta tissue from each chamber was carefully removed from the chamber unit and then placed 
in 10% formalin solution for preservation.  After 72 hours of fixation in formalin, the three 
aorta segments were removed (one low shear and two high shears) and each segment was 
sectioned into eight equal pieces with a width of 1mm with the central cross-sectional area of 
each aorta piece representing the area over which the thrombus had formed.  All the pieces 
were placed in a total of six histocassettes and labelled as follows: 
1) Low shear unit:   A1,A2,A3,A4        B1,B2,B3,B4 
2) High shear unit:  C1,C2,C3,C4       D1,D2,D3,D4 
3) High shear unit:  E1,E2,E3,E4        F1,F2,F3,F4 
The samples were then embedded in liquefied wax and each aorta piece was then sectioned to 
0.4 µm width sections using micotome.  Post sectioning each sample was stained using 
modified Masson trichrome stain and then placed in a glass slide.  These procedures were 
carried out in the Cellular Pathology department at the Royal Victoria Infirmary. 
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The Masson trichrome staining of the aorta segments enables differentiation of the thrombus 
from the tunica media over which it has formed.  Post staining the thrombus with fibrin appears 
red, the elastin of the aorta segment appears green the smooth muscle within the media appears 
pink.  This modification has been validated by the Thrombosis Research Unit, Mount Sinai 
Hospital, New York (Osende et al., 2001). 
 
3.4.4 Image acquisition 
The slides were viewed using a high precision light microscope (Leica DM 2000, Leica 
Microsystems, Wetzler, Germany).  The slides were placed on the microscope lens and the 
thrombus images were magnified X10 with the red visible thrombus on top of the tunica media 
which was pink (Figure 3-10).  A digital camera with a high resolution (KY-F1030, JVC, 
Japan) was used to capture the images electronically.  The microscope was calibrated on a 
regular basis and was cleaned, inspected and serviced by a technician once a year.   
 
 
Figure 3-10 Visualisation of thrombus when placing each slide under a microscope.   
Magnification X10 shows the thrombus in red having formed over the tunica media outlined 
in pink.  For each chamber study there were 24 such images to analyse which represented the 







3.4.5 Measurement of thrombus area 
Each thrombus image was opened in jpeg format and analysed using the software Image-Pro 
Plus Version 4 (Media Cybernetics Inc, MD, USA).  The software enabled the brightness and 
contrast of each image to be standardised enabling clearer visualisation of the thrombus.  A 
cursor was used to trace carefully around the thrombus and at the border of the thrombus and 
tunica media where extra care was taken to ensure that no portion of the tunica media was 
included as this would lead to overestimation in thrombus area.  The thrombus area was 
calculated by the software’s differentiation of dark objects within the cursor border which was 
recognised as developed thrombus.  The thrombus area was attained for each of the 24 segments 
of aorta (8*low shear and 16*high shear) with the measurement expressed as µ2 per millimetre 
aorta surface area (µ2/mm).  This enabled a mean thrombus area to be attained for both low 
shear and high shear aorta segments  
There were sections which were unsuitable for analysis.  Such reasons included: 
a) Excess dye used whilst preparing the slides 
b) Sections which were damaged whilst preparing the samples as this would led to 
underestimation 
c) Sections with flaps as this would lead to sluggish flow and excess thrombus formation 
d) Sections with minimal thrombus at less than 500 µ2/mm as this was indicative of wash 
artefact. 
The images were checked by two observers which included an experienced chamber 
researcher, who had significant experience in using the Badimon chamber, and myself.  
Sections of aorta unsuitable for analysis were excluded. 
 
3.4.6 Quality control  
For the Badimon chamber, the performance of the circuit was checked with 0.01M phosphate 
buffer solution prior to starting each patient test and involved priming with the solution at 
10ml/min (standard laminar flow) and at 150ml/min.  Secondly, the chamber was performed 
on 2 individuals on 3 separate occasions one month apart in exactly the same conditions to the 
study and the mean thrombus area µ2/mm for subject 1 was 7543, 7928 and 7399 whereas for 
subject 2 the thrombus area was 6099, 6781 and 6542.  These were not statistically different.  
For analysis of thrombus area, intra-observer variability was performed on fifteen slides, two 
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weeks apart, giving a coefficient of variation of 4.1%.  The same slides were analysed by an 
experienced chamber researcher giving an inter-observer coefficient of variation of 4.5%. 
 
 
3.5 Thromboelastography (TEG) and platelet mapping in assessing visco-
elastography 
3.5.1 Background and technique 
TEG is a viscoelastic haemostatic assay which measures the viscoelastic properties of clot 
formation within the blood.  Current laboratory tests used in hospitals have limitations by 
measuring individual components of the haemostasis process which does not represent how 
such components interact in clot formation.  Therefore, such tests do not necessarily indicate 
how well haemostasis is functioning.  TEG measures the rate and strength of clot formation 
induced by thrombin which activates platelets and the coagulation cascade.  By assessing 
thrombus formation continuously over a period of time, TEG reflects whole blood thrombosis 
by showing the interaction between platelets leading to platelet aggregation; and the interaction 
of platelets with fibrin and the coagulation cascade.  This involves measuring each cycle of clot 
formation and the susceptibility of the clot to autolyse.  Therefore, the rate of clot formation is 
determined by platelet function, fibrinogen levels, the coagulation system, fibrinolysis and 
medications which inhibit these systems.  Measuring the process of clot formation and auto 
lysis enables the researcher to understand both the thrombotic and bleeding tendency and this 
can guide adequate blood product replacement if needed such as during and after 
cardiopulmonary bypass surgery.  This has been shown to decrease transfusion rates during 
surgery (Shore-Lesserson et al., 1999).  TEG can also be used acutely to measure the inhibitory 
effect of aspirin and P2Y12 inhibitors on platelet aggregation to help decide timing for surgery 
(Mahla et al., 2012).   
TEG is a point of care test in which a result can be attained within 30 minutes after taking blood 
from a patient.  The measurement of the viscoelastic properties is via a pin suspended in a cup 
(heated to 37 degrees Celsius) from a torsion wire which is connected to an electrical 
transducer.  The blood is placed within the cup and the motion of the cup does not affect the 
pin initially as the blood is unclotted allowing free movement (Figure 3-11).  The cup rotates 
in an oscillating manner every 10 seconds at 4.45 degrees.  As clot starts forming, the rate of 
cup movement decreases around the pin with the rate of movement being inversely proportional 
to clot formation.  The interlinking of clotting factors, fibrin and platelets form a strong 
83 
 
connection between the cup and pin and this energy is measured by the torsion wire as kinetic 
energy which is a measure of viscoelastic clot strength over time.  This energy is converted to 
an electric signal which is displayed as a graphical and numerical output (Figure 3-11).   
Therefore, TEG measures the rate of thrombus formation and the maximum strength of the clot 
by giving a measurement of maximum amplitude (MA) on the graph.  TEG also evaluates clot 
lysis by assessing the decrease in amplitude from the MA over a period of time. In addition to 
TEG, another viscoelastic analyser is rotational thromboelastometry (ROTEM).  The main 
difference with ROTEM is that the cup is immobile whereas the pin slowly oscillates.  No 
randomised controlled trial has compared both TEG and ROTEM.  The use of both analysers 






Figure 3-11 Thromboelastography. 
The top diagram shows the basic principle of TEG with the pin extending from a torsion wire 
which is connected to a transducer.  As the cup oscillates, changes in the rate of cup movement 
is dependent on blood viscosity and this is transmitted as kinetic energy giving a corresponding 




3.5.2 Parameters derived from TEG graph 
R time, in min - reaction time; time taken from placing blood in the cup till initial fibrin 
formation.  This is the time from beginning of the TEG trace when the test starts till initial 
fibrin formation with an amplitude of 2 mm.  It is dependent on clotting factors of the initial 
enzymatic cascade which start the process of thrombus formation.  This value will be shortened 
if the blood is hypercoagulable due to excess clotting factors and prolonged in a coagulopathy.  
Normal time is 2-8 mins. 
K time, in min - kinetics; time taken to reach a fixed level of clot strength i.e 20 mm.  This is 
the time for the thrombus to become firm and is dependent on the conversion of fibrin to 
fibrinogen.  Normal time is 1-3 mins. 
α-angle - the angle of the slope between R and K when a clot strength of 20 mm is reached.  It 
measures the rate of fibrin build up and the cross linking with platelets and therefore represents 
the speed of thrombus formation.  Normal angle is 55-78. 
MA, in mm - maximum amplitude; measures the maximum distance between the two arms of 
the graph.  This is the maximum viscoelastic strength of the thrombus and is dependent on 
fibrin and platelet interaction.  This is the most consistent measurement among all the TEG 
measurements and can be used to study the effect of different anti platelets on thrombus 
formation.  Normal time is 51-69 mins. 
Clot index - dimensionless parameter which takes into account each of the 4 stages of thrombus 
formation in TEG (R, K, α-angle and MA) into one equation CI = - (0.1227)R + (0.0092)K + 
(0.1655)MA - (0.041)α - 5.0220.  It is an overall measure of thrombus strength and measures 
the combined effect of fibrinogen and platelets on thrombus.  Normal value is -3 to 3.  
LY30 - the percentage decrease in amplitude 30 mins after reaching MA.  This gives a measure 
of early fibrinolysis during clot breakdown.  Normal value is 0-8. 
LY60 - the percentage decrease in amplitude 60 mins after reaching MA.  This gives a measure 
of late fibrinolysis during clot breakdown.  Normal value is 0-15. 
L-parameter, mm/min – the thrombus lysis parameter which measures the average reduction 
in amplitude per unit of time.  This measures the changes in the viscoelastic property of the 






Figure 3-12  The different components of clot formation corresponding to the TEG trace.  
The interpretation of the TEG trace enables the researcher to identify the contribution of the 













3.5.3 Platelet mapping 
Clot formation is determined by the interaction of the coagulation cascade with platelets.  
Standard TEG measures the rate of clot formation via thrombin which is important in the 
coagulation cascade by converting fibrinogen to fibrin as well as being the most potent platelet 
activator leading to platelet aggregation.  Therefore, in routine TEG, kaolin is added to citrated 
blood which leads to thrombin activation of platelets and the coagulation cascade with the end 
result being the strongest clot formation possible independent of antiplatelet agents.  Therefore, 
the MA derived from the TEG graph is the maximum viscoelastic strength of the clot in that 
individual. 
Platelet mapping is an addition to TEG which enables the operator to know the effects of each 
antiplatelet agent on platelet inhibition.  This is achieved by measuring the effects of the platelet 
activators arachidonic acid and ADP on platelet receptors which have not been inhibited by 
antiplatelets.  Usually thrombin activation by kaolin is so significant that it will mask the effect 
of platelet activation by other activators such as AA and ADP.  Therefore platelet mapping is 
carried out on heparinised blood in which the thrombin is inhibited.  By inhibiting thrombin, 
activator F (labelled AP1) was added leading to production of the fibrin meshwork by 
conversion of fibrinogen to fibrin and activation of Factor XIIIa.  This was followed by the 
addition of either AA or ADP activators in individual cups to measure platelet inhibition by 
each antiplatelet (Figure 3-13).  
The end result of standard TEG and platelet mapping is 4 tracings (Figure 3-14).  The first trace 
represents thrombin activation by kaolin which represents the highest MA (MA thrombin) 
whereas the pending three traces are for activator F (MA activator), ADP (MA ADP) and AA 
(MA AA).  Platelet mapping isolates the contribution of fibrin and platelets to the clot’s 
strength.  The trace for MA activator represents the estimation of fibrinogen contribution to 
clot strength independent of platelets.  The MA ADP and MA AA tracings represent the 
contribution of the platelets with fibrin to clot strength based on activation by the activators 
ADP and AA.  The difference between the MA of these curves gives the individual contribution 
of fibrin, ADP and AA to clot strength.  Additionally, the inhibitory effect of aspirin and the 
P2Y12 antagonist is derived from the equation: 
Percentage maximum amplitude reduction or MA reduction 





Figure 3-13  Diagram representing the 4 channels of TEG and the individual components. 
 Channel 1: Kaolin activated citrated blood which leads to thrombin activation.  The TEG 
results from thrombin activation of fibrinogen and platelets leading to the strongest clot 
possible 
 Channel 2: Activator was added to heparinised blood without a platelet agonist.  The TEG 
curve results from fibrin dependent clot formation. 
 Channel 3: Activator added with ADP platelet agonist to heparinised blood.  ADP activates 
platelet receptors not inhibited by the P2Y12 inhibitor.  The activator converts fibrinogen to 
fibrin.  The TEG curve results from a clot formation dependent on fibrin and non-inhibited 
platelet receptors activated by ADP.  This shows how effective the P2Y12 inhibitor has been 
in inhibiting platelets. 
 Channel 4: Activator added with AA platelet agonist to heparinised blood.  AA activates 
platelet receptors not inhibited by aspirin.  The TEG curve results from a clot formation 
dependent on fibrin and non-inhibited platelet receptors activated by AA.  This shows how 













Figure 3-14 TEG and platelet mapping tracings. 
The MA thrombin tracing represents maximum platelet activation due to thrombin resulting in 
the highest amplitude curve.  The MA fibrin tracing represents clot strength solely due to fibrin 
activation resulting in the lowest amplitude curve.  The MA ADP and MA AA curves are 
thrombus formation from activation of non-inhibited platelets by the respective antiplatelet 
agents.  The amplitude of these curves is dependent on platelet inhibition.  Platelet inhibition 
is calculated using the formula: MA reduction = 100 – (([MAAA or ADP - MAactivator]/[MAthrombin 
– Maactivator])*100).  This represents percentage maximum amplitude reduction.  The higher the 















3.5.4 Study protocol 
The protocol as per the manufacturer’s guidelines were followed (Hemoscope, CA, USA).  
Citrated and heparinised bloods were collected from each patient.  For the standard TEG, 1 ml 
of citrated blood was added to kaolin and then 340µl of this dilution was added to the cup in 
channel 1 into which 20µl of CaCL2 had already been pipetted.  For platelet mapping, 
heparinised blood was added to the cups in channel 2, 3, and 4 into which the activator (AP1) 
and respective agonists (ADP and AA) had been pipetted.  The TEG ran for 90 mins and all 
data was displayed graphically in time as the samples were being processed.   
 
Kaolin activated TEG 
1. Add 1ml of citrated blood into kaolin tube supplied by the manufacturer. 
2. Mix by gentle inversion 5 times. 
3. Pipette 20µl of CaCL2 into a cup in channel 1 of the TEG machine. 
4. Pipette 340µl of kaolin dilution into cup and start, slide the carrier up and move lever 
to the test position and click the start button on the software main toolbar. 
Platelet mapping 
1. Add 50µl of distilled water to aliquot vial containing A-P1 (activator) and give 5 mins 
to mix. 
2. Add 100µl of distilled water to the aliquot vial containing ADP and a 100µl of distilled 
water to the vial containing AA. 
3. Pipette 10µl of A-P1 into each cup of channel 2, 3 and 4. 
4. Add 10µl of ADP into cup of channel 3. 
5. Add 10µl of AA into cup of channel 4. 
6. Pipette 360µl of heparinised blood into A-P1 cup in channel 2, mix gently by pipetting 
sample up and down 5 times and then start test. 
7. Pipette 360µl of heparinised blood into ADP cup in channel 3, mix gently by pipetting 
sample up and down 5 times and then start test. 
8. Pipette 360µl of heparinised blood into AA cup in channel 4, mix gently by pipetting 






3.5.5 Quality control for TEG 
For TEG, quality control prior to starting each test was performed which ensured equilibrium 
of both the torsion wire and central pin.  These results were stored electronically.  Once every 
fortnight, quality control on the control sample provided by the manufacturer was also 
performed, which was repeated for each new batch of reagents to ensure that the results were 
within the manufacturer’s recommended range.  Furthermore, the reproducibility was assessed 
by performing TEG on 6 individuals on 2 separate occasions and a coefficient of variation of 


































3.6 Measuring platelet aggregation with VerifyNow 
3.6.1 Principles of VerifyNow 
VerifyNow (Accumetrics, CA, USA) is a point of care test which measures platelet aggregation 
and reactivity allowing the operator to determine the antiplatelet effects of aspirin and P2Y12 
inhibitors.  Platelet aggregation is determined by the use of different agonists such as AA, ADP 
and thrombin receptor activating peptide (TRAP).  The system consists of a cartridge into 
which the blood is drawn.  The blood then passes into a staging well allowing heating to 37 
degrees Celsius.  The blood is then passed into 4 wells which contain the specific platelet 
agonist and fibrinogen coated beads.  The platelet agonist causes platelet activation whereas 
the fibrinogen interacts with the glycoprotein IIb/IIIa receptors leading to platelet aggregation.  
The cartridge is placed between a light source and an optical sensor which detects the light.  
The light absorbance of the sample is measured up to 16 times per second with the light 
transmittance being proportional to platelet aggregation.  The effect of an antiplatelet in 
inhibiting platelets is measured by changes in light transmittance over a unit of time using 
arbitrary units.  The greater the antiplatelet inhibiting effect, the less platelet aggregation takes 
place in response to the specific agonist leading to less light transmittance and hence lower 
reactive units (Figure 3-15).  
Two different cartridges were used for measuring platelet inhibition: one for measuring the 
effects of aspirin and the second for measuring the effects of P2Y12 inhibitors (clopidogrel, 
ticagrelor and prasugrel).  The cartridges differed based on the platelet agonist within them.   
 
3.6.2 VerifyNow aspirin assay 
The VerifyNow aspirin assay consists of a cartridge with AA as the agonist to activate platelets.  
The AA is converted by cyclooxygenase (COX) to thromboxane A2 leading to platelet 
activation.  As platelet aggregation increases, the transmittance of light increases and the 
change in light transmittance is reported as aspirin reactive units (ARU).  An ARU cut off of 
495 was used with a value ≥495 representing platelet hyperactivity despite being on treatment 
(hyporespnder).   
The use of VerifyNow has been validated in studies.  In one study, the use of VerifyNow was 
compared with traditional platelet aggregometry (Malinin et al., 2004). The overall agreement 
between the two methods for determining aspirin response was 87% and the correlation was 
0.9. In another study the VerifyNow was compared to light transmittance aggregometry and 
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the Platelet Function Analyzer (PFA)-100 in patients treated with aspirin post ischaemic stroke 
(10).  Seventeen percent of patients were identified as hyporesponders to aspirin by VerifyNow, 
22% by PFA-100 and 5% by light transmittance aggregometry (Harrison et al., 2005). 
 
3.6.3 VerifyNow P2Y12 assay 
The VerifyNow P2Y12 assay consists of a cartridge with ADP as the agonist to activate 
platelets.  Platelet reactivity is measured as P2Y12 reactive units (PRU).  The change in light 
transmittance due to platelet aggregation by ADP is reported as PRUz.  Responsiveness to 
P2Y12 inhibitors is expressed as a percentage of the baseline platelet reactivity.  For this 
reason, in one of the channels iso-TRAP is used as an agonist as it is unaffected by P2Y12 
inhibitors allowing a baseline value for platelet function to be obtained in the form of PRUb.  
Therefore, the VerifyNow provides 3 measurements: PRUz (inhibited platelet function), PRUb 
(baseline platelet function) and % inhibition.  Percentage inhibition due to the P2Y12 inhibitor 
is calculated from the formula (1-PRUZ/PRUB)*100.  Consequently if a P2Y12 inhibitor 
produces significant platelet inhibition, the PRUZ value will be lower and the percentage 
inhibition higher.  A PRUZ of 240 and a percentage inhibition of 40% was used as a cut off 
with a value ≥240 and inhibition less than 40% representing platelet hyperactivity despite being 
on treatment (hyporesponder).  This is based on a paper by Marcucci et al who demonstrated a 
higher risk of cardiovascular death and non-fatal myocardial infarction in patients with a PRUz 













Figure 3-15 The principles of VerifyNow. 
Blood is drawn into the 4 chambers which contain fibrinogen coated beads to initiate platelet 
aggregation.  In addition, each chamber contain a specific agonist such as ADP or arachidonic 
acid and therefore platelet aggregation depends on residual antiplatelet activity.  The greater 
the antiplatelet inhibiting effect, the less platelet aggregation takes place in response to the 




3.6.4 Study protocol 
Blood was collected in sodium citrate tubes and gently mixed by inverting at least 5 times.  The 
VerifyNow cartridges were taken out of the packaging and inserted into the well of the device.  
The blood tubes were inverted further before being fixed to the needle within the cartridge.  
The cover of the assay device was closed to prevent light from entering.  Platelet aggregation 
was measure between 3-5 minutes with results displayed as ARU or PRU respectively.  Further 
details are provided below. 
 
1. Perform electronic QC on cartridge provided by manufacturer. 
 
2. With the aspirin citrated plasma tubes, mix gently by inverting 5 times. 
 
3. Open the aspirin assay cartridge from the pack and insert the device into the machine 
column. 
 
4. Remove the needle covering being careful in avoiding any needle injuries. 
 
5. Mix the blood again 5 times in the plasma tubes and then insert the tube upside down 
into the well allowing contact between the needle and plasma tube. 
 
6. Close the cover of the assay device to prevent light from entering. 
 
7. After 300 seconds of analysing, the result will be displayed as an ARU. 
 
8. Remove the aspirin cartridge and discard in a sharps container. 
 
9. Repeat this procedure with the P2Y12 cartridge. 
 
10. The results will be displayed as PRUz, PRUb and %inhibition. 
 









3.6.5 Quality control for VerifyNow 
VerifyNow is provided with its own manufacturer control which is used prior to starting each 
test to ensure the control results are not outside the range for both ARU and PRU.  Additional 
quality control tests were performed on separate samples provided by the manufacturer every 
fortnight to ensure the results were in range.  In addition, the reproducibility of the test was 
evaluated in 10 healthy individuals on two occasions with coefficient variation for ARU being 

























3.7 Measuring endothelial function using EndoPAT 
3.7.1 Priniciples of EndoPAT 
EndoPAT (Itamer Medical LTD, Caesarea, Israel) uses a pneumatic probe with a 
plethysmographic cuff to measure changes in pulsatile blood volume within the fingertip 
vasculature with each heartbeat.  By using one arm for the experiment and the other arm as a 
control, EndoPAT can account for general systemic changes that’s occurs during the test and 
corrects for this when giving a final reactive hyperaemia index (RHI) score.  A probe was 
placed on the index finger of each arm and then a blood pressure cuff was placed on the forearm 
of the experimental arm to induce transient ischaemia by occluding the brachial artery.  Firstly, 
baseline blood flow measurements were taken for both arms for 5 mins which gave similar 
pulsatile waveform activity in both arms.  Then, transient ischaemia was induced by inflating 
the blood pressure cuff to 60mmHg above the systolic blood pressure for 5 minutes in the 
experimental arm.   This induced reactive hyperaemia and when the blood pressure cuff was 
released, PAT signal measurements were taken for a further 5 minutes with changes in PAT 
signal amplitude representing changes in endothelium mediated vascular tone induced by NO.  
EndoPAT gave a RHI measurement which represented dilatation, and this manifested as 
changes in the PAT signal amplitude.  Since the PAT signal is influenced by the autonomic 
nervous system, all tests were performed in a stress-free environment which included a quiet 










Figure 3-16  Pulsatile PAT signal waveforms showing normal endothelial function and 
endothelial dysfunction. 
The two pairs of tracing are for two different patients.   The upper PAT signal tracings represent 
the control arms with the same continuous waveform throughout the 15 minutes.  The lower 
tracings represent the experimental arms.  After 5 minutes, the cuff is inflated restricting blood 
flow resulting in no pulsatile activity as shown by the flat line.  The cuff is deflated after 5 
minutes of occlusion inducing reactive hyperaemia. This results in an increase in the waveform 
amplitude compared to baseline if the endothelial function is normal whereas in endothelial 
dysfunction there is no increase waveform amplitude. 
 
The RHI score is a measurement of endothelial function and is derived from a ratio of the post 
to pre-occlusion PAT signal in the tested arm divided by the post to pre PAT signal in the 
control arm.  The higher the RHI score, the healthier the endothelium giving a lower risk for 
future cardiovascular events.  A score below 1.68 represents inadequate endothelial function 
indicating a significant change in lifestyle plus consideration of pharmacological therapy if 
there are any additional risks.  A score between 1.69 and 2 represents healthy endothelial 
function with further improvements in life style necessary whereas a score above 2 represents 
optimal endothelial function and cardiovascular protection.  EndoPAT has been used in the 
Framingham Heart Study to test endothelial function in over 5,000 subjects with Hamburg et 
al demonstrating an inverse relationship between RHI values and multiple cardiovascular risk 







3.8 Quality of life and patient reported outcomes 
Quality of life (QOL) and patient-reported outcome measures were evaluated by validated 
questionnaires, at baseline and at 52 weeks.  The three different questionnaires used included:  
the Short Form 12 four-week recall (SF-12 v2), Minnesota Living with Heart Failure 
Questionnaire, and the Centre for Epidemiologic Studies Depression Scale (CES-D) (See 
appendix 1). 
SF-12 v2 - has been extensively studied and used as a valid measure of health-related quality 
of life in variety of population groups (Gandek et al., 1998).  The scoring consists of a physical 
and a mental component and is designed to have a similar performance to the longer version 
SF-36, with less time to complete.  The physical scores range from 20 to 56, with higher scores 
indicating better physical health.  The mental scores range from 41 to 61, with higher scores 
indicating perceived better mental health.   
Minnesota Living with Heart Failure Questionnaire – Has been used and approved to assess 
heart failure specific quality of life (Garin et al., 2014).  Scores range from 0 to 105, with higher 
scores indicating increase in symptoms from heart failure 
CESD - This is a 20 item questionnaire which asked patients to rate how often they may have 
experienced symptoms associated with depression.  The CES-D has been shown to identify an 
individual with clinical depression, with very good sensitivity and specificity (Lewinsohn et 
al., 1997).  Scores range from 0 to 60, with higher scores indicating greater depressive 











4 Chapter: Results 
4.1 Prevalence and predictors of thyroid dysfunction and the relation of thyroid function 
with troponin levels in Acute Myocardial Infarction – the ThyrAMI 1 study 
 
4.1.1 Prevalence and predictors of thyroid dysfunction 
A total of 1915 patients were recruited to the ThyrAMI 1 Study of which 113 (5.9%) were on 
LT4 therapy for hypothyroidism.   Of the remaining 1802 patients, 1440 (79.9%) patients were 
euthyroid, 312 (17.3%) had SCH, 22 (1.2%) had SHyper, 25 (1.3%) had LT3S, 2 (0.1%) had 




Figure 4-1 Prevalence of thyroid dysfunction in the Thyrami-1 Study. 

























The baseline demographic and clinical characteristics of all participants with euthyroidism, 
SCH, SHyper and LT3S are outlined in Table 4-1. The SCH and LT3S patients tended to be 
older, included a higher percentage of females and had higher serum creatinine levels compared 
to the euthyroid and SHyper groups. Furthermore the SCH and LT3S groups had higher 
standardised troponin levels.  Patients with STEMIs were observed more frequently in the SCH 
and SHyper groups. Interestingly, patients with LT3S had more patients with existing 
ischaemic heart disease than the other groups.  As expected, the SCH group had higher median 

































70.9 (±12.5) 0.001 




16 (64.0) 0.08 
Body mass index 




27.9 (±5.6) 0.25 




142.9 (±35.6) 0.42 




82.9 (±19.7) 0.48 




79.6 (±20.4) 0.32 




9 (36.0) 0.87 









1.6 (1.0-2.9) <0.001 




13.9 (2.5) 0.007 




2.7 (±0.5) <0.001 




30 (28-120) <0.001 




4 (1-52) 0.39 
Total Cholesterol 




4.98 (±1.5) 0.42 




















13 (52.0) 0.009 
Type 2 diabetes mellitus 




4 (16.0) 0.87 




13 (52.0) 0.66 
Hypercholesterolaemia 




5 (20.0) 0.55 
Cerebrovascular disease 




2 (8.0) 0.53 




1(4.0)  0.83 
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Table 4-1 Characteristics of patients presenting with acute myocardial infarction by thyroid 
status. 
SCH - subclinical hypothyroidism, SHyper – subclinical hyperthyroidism, NSTEMI – non-ST-
elevation myocardial infarction, STEMI – ST-elevation myocardial infarction, TSH – 
thyrotropin, FT4 – free thyroxine, FT3 – free triiodothyronine, TPOAb – thyroid peroxidase 
antibody, IHD – ischaemic heart disease. 
Standardised troponin – The troponin T and troponin I were standardised, centred and then 
combined to form a standardised single troponin variable. 
Data are presented as mean (± SD), numbers (%) or median (IQR).   
Means compared using ANOVA. 
Medians compared using Kruskal-Wallis test. 


















Predictors of thyroid dysfunction (SCH, SHyper and LT3S) were assessed using multivariable 
logistic regression analysis. Overt hypo- and hyperthyroidism were not analysed due to few 
patients being classed in this category. The predictor variables included age, sex, body mass 
index, smoking status, type of AMI, st Troponin, serum creatinine, hs CRP levels, TPOAb 
levels, time-period of sampling, and presence of ischaemic heart disease, hypertension, type 2 
diabetes, hypercholesterolaemia, cerebrovascular disease and atrial fibrillation. Missing data 
was dealt with by using multiple imputation method. Ten imputed datasets were created and 
pooled results were summarised. A sensitivity analysis was performed for predictors of SCH, 
SHyper and LT3S by analysing the original non-imputed dataset.  
Predictors for SCH were increasing age, female sex, higher TPOAb levels, higher serum 
creatinine levels, and the time of blood sampling (Table 4-2). With regard to the time of 
sampling, patients who had their thyroid function tested between 00:01 and 06:00 hours were 
more likely to have SCH than those sampled at other time points (p for trend <0.001). 
Significant predictors for SHyper were lower BMI and time of blood sampling (Table 4-3). 
With regards to the latter, those sampled between 00:01 and 06:00 had the least likelihood of 
being diagnosed with SHyper (p for trend 0.02).  The only significant predictors for LT3S were 
increasing age, higher creatinine levels and presence of ischaemic heart disease (Table 4-4). 
Neither time of sampling, larger infarcts (as measured by peak st troponin levels) or higher 
hsCRP levels were significant predictors.   
In the sensitivity analysis, the complete case data was analysed without the imputed values.  
The overall strength and direction of associations remained similar to the main analysis 









 Odds ratio (95% CI) P-value 
Age (years) 1.03 (1.01-1.05) <0.001 
Sex 
         Male 
         Female 
 





Body mass index (kg/m2) 1.00 (0.98-1.03) 0.54 
Smoking 
        Never smoked 
        Current smokers 








Type of AMI 
       NSTEMI 
       STEMI 
 





Standardised Troponin 1.16 (0.99-1.36) 0.071 
Creatinine (µmol/dL) 1.00 (1.00 – 1.00) 0.040 
hs CRP (mg/L) 0.99 (0.99-1.00) 0.40 
TPOAb (mU/L) 1.01 (1.01-1.03) <0.001 
Time of sampling (24-
hour clock) 
        00:01-06:00 
        06:01-12:00 
        12.01-18:00 











Ischaemic heart disease 
          Absent 
          Present 
 
1.0 (Ref) 





         Absent 
         Present 
 
1.0 (Ref)  






Type 2 diabetes mellitus 
         Absent 
         Present 
 
1.0 (Ref) 





        Absent 








        Absent 








        Absent 







Table 4-2 Predictors of SCH in patients with acute myocardial infarction. 
BMI - Bodymass index, AMI – Acute myocardial infarction, CRP – C reactive protein 
STEMI – ST elevation myocardial infarction, NSTEMI – Non ST elevation myocardial 































 Odds ratio (95% CI) P-value 
Age (years) 0.99 (0.95-1.04) 0.68 
Gender 
         Male 
         Female 
 





Body mass index (kg/m2) 0.88 (0.78-0.98) 0.02 
Smoking 
        Never smoked 
        Current smokers 
        Ex-smokers 
 




Type of AMI 
       NSTEMI 
       STEMI 
 





Standardised Troponin 0.71 (0.43-1.15) 0.17 
Creatinine (µmol/dL) 1.00 (0.98-1.02) 0.87 
hs CRP (mg/L) 1.00 (0.98-1.02) 0.84 
TPOAb (mU/L) 0.99 (0.99-1.00) 0.28 
Time of sampling (24-
hour clock)  
        00:01-06:00 
        06:01-12:00 
        12.01-18:00 









Ischaemic heart disease 
          Absent 
          Present 
 






         Absent 
         Present 
 







Type 2 diabetes mellitus 
         Absent 
         Present 
 






        Absent 
        Present 
 






        Absent 








        Absent 







Table 4-3  Predictors of Subclinical Hyperthyroidism in patients with acute myocardial 
infarction. 















 Odds ratio (95% CI) P-value 
Age (years) 1.06 (1.01-1.11) 0.01 
Gender 
         Male 
         Female 
 





Body mass index (kg/m2) 1.03 (0.95-1.11) 0.54 
Smoking 
        Never smoked 
        Current smokers 
        Ex-smokers 
 




Type of AMI 
       NSTEMI 
       STEMI 
 





Standardised Troponin 1.06 (0.65-1.74) 0.81 
Creatinine (µmol/dL) 1.01 (1.00-1.03) 0.03 
hs CRP (mg/L) 1.00 (0.99-1.01) 0.42 
TPOAb (mU/L) 0.99 (0.99-1.00) 0.75 
Time of sampling (24-
hour clock) 
        00:01-06:00 
        06:01-12:00 
        12.01-18:00 









Ischaemic heart disease 
          Absent 
          Present 
 






         Absent 
         Present 
 





Type 2 diabetes mellitus   
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         Absent 
         Present 





        Absent 
        Present 
 






        Absent 








        Absent 







Table 4-4  Predictors of low T3 syndrome in patients with acute myocardial infarction. 




















4.1.2 Thyroid dysfunction and time of sampling 
Prevalence of Subclinical thyroid disease and baseline characteristics by time of sampling  
Logistic regression analysis had shown a higher prevalence of SCH between 00:01 and 06:00 
and SHyper between 12:01 and 18:00.  Therefore the baseline characteristic of participants 
across each time period was analysed and described (Table 4-5).  Clinical, biochemical and 
pre-existing medical conditions were similar across the various time-periods.  However, there 
were less STEMI admissions in the 12:01–18:00 hrs time period than the other time-periods. 
In addition, serum TSH and FT3 were highest between 00:01–06:00 hrs and lowest in the 
12:01–18:00 time-period whereas there was no significant difference between FT4 levels. 
Consequently, the diagnosis of SCH was highest in the 00:01–06:00 time-period (20.9%) and 
lowest in the 12:01–18:00 time-period (8.7%). Conversely, the prevalence of SHyper was 
lowest in the 00:01–06:00 time-period (0.7%) and highest in the period between 12:01–18:00 






























Age, mean ( SD), years 63.7  12.3 64.5  12.4 64.9  11.7 62.9  11.8 0.06 
Females, n (%) 108 (30.0) 175 (30.7) 160 (28.1) 118 (28.2) 0.73 
Current smokers, n (%) 128 (35.6) 164 (28.8) 161 (28.2) 143 (34.3) 0.07 
BMI, mean ( SD), kg/m2 28.4  5.7 28.2  5.1 28.6  5.6 28.9  5.7 0.22 
STEMI, n (%) 191 (53.1) 288 (50.5) 252 (44.2) 204 (48.7) 0.04 
Pulse rate, mean (SD), 
beats/minute 
76.8  16.9 76.8  17.4 75.4  17.3 76.7  19.2 0.75 
Blood pressure, mean (SD), 
mm Hg 
    Systolic 





















Ischaemia time, median 
(IQR), minutes* 
165 (118 – 
252) 
158 (112 – 
251) 
160 (114 – 
248) 
161 (107 – 
244) 
0.38 
Coronary artery affected, n 
(%) 
Left main stem 




































Thyrotropin, median (IQR), 
mU/L 
2.60 (1.50 – 
4.23) 
1.93 (1.31 – 
2.93) 
1.80 (1.16 – 
2.74) 
2.10 (1.36 – 
3.60) 
<0.001 
Free thyroxine (FT4), mean ( 
SD), pmol/L 
16.4  3.4 16.3  4.1 16.1  3.2 16.4  3.9 0.43 
Free triiodothyronine (FT3), 
mean ( SD), pmol/L 
4.9  1.0  4.7  0.8 4.6  0.7  4.7  0.9 <0.001 
Thyroid status, n (%)$ 
    Euthyroid 
    SCH 




    1 (0.3) 
 
449 (84.4) 
  79 (14.8) 
   4 (0.8) 
 
464 (85.5) 
  65 (12.0) 
   14 (2.6) 
 
312 (79.4) 
  77 (19.6) 




TPOAb, median (IQR), (U/L) 13.3 (8.8 – 
28) 
12.1 (9.2 – 
28) 
12.7 (9.3 – 
28) 
11.9 (9.3 – 
28) 
0.84 
TPOAb positive, n (%) 65 (18.0) 94 (16.4) 95 (16.7) 61 (14.5) 0.77 
Creatinine, mean ( SD), 
mol/L  
92.3  39.8 90.8  51.3 90.8  38.3 88.9  28.2 0.74 
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Past medical history, n (%) 
 
  Treated hypothyroidism 
   
  Ischaemic heart  
  disease 
 
  Hypertension 
 
  Atrial fibrillation 
 
  Type 2 diabetes     
  mellitus 
 
  Cerebrovascular   
  disease 
 



























































































Table 4-5  Baseline characteristics and prevalence of thyroid dysfunction by time of blood 
sampling. 
* Calculated as the length of time from onset of pain till blood sample obtained. 
$ After excluding individuals on levothyroxine therapy; therefore, total numbers do not add up 
to the sample size for the whole group for each time-period. 
Means compared using ANOVA. 
Medians compared using Kruskal-Wallis test. 
Proportions compared using Chi square test. 
BMI = body mass index, STEMI = ST-elevation myocardial infarction, SCH = subclinical 













Association of time of sampling with thyroid function and TPOAb parameters 
Time of sampling as a continuous variable over 24 hours (from 0 to 1440 minutes) was 
significantly associated with serum TSH and FT3 levels in an independent and nonlinear 
manner (Figure 4-2).  No significant relationship was observed between time of sampling and 























































P for nonlinearity=<0.001 
P value=0.39 
P for nonlinearity=0.18 
 
P value=<0.001 








Figure 4-2  The relationship between time of sampling over 24 hours and thyroid function 
parameters and TPOAb levels using restricted cubic spline plots with 3 knots. 
All associations adjusted for age, gender, centre, body mass index, smoking status, type of 

































     00:00                          06:00                     12:00                            18:00 
P value=0.63 





Normalisation of thyroid function versus those that remained in Subclinical thyroid 
disease state 
Of the 308 patients with subclinical thyroid disease (SCTD) diagnosed on admission that had 
repeat thyroid function assessed, 137 (44%) of 312  of individuals with SCH and 13 (61%) of 
22 of individuals with SHyper normalised serum TSH levels. There was a significant difference 
in normalisation rates depending on baseline time-period of sampling. In the baseline SCH 
group, 58% of patients from 00:01–06:00 hrs normalised serum TSH on repeat testing whereas 
only 28% of those from 12:01–18:00 normalised (p<0.001) (Figure 4-3).  In the SHyper group 
at baseline, no analysis was performed due to the small number of participants in each time-
period. The one participant with SHyper at baseline time-period of 00:01–06:00 hrs remained 
in SHyper state whereas 5 participants (of the 11 with repeat data available) in the 12:01–18:00 
hrs normalised.  
Time of sampling for the initial thyroid function testing was an independent predictor of 
subsequent thyroid status. Those individuals who had initial thyroid function test drawn 
between 12:01–18:00 hours were more likely to remain in the SCH state than those who had 
initial sampling between 00:01–06:00 hours [OR 2.56 (1.09 – 5.95)] or between 18:01–00:00 
hours [OR 2.33 (1.01 – 5.26)].  Other variables that were significantly associated with 
remaining SCH were higher initial serum TSH level [OR 1.32 (1.13 – 1.55) and those that were 
TPO antibody positive [OR 2.56 (1.67 – 3.58)].  Participant’s age, gender, interval time-period 
between the two thyroid function tests, type of AMI and smoking status were not significantly 









































































4.1.3 Relationship between thyroid dysfunction and peak troponin levels 
Subclinical hypothyroidism and peak troponin  
The association of SCH with troponin levels was analysed to assess whether SCH patients had 
higher troponin levels compared to euthyroid patients.  Firstly, the baseline demographic and 
clinical characteristics were compared in both groups and are outlined in the Table 4-6.  The 
SCH patients were significantly older, had a higher percentage of females, had a higher 
prevalence of STEMI, and as expected, had higher TSH levels.  Furthermore, SCH patients 
had a significantly higher median TPO antibody level compared to euthyroid patients: 128 (28-
286) vs. 39 (28-190), p<0.001.  Due to the study being multi-centred, all patients had either a 
troponin T or troponin I measured depending on the assay in clinical use at each site.  There 
was a significant difference in median (interquartile range) peak troponin T in SCH patients 
compared to those who were euthyroid: 580 (146-2378) vs 340 (101-1516) ng/L; p=0.001. 
There was no significant difference in median (interquartile range) peak troponin I in SCH 
patients compared to those who were euthyroid: 16984 (4157-50,000) vs 16524 ng/L (3154-
50,000); p=0.53. 
Multiple regression analysis was performed to assess whether an increase in troponin levels in 
SCH individuals were independent of other variables. A standardised troponin was used as the 
dependent variable, which took into account differences in the troponin T and troponin I assay.  
Standardisation of the troponin values transformed the troponin T and troponin I values, in 
order to combine and analyse them together.  There was a significant difference in median 
(interquartile range) standardised troponin with SCH patients having a higher troponin than 
euthyroid patients: 0.21 (-0.59-0.90) vs 0.004 ng/L (-0.78-0.88), p=0.003 using the Student t-
test. However, on multiple regression SCH was not significantly associated with elevated 
troponin levels after adjusting for other confounders (p=0.077) (Table 4-7).  The significant 
predictors for an elevated troponin were gender (p=0.029), STEMI (p<0.001), a past history of 
ischaemic heart disease (p=0.001) and C-reactive protein (CRP) levels (p=0.005).  Multiple 
regression analysis was performed using time specified reference ranges, to diagnose SCH, and 






Table 4-6 Characteristics of patients presenting with acute myocardial infarction by thyroid 
status (euthyroidism and subclinical hypothyroidism). 
 Euthyroid (n=1440) SCH (n=312) P-value 
Age (years) 63.4 (±12.0) 65.8 (±11.3) 0.001 
Males (n, %) 1074 (72.7) 213 (68.3) 0.013 
Body mass index (kg/m2) 28.5 (±5.4) 28.4 (±6.1) 0.32 
Systolic BP (mmHg) 141.8 (±27.4) 140 (±29.3) 0.42 
Diastolic BP (mmHg) 80.3 (±23.4) 82.1 (±16.9) 0.48 
Pulse rate (bpm) 77.1 (±18.7) 80.3 (±18.3) 0.52 
Current smoker (n, %) 457 (31.7) 94 (30.1) 0.40 
STEMI (n, %) 695 (48.3) 181 (58.0) 0.004 
TSH (mIU/L) 1.8 (1.3-2.5) 5.3 (4.5-6.5) <0.001 
FT4 pmol/L 16.3 (±2.9) 15.9 (±2.9) 0.09 
FT3 pmol/L 4.7 (±0.8) 5.0 (±1.0) <0.001 
TPOAb U/L 39 (28-190) 128 (28-286) <0.001 
Total Cholesterol (mmol/L) 4.97 (±1.4) 4.91 (±1.3) 0.52 
Creatinine (µmol/dL) 88.9 (±33.5) 95.2 (±66.2) 0.35 
Standardised troponin 
 
0.004 (-0.78-0.88) 0.21 (-0.59-0.90) 0.003 
IHD (n, %) 373 (25.9) 74 (23.7) 0.36 
Type 2 diabetes mellitus (n, %) 237 (16.5) 55 (17.6) 0.71 
Hypertension (n, %) 580 (40.3) 122 (39.1) 0.49 
Hypercholesterolaemia (n, %) 369 (25.6) 71 (22.7) 0.22 
Cerebrovascular disease (n, %) 65 (4.5) 18 (5.8) 0.44 
SCH – subclinical hypothyroidism, NSTEMI – non ST-elevation myocardial infarction, 
STEMI – ST-elevation myocardial infarction, TSH – thyrotropin, FT4 – free thyroxine, FT3 – 
free triiodothyronine. 
 










95% confidence interval P-value 
Male gender .104 .011 .196 .029 
Age .003 -.001 .007 .150 
BMI .005 -.003 .013 .188 
Smokers .001 -.051 .053 .959 
STEMI 1.075 .990 1.159 .000 
Creatinine .001 .000 .002 .121 
IHD .199 .101 .298 .000 
DM .014 -.098 .125 .812 
HTN .024 -.068 .116 .612 
Hypercholestrolaemia .038 -.059 .135 .444 
CVD -.056 -.245 .133 .561 
PVD -.004 -.223 .214 .970 
SCH .095 -.010 .200 .077 
CRP .003 .001 .004 .005 
Table 4-7 Variables associated with standardised troponin levels at the time of acute 
myocardial infarction whilst comparing euthyroid patients with SCH patients.   
BMI - Body mass index, STEMI - ST-elevation myocardial infarction, IHD - Ischaemic heart 
disease, DM - Diabetes mellitus, HTN - Hypertension, Chol – Hypercholestrolaemia, CVD - 
Cerebrovascular disease, PVD - Peripheral vascular disease, SCH - Subclinical 















Relationship between FT3 levels and peak troponin levels in AMI patients 
When patients with low T3 were compared with euthyroid patients, there was no significant 
different in median (interquartile range) standardized troponin: 0.21 (-0.82-0.65) vs -0.01 (-
0.78-0.88) ng/L, p=0.85.  On multiple regression LT3S was not significantly associated with 
troponin levels after adjusting for other confounders (p=0.75). 
Multiple regression was performed to assess whether T3 levels, as a continuous variable, was 
associated with standardized troponin levels.  Included in the analysis were euthyroid and LT3S 
patients whereas SCH, SHyper and patients on LT4 therapy for hypothyroidism were excluded.  
Positive predictors of an elevated troponin were male gender (p=0.010), STEMI (p<0.001), a 
past history of ischaemic heart disease (p=0.001) and CRP levels (p=0.005) (Table 4-8).  FT3 





95% confidence interval P-value 
Male gender .148 .036 .259 .010 
Age .002 -.002 .007 .337 
BMI .006 -.003 .015 .214 
Smokers -.002 -.062 .059 .955 
STEMI 1.084 .986 1.182 .000 
FT3 -.047 -.111 .017 .151 
Creatinine .001 .000 .003 .065 
IHD .199 .087 .312 .001 
DM .014 -.118 .146 .834 
HTN .010 -.097 .117 .859 
Hypercholestrolaemia .029 -.085 .142 .619 
CVD -.067 -.292 .158 .561 
PVD .145 -.099 .390 .243 
CRP .003 .001 .005 .016 
Table 4-8  Multiple regression to assess the relationship between T3 and standardised troponin 







Figure 4-4  The relationship between FT3 and standardised troponin using the multivariable 
model, corrected for each individual variable in the multiple regression analysis. The 





















Troponin levels in patients on Levothyroxine therapy 
Standardised median troponin levels in patients on LT4 therapy were not significantly lower 
than those not on LT4 (-0.1 v 0.01 ng/L; p=0.303). Multivariate regression analysis revealed 
no significant association between LT4 use and standardised troponin levels after adjusting for 
other confounders (p=0.90) (Table 4-9). Of the 113 patients on LT4 therapy, 26 (23%) patients 
had elevated and 6 (5.3%) had low serum TSH levels suggesting under and over replacement, 
respectively. The small number of participants with poorly controlled hypothyroidism 





95% confidence interval P-value 
Male gender .102 .047 2.265 .024 
Age .003 .040 1.703 .089 
BMI .006 .031 1.494 .135 
Smoking -.004 -.003 -.146 .884 
STEMI 1.080 .543 26.212 .000 
LT4 use .010 .002 .122 .903 
Creatinine .001 .041 2.003 .045 
IHD .189 .084 3.950 .000 
DM .043 .017 .809 .419 
HTN .011 .005 .241 .809 
Hypercholestrolaemia .032 .014 .676 .499 
CVD -.039 -.008 -.428 .669 
PVD -.023 -.004 -.216 .829 
CRP .003 .060 3.090 .002 
Table 4-9  Variables predicting troponin levels post-acute myocardial infarction by euthyroid 











This study demonstrates a high prevalence of thyroid dysfunction in AMI patients confirming 
previous reports. In particular, SCH is the most frequent abnormal thyroid state noted with 
almost one in six individuals being diagnosed with this condition. The prevalence of LT3S and 
SHyper, on the contrary, are lower with approximately 1 in 100 patients being affected. 
Importantly, the study also provides information on predictors of these thyroid dysfunction 
states, which may be useful for clinicians managing patients with AMI.   
Several observational studies have shown the prevalence of thyroid dysfunction in patients with 
AMI to be relatively high (Ertugrul et al., 2011; Mukherjee et al., 2018; Zahler et al., 2019). 
The results of this analysis, for the first time as far as we are aware, add to this and identify risk 
factors for the common thyroid dysfunction states.  Older individuals, females, those with 
higher TPOAb levels or higher creatinine concentrations had a higher risk of being classed as 
having SCH.  In addition, patients who had their thyroid function samples obtained in the early 
hours of the morning also had a higher risk of being classed as having SCH.  These findings 
are consistent with previous reports obtained from community-dwelling adults (Canaris et al., 
2000; Hollowell et al., 2002; Vadiveloo et al., 2011). 
The NHANES III Study showed females to have higher TSH values whereas in a recent large 
population study, the TSH reference intervals were wider and higher in females compared to 
males (0.56–7.43 mIU/L vs. 0.62–6.57 mIU/L) (Hollowell et al., 2002; Park et al., 2018b).  
With regard to an increase in the prevalence of SCH with age, Vadiveloo et al in TEARS Study 
assessed thyroid function tests retrospectively in over 150000 subjects without thyroid disease 
and found the 97.5th median TSH centile to increase from 3.98, in subjects 30-40 years of age, 
to 5.94 in those above 90 (Vadiveloo et al., 2013).  The NHANES III and the cardiovascular 
health allstars study showed TSH levels to increase with age and be more significant after the 
age of 70 (Hollowell et al., 2002; Waring et al., 2012).  However, this increase in the upper 
limit TSH interval with age may not represent true SCH, although international guidelines do 
not define SCH according to age and TSH cutoff values.   
The relationship between TPO antibodies and SCH has been well studied and provides an 
additional explanation for the increased prevalence SCH in females.  For example in the 
NHANES III Study, 60% of SCH cases were associated with elevated TPO antibodies and such 
levels were higher in females and increased with age whereas the Rotterdam Study showed 
individuals positive for TPO antibodies to have higher TSH levels and lower T4 levels than 
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those who had levels within the normal range (Hollowell et al., 2002; Chaker et al., 2016).  In 
a further study by Surks et al, 67.4% of patients between 40-49 with SCH had elevated TPO 
antibodies whereas a 20 year follow up of the Whickham Survey demonstrated that progression 
of SCH to overt hypothyroidism was not only dependent on the baseline TSH but also on TPO 
antibody levels (Vanderpump et al., 1995; Surks and Hollowell, 2007). 
The results of this analysis have shown the diagnosis of subclinical thyroid disease and 
subsequent rates of normalisation of serum TSH levels in patients with AMI to be influenced 
by the time of sampling. Interestingly, the time of blood sampling from participants was a 
strong predictor of SCH with samples taken between 00:00 and 06:00 followed by samples 
between 18:00 and 24:00 being the strongest predictors of SCH.  However, patients who had 
SCH diagnosed between 12:00 and 18:00 were more likely to remain in SCH on repeat testing.  
These results contest the previously held view that the time of sampling has very little impact 
on the width of the TSH reference range and suggest the time of sampling should be considered 
when evaluating whether a given TSH result is abnormal.  The circadian variation of TSH, has 
previously been well established with the lowest TSH concentration in the afternoon and the 
TSH concentrations subsequently increasing after midnight (Andersen et al., 2003).  In an 
analysis of TSH values of over 400000 euthyroid individuals, there was a significant nocturnal 
TSH surge which resulted in a higher upper limit TSH reference interval with age indicating 
how the reference interval for TSH can vary by time of day (Ehrenkranz et al., 2015).  
Similarly, another retrospective laboratory database interrogation of TSH data from more than 
19,000 outpatient visits concluded that the prevalence of SCH reduced from 14.1% to 7.9% 
and that of SHyper increased from 6.8% to 7.9% between 7-8am and 2-3pm, respectively 
(Andersen et al., 2015).  These previous studies combined with the present data suggests that 
the time of sampling should be considered when devising the reference range for TSH to avoid 
the inappropriate classification of individuals with thyroid dysfunction. 
The present study demonstrated increased creatinine levels to be a significant predictor of SCH 
and low T3; further supporting the view that thyroid dysfunction may be related to renal 
function. The relationship between elevated TSH levels and kidney disease has previously been 
investigated with studies showing SCH and overt hypothyroidism to be strongly associated 
with increased creatinine levels and the progression to chronic kidney disease (Asvold et al., 
2011; Zhang et al., 2018). Studies have also demonstrated a reduction in the decline in kidney 
function with levothyroxine therapy (Shin et al., 2013; Lu et al., 2016). A possible explanation 
for the observed relationship between renal impairment and underactive thyroid states include 
125 
 
diastolic dysfunction, reduced cardiac output and increased systemic resistance which all result 
in reduced renal perfusion (Klein and Ojamaa, 2001).  Low T3 in kidney disease and AMI may 
be due to reduced deiodinase activity leading to less conversion of T4 to T3 in chronic disease 
states (Xu et al., 2016). 
Our data also assessed the relationship between thyroid dysfunction and troponin levels to see 
whether an elevated troponin may provide an explanation for the adverse outcomes seen in 
SCH and low T3 syndromes from previous studies (Friberg et al., 2001; Iervasi et al., 2003; 
Lazzeri et al., 2012).  For example, Iervasi and colleagues found patients with SCH (6.7% of 
the total cohort) and low circulating T3 levels (29.2%), after admission with cardiac disease, 
to have a higher risk of cardiovascular and all-cause mortality than euthyroid individuals 
(Iervasi et al., 2007).  Experimental studies have shown low circulating T3 to be associated 
with an increase in infarct size post AMI and restoration of T3 levels reduces progression to 
heart failure (Chen et al., 2008; Forini et al., 2011).  In the present study, patients with SCH at 
the time of AMI had a higher serum troponin levels than euthyroid patients although this was 
not significant with multiple regression analysis.  Furthermore FT3 levels were not associated 
with increased troponin levels when FT3 levels were first assessed as a categorical variable, 
comparing LT3 patients with patients who had normal T3 levels, and then as a continuous 
variable.  Our results therefore show such worse outcomes in SCH and LT3 patients with AMI 
to be unlikely related to troponin levels or potential infarct size. 
Another study of 2430 patients undergoing percutaneous coronary intervention showed 
patients on LT4 therapy for hypothyroidism had an increased incidence of major adverse 
cardiac events during follow-up in comparison to euthyroid patients. In the same study, 
individuals with poorly controlled hypothyroidism whilst on TH replacement similarly had 
higher cardiovascular events than people with serum TSH within the reference range on LT4 
therapy (Zhang et al., 2016). Our study demonstrated that nearly 30% of patients on 
levothyroxine had an abnormal TSH level indicating inadequate thyroid hormone replacement.  
This finding, has been previously reported, is important as both suppressed and high serum 
TSH have been associated with increased risk of cardiovascular disease (Flynn et al., 2010).  
However, our analysis shows that in patients admitted with AMI, prior treatment for 
hypothyroidism does not impact on troponin levels. Therefore alternative mechanisms could 
potentially accelerate cardiovascular disease progression, in known hypothyroid patients, such 
as hyperlipidemia, endothelial dysfunction, systemic inflammation, thrombogenesis and 
cardiac dysfunction (Jabbar et al., 2017).  
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The strengths of this study are the relatively large number of patients analysed, the prospective 
and uniform method of recruitment and assay analysis.  For instance, samples were obtained at 
the first opportunity after presentation to hospital (so the impact of non-thyroidal illness was 
minimised) and prior to diagnostic coronary angiography (coronary angiographic dyes contain 
iodine in supra-physiological amounts that could affect thyroid function).  Our analysis has 
several limitations too.  Firstly, patients’ thyroid status was determined based on a single 
thyroid function assessment within 24 hours of hospital admission (mostly immediately at the 
time of presentation). Although this process reduced heterogeneity and variability amongst 
each participating site, fluctuations of thyroid function were not taken into account by repeat 
testing.  This may help explain, at least in part, the high proportion of patients with SCH and 
low number of patients with LT3 observed in our cohort. Secondly, the number of patients in 
certain subgroups (subclinical hyperthyroidism and low FT3) are limited and therefore no 
meaningful analyses could be performed. Nevertheless, to our knowledge, this is the largest 
cross-sectional study to date in which the complete thyroid profile including T3 has been 
assessed in patients presenting with an AMI. Finally, important clinical endpoints such as left 
ventricular function or infarct size determination via robust imaging techniques were not 
examined in this study. However, troponin release after AMI has been shown to be a strong 
predictor of outcomes and this study provides useful information regarding its association with 
thyroid function which was previously lacking (Matetzky et al., 2000).  
In conclusion, thyroid dysfunction is relatively common in patients admitted with AMI with 
SCH being observed in one in six individuals. Other thyroid dysfunction states such as SHyper 
and LT3S are relatively less frequent. Older individuals and those with higher creatinine levels 
are both likely to have SCH or LT3S, whereas women, and those with higher TPOAb levels 
and samples obtained in the early hours of the morning are more likely to be diagnosed with 
SCH.  We have shown a high prevalence of SCH in AMI patients and this is not associated 
with increased myocardial damage as measured by increased troponin release.  Finally, our 
analysis suggest that both the initial diagnosis of SCTD in patients with AMI and the proportion 
that subsequently normalise thyroid function is independently and significantly associated with 
time of sampling.   This suggests the time of sampling should be considered when devising the 





4.2 The effect of levothyroxine on clinical outcomes, cardiac function and infarct size 
using cardiac MRI 
 
4.2.1 Baseline characteristics and peri-procedural data 
For the RCT, patients had a baseline CMR scan after randomisation, within three weeks of 
their AMI, and then at 52 weeks post treatment.  During the enrolment period, between January 
2015 and December 2016, 2,147 patients were admitted to the participating hospitals with acute 
myocardial infarction and 1,996 consented to have their thyroid function screened (Figure 4-5).  
Of these, 314 (16%) participants were identified with subclinical hypothyroidism, and after 
assessments of trial inclusion and exclusion criteria, 95 participants were recruited to the trial 
with 46 randomised to the levothyroxine group and 49 to the placebo group.  Ten randomised 
participants did not have either the baseline, final-visit, or both cardiac MRI scans (7 in the 
levothyroxine group and 3 in the placebo group), leaving 85 participants for the analysis of the 
primary outcome 
Baseline data for both groups are shown in Table 4-10.  Baseline characteristics were similar 
in both the LT4 and placebo groups indicating both were well matched.  Both groups were 
similar with regard to age and past medical history which included cardiovascular risk.  The 
median number of days of starting treatment post AMI was not significantly different in both 
groups, 17 (14.5-20) vs. 16 (14.0-19.5) in placebo, p=0.36.  The thyroid profile was similar in 
both groups at the start of the study with a median TSH 5.75 (4.95-7.05) vs. 5.7 (4.7-7.3) in the 
placebo group, p=0.96.  Furthermore the procedural data showed both groups were well 
matched in the treatment for their AMI which could have impacted on cardiac function (Table 
4-11).  For patients presenting with a STEMI, the median time from onset of symptoms to 
coronary intervention was 120mins (81-172) in the LT4 group and 137mins (71.5-209) in the 
placebo group, p=0.46.  Both groups were similar with regard to the TIMI flow pre and post 
PCI, the use of drug eluting stents, the culprit coronary artery, the use of antiplatelet 

















































2147 Patients presented with AMI 




    17 On medications affecting thyroid function 
(amiodarone, lithium and anti-epileptic dugs)  
    28 Declined to provide consent 
    19 Age more than 75 years 
    22 Could not consent due to language barriers 
    54 Final diagnosis other than AMI 
    11 Advanced malignancy 
 
1996 Participants had thyroid function evaluated 
 
94 participants randomised 
46 randomised to receive LT4 
 
49 randomised to receive placebo 
 
39 Underwent cardiac MRI at baseline and 
12 months 
    6 Did not undergo cardiac MRI  
           2 Experienced claustrophobia 
           1 High BMI 
           2 Insufficient image quality 
           1 Died 
 
 
46 completed cardiac MRI scans at baseline 
and 12 months 
 3 Did not undergo cardiac MRI 
1 Experienced claustrophobia 
1 Refused  
1 Died 
 
1682 further excluded 
    1466 Euthyroid  
      113 On Levothyroxine therapy for 
hypothyroidism 
        23 New diagnosis of Subclinical 
hyperthyroidism 
          3 New diagnosis of Overt hyperthyroidism 
          2 New diagnosis of Overt hypothyroidism 
        48 TSH not measured 
        27 TSH measured more than 24 hours after     
              admission 
 
314 Participants with SCH 
 
219 Excluded 
  127 Normalised TSH on repeat thyroid 
testing 
    81 Refused participation 
      8 Recruited to other clinical trials 




 All (n=95) LT4 (n=46) Placebo (n=49) 
Age (years) 63.5 (±9.5) 64.1 (±9.4) 62.9 (±9.7) 
Male sex 72 (75.8%) 36 (78.3%) 36 (73.5%) 
Systolic BP (mmHg) 126.6 (±16.8) 127 (±16.3) 126.3 (±17.5) 
Diastolic BP (mmHg) 74.9 (±9.7) 76 (±8.56) 73.8 (±10.6) 
Heart rate (bpm) 61.4 (±9.4) 60.1 (±9.5) 62.6 (±9.2) 
BMI (kg/m2) 28.7 (±4.2) 28.1 (±3.9) 29.2 (±4.4) 
Current smoker 25 (26.3%) 14 (30.4%) 11 (22.9%) 
Ex-smoker 37 (38.9%) 21 (45.7%)  16 (32.7%) 
NSTEMI 29 (30.5%) 13 (28.3%) 16 (32.7%) 
STEMI 65 (68.4%) 32 (69.6%) 33 (67.3%) 
TSH (mU/L) study start* 5.7 (4.8-7.3) 5.75 (4.95-7.05) 5.7 (4.7-7.3) 
FT4 pmol/L 14.7 (±2.1) 14.7 (±2.1) 14.6 (±2.5) 
FT3 pmol/L  4.5 (±0.69) 4.6 (±0.76) 4.4 (±0.62) 
    
Days since starting 
treatment* 17 (14.0-20) 17 (14.5-20) 16 (14.0-19.5) 
NYHA 1 15 (15.8%) 7 (15.2%) 8 (16.3%) 
             2 74 (77.9%) 36 (78.3%) 38 (77.6%) 
             3 5 (5.3%) 2 (4.3%) 3 (6.1%) 
    
Total Cholesterol (mmol/L) 4.8 (±1.39) 4.78 (±1.3) 4.83 (±1.2) 
Creatinine (µmol/dl) 94.2 (±44.5) 93 (±36.5) 96.9 (±66.2) 
Ischaemic heart disease 7 (7.4%) 3 (6.5%) 4 (8.2%) 
Diabetes mellitus 18 (18.9%) 8 (17.4%) 10 (20.4%) 
Hypertension 37 (38.9%) 18 (39.1%) 19 (38.7%) 
Hypercholestrolaemia 27 (28.4%) 13 (28.3%) 14 (28.5%) 
Cerebrovascular disease 5 (5.3%) 2 (4.3%) 3 (6.1%) 
Table 4-10 Baseline characteristics comparing both the LT4 and placebo groups.  The table 
shows there is no significant difference in each variable between both groups.  Continuous 
variables are shown as mean (±SD) and median (IQR) whereas categorical variables as 
numbers (%). 
 *Non-normally distributed data, analysed after log-transformation with Student’s  t-testing 
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SCH – subclinical hypothyroidism, NSTEMI – non ST-elevation myocardial infarction, 





 LT4 (n=46) Placebo (n=49) 
Symptom to PCI time(mins)* 120 (81-172) 137 (71.5-209) 
Glycoprotein IIb/IIIa inhibitor 21 (45.6%) 20 (40.8%) 
Timi pre-PCI grade   
         Pre-PCI grade 0 10 (21.7%) 12 (24.5%) 
         Pre-PCI grade 1 5 (10.9%) 9 (18.4%) 
         Pre-PCI grade 2 18 (39.1%) 17 (34.7%) 
         Pre-PCI grade 3 13 (28.3%) 11 (22.4%) 
Timi post-PCI grade   
        Post-PCI grade 2 3 (6.5%) 2 (4.1%) 
        Post-PCI grade 3 43 (93.5%) 47 (95.9%) 
Drug eluting stent use 40 (86.9%) 45 (91.8%) 
Left main coronary artery 0 2 (4.1%) 
Left anterior descending artery 11 (23.9%) 18 (36.7%) 
Right coronary artery 22 (47.8%) 23 (46.9%) 
Left circumflex artery 7 (15.2%) 5 (10.2%) 
Other artery 6 (13%) 1 (2.0%) 
Subsequent PCI 5 (10.9%) 9 (18.4%) 
Aspirin 46 (100%) 49 (100%) 
Second antiplatelet agent 46 (100%) 49 (100%) 
      Clopidogrel 13 (28.3%) 14 (28.6%) 
      Ticagrelor 12 (26.7%) 12 (24.5%) 
      Prasugrel 21 (46.7%) 23 (46.9%) 
Beta blocker 43 (95.6%) 48 (97.9%) 
ACE or ARB 44 (97.8%) 48 (97.9%) 
Statin 46 (100%) 49 (100%) 
Table 4-11 Periprocedural details comparing both the LT4 and placebo groups.  Continuous 
variables are shown as mean (±SD) and median (IQR) whereas categorical variables as 
numbers (%). 
Symptom to PCI time and Glycoprotein IIb/IIIa inhibitor use were for STEMI patients only. 
*Non-normally distributed data, analysed after log-transformation with Student’s  t-testing 
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PCI – primary coronary intervention, ACEI-angiotensin - converting enzyme inhibitor; ARB - 
angiotensin receptor blocker; TIMI - Thrombolysis In Myocardial Infarction 
 
 
4.2.2 TSH variability between both groups and the effect of levothyroxine on clinical 
outcomes and adverse events 
 
The median TSH was significantly lower in the LT4 group after 1 year of treatment, TSH 1.8 
(1.3-2.2) vs. 3.2 (2.7-4.2) in the placebo group, p=0.002 (Table 4-12).  Throughout the study 
visits, the median TSH significantly decreased in the LT4 group with the TSH at visit V1 being 
5.75 (4.9-7.1) vs. 1.8 (1.3-2.2) at V6, p<0.001.  The mean FT4 was significantly higher in the 
LT4 group at the end of the study with a FT4 at visit 6 of 17.2±2.7 vs. 14.6±2.1 in the placebo 
group, p<0.001.  There was no significant difference in the mean (±SD) FT3 between both 
groups at the end of the study, 4.7±0.6 vs. 4.8±0.6 in the placebo group, p=0.52.   Furthermore, 
there was a significant increase in the LT4 dose prescribed at each study visit in the LT4 group 
starting from a median dose of 25 (25-25) mcg at V1 to 50 (50-75 mcg at V6, p<0.001.   
With regard to serious adverse events (SAEs), there were 10 SAEs in 8 patients in the LT4 
group and 17 SAEs in 10 patients in the placebo group (Table 4-13). The SAEs were divided 
into cardiovascular and non-cardiovascular events.  In the LT4 group, there were 2 
cardiovascular SAEs which included one patient having a NSTEMI needing a further stent and 
one patient developing new paroxysmal atrial fibrillation.  In the placebo group there were 6 
cardiovascular SAEs which included: a NSTEMI managed conservatively due to minor in stent 
restenosis, pulmonary oedema due to nephrotic syndrome flare, bilateral pitting oedema 
needing diuresis, a NSTEMI with small branch occlusion managed conservatively, dyspnoea 
needing admission which was secondary to ticagrelor, and a NSTEMI needing a further stent.  
Adverse events were compared between both groups using logistic regression.  The 
independent predictors included age, gender, type of AMI and allocation to LT4/placebo.  The 
cardiovascular and non-cardiovascular were not significantly different between both groups.  










  V1 V2 V3 V4 V5 V6 












 FT4 pmol/L 14.7 (±2.1)     17.2±2.7 
 FT3 pmol/L 4.5 (±0.69)     4.7±0.6 




25 25 (25 – 
25) 
50 (25 – 
50) 
50 (25 – 
68.8) 
50 (25 – 
75) 
50 (50 – 
75) 
        












 FT4 pmol/L 14.6 (±2.5)     14.6±2.1 
 FT3 pmol/L 4.4 (±0.62)     4.8±0.6 
Table 4-12 A comparison of the variation in TSH  between both groups throughout the study 
visits and the mean dose of LT4 given during each visit. The median TSH decreased throughout 
the study with a subsequent increase in the LT4 dose in the LT4 group.  
Values are shown as mean (±SD) or median(IQR). 
TSH – Thyrotropin, FT4 – free thyroxine, FT3 – free triiodothyronine, IQR – interquartile 














    Moderate  








OR 0.88 (0.33-2.32) 






   Moderate 











OR 1.33 (0.55-3.21) 





Death 1 (2.2) 1 (2.0) 
 
0.95 
Table 4-13 Adverse events and clinical outcomes reported by treatment allocation. Adverse 
events and clinical outcomes were compared using logistic regression. 




 LT4 group (n=46) 
SAEs                       AEs 
Placebo group (n=49) 
SAEs                   AEs 
Cardiovascular   
Atrial fibrillation 1 2 
Acute coronary syndrome 1 2 
Heart Failure  2 
Pedal edema  2 
Elective angiogram/PCI 2 1 
Bradycardia 3 2 
Left ventricular thrombus 1  
Postural drop in blood pressure 1  
Angina 3 3 
Low blood pressure 3 3 
Palpitations 2 1 
Vasovagal faint  3 
Left ventricular hypertrophy  1 
Dyspnea secondary to ticagrelor  2 
   
Nervous system   
Headaches 1                                       1  
Transient ischemic attack  1 
Essential tremor 1  
Peripheral neuropathy  1 
Sciatic back pain 1  
   
Respiratory   
Exacerbation of asthma 1 1 
Exacerbation of COPD  1                                   2 
Lung malignancy 1  
Pneumonia  1 
Dyspnea other causes 1 1                                   1 
Chest infection 3 2 
Incidental lung nodule 1  
   
Gastrointestinal   
Gastrointestinal bleed 1 2 
Duodenal ulcer  1 
Gastrointestinal malignancy 1  
Iron deficiency anaemia  1                                   1 
Acute abdominal pain 1  
Incisional hernia pain 1  
Gastroenteritis 1  
Deranged liver function tests  1 
Reflux oesophagitis 3 5 
Vomiting 2  
Constipation 1  
   
Urogenital   
Urine infection 1  
Renal calculus 1  
Papillary bladder tumour  1 
Acute kidney injury 1  
   
Others   
Atypical chest pain 5 1                                   4  
Musculoskeletal chest pain 2                                      1 
Epistaxis  1 
134 
 
Ankle tendon tear 1  
Raynaud’s disease 1  
Skin rash  1 
Gout 1  
Dog bite  1 
Fatigue 1  
Peripheral claudication  2 
Leg cramps  1 
Common cold 2 1 
Oral thrush 1  
Fractured clavicle  1 
Low mood 1 1 




























4.2.3 The effect of levothyroxine on cardiac function 
At V1, the start of the study, the mean left ventricular ejection fraction (LVEF) in the LT4 and 
placebo groups were 51.29±9.14 vs. 54.01±7.9 in the placebo group, p=0.14 using the 2-sample 
t test (in %, mean±SD).  Patients in the LT4 and placebo groups had no statistical difference in 
LVEF after 1 year of treatment, 53.8±9.67 vs. 56.09±7.91 in placebo group, p=0.237 (Figure 








































Figure 4-6  A comparison of mean LVEF between LT4 and placebo groups at baseline and 






Multiple linear regression analysis was used to ascertain the relationship between LVEF at the 
end of study and allocation to either LT4 or placebo (Table 4-15).  LVEF at the end of the study 
was the dependent variable whereas the various independent variables included gender, age, 
type of AMI, infarct territory, LVEF at visit 1 and finally allocation to either LT4 or placebo.  
The relationship between LVEF at the end of study and other continuous predictor variables 
(age and baseline LVEF) confirmed a linear relationship.  Normal distribution of residuals was 
evaluated and confirmed by Q-Q plot (Figure 4-7).  Multicollinearity was excluded as the 
variance inflation factor levels were below 2.5.  
Allocation to LT4 was not a significant predictor (p=0.37) with the adjusted difference (95% 
confidence interval) in LVEF being 0.76% (-0.9 - 2.45) higher in the LT4 group compared to 
placebo.  Gender (p=0.022), increasing age (p=0.004) and LVEF V1 (p<0.001) were the 
positive predictors of LVEF at end of the study.  An increase in EF by 1% at V1 was associated 




95% confidence interval P-value 
Age (years) -0.114 -0.201 -0.026 0.004 
Male gender -2.383 -4.408 -0.357 0.022 
STEMI -0.194 -2.144 1.757 0.844 
Infarct territory -0.211 -1.167 0.745 0.662 
LT4 vs placebo 0.764 -0.928 2.457 0.371 
LVEF V1 (%) 0.891 0.788 0.994 0.000 




Figure 4-7 Normal distribution of residuals was evaluated and confirmed by Q-Q plot. 
 
 
Sensitivity analysis assessed the interaction between allocation code and each of the variables 
of age group, sex, baseline LVEF, type of AMI, and baseline serum TSH, FT4 and FT3 and 
suggested that the result obtained was robust, and not due to differences in relevant baseline 
characteristics (Table 4-16).  For each interaction variable, allocation to LT4 did not result in 
a significant improvement in LV function.  For patients with an LVEF of <55%, LT4 was 
associated with a higher LVEF although the p for interaction was non-significant when 













Variable LT4            Placebo 
(n=39)            (n=46) 





  Male 
  Female 
 
31                     35 
 
8                  11 
 
0.55 (-1.4 - 2.6) 




Age groups, years 
  Below median ( 62.7) 
  Above median (> 62.7) 
 
18                  25 
 
21                  21 
 
0.64 (-1.9 - 3.2) 
0.37 (-2.5 - 3.3) 
 
0.91 
Type of AMI 
  STEMI 
  NSTEMI 
 
29                    33 
10                    13 
 




Baseline LVEF, % 
  Normal (≥55) 
  Reduced (<55) 
 
 
13                    19 
 
26                 27 
 
-0.05 (-2.80 to 1.79) 
 




Baseline serum TSH, 
mU/L 
  Below median ( 5.7) 
  Above median (> 5.7) 
 
 
17                  24 
 
22                  22 
 
 
0.35 (-2.96 - 3.66) 
 
1.02 (-1.21 - 3.25) 
 
0.47 
Baseline serum FT4, 
pmol/L 
  Below median ( 14.4) 
  Above median (> 14.4) 
 
 
22                   21 
 
17                   25 
 
 
0.36 (-1.91 - 2.63) 
 
0.87 (-1.98 - 3.72) 
 
0.95 
Baseline serum FT3, 
pmol/L  
  Below median ( 4.5) 
  Above median (> 4.5) 
 
 
21                   24 
 
15                   20 
 
 
0.05 (-2.26 - 2.36) 
 
1.65 (-0.89 - 4.18) 
 
0.39 
Table 4-16 Effect of Levothyroxine compared with Placebo on LVEF according to prespecified 
subgroups. 
 Adjusted for baseline age, sex, type of AMI, baseline LVEF and infract territory. 
 Free T3 levels at baseline were available for 36 and 44 participants on LT4 and placebo, 
respectively. 
LVEF – left ventricular ejection fraction; AMI – acute myocardial infarction; TSH – 










Figure 4-8  Dot and Whisker plot to show a comparison of LT4 and placebo treatment on LVEF 
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            LVEF  55 
  TSH > 5.7 
  TSH  5.7 
      T4 > 14.4 
      T4  14.4 
            T3 > 4.5 
            T3  4.5 
 




Other measurements derived from the CMR analysis are shown in (Table 4-17). Important 
measurements in addition to the EF were end-diastolic volume (EDV) and end-systolic volume 
(ESV).  For each measurement, multiple regression was used to compare LT4 treatment with 
placebo with the independent predictors including age, gender, type of AMI, infarct territory, 
baseline results at visit 1, and allocation to LT4/placebo.  Allocation to LT4 was not a 
significant predictor for each measurement with the adjusted difference (95% confidence 
interval) being non-significant.   
For EDV/BSA at visit 2, allocation to LT4/placebo was not a significant predictor  (p=0.078) 
(Table 4-18).   The only positive predictor was EDV/BSA at visit 1 (P<0.001).  For ESV/BSA 
at visit 2, allocation to LT4/placebo was not significant a predictor (p=0.11) (Table 4-19).  The 
positive predictors were gender (p=0.041) and ESV/BSA at visit 1 (p<0.001).  Although there 
was no significant difference between LT4 and placebo with regard to LV volumes, the analysis 
demonstrated a trend towards an improvement of volumes with LT4 therapy as shown by a 










 Baseline                      V6 Baseline                      V6   
Secondary end 
points 
(n=45) (n=49)     
EDV/BSA ml/m2 68.6 (±17.2) 66.7 (+-16.6) 70.5 (13.8) 70.4 (+- 13.1) -4.27 (-9.03-0.49) 0.08 
ESV/BSA ml/m2 34.4 (±14.1) 31.1 (+-12.1) 32.9 (±9.9) 31.4 (+- 10.2) -2.44 (-5.46-0.58) 0.11 
Stroke index ml/ m2 34.4 (±6.6) 34.9 (+-7.8) 37.6 (±7.9) 38.9 (+- 6.9) -1.74 (-4.11-0.64) 0.15 
Cardiac output 
L/min 
3.9 (±0.7) 4.1 (+-0.87) 4.6 (±1.1) 4.6 (+- 0.96) -0.14 (-0.47-0.18) 0.38 








Table 4-17 Other measurements derived from CMR analysis.  Outcomes were compared using 
multiple regression with the independent predictors used including age, gender, type of AMI, 







95% confidence interval P-value 
Age (years) -0.096 -0.343 0.151 0.442 
Male gender 4.211 -1.253 9.675 0.129 
STEMI -1.359 -6.633 3.916 0.609 
Infarct territory 1.508 -1.186 4.201 0.268 
EDV/BSA ml/m2 V1 0.660 0.507 0.814 0.000 
LT4 vs placebo 4.270 -0.489 9.030 0.078 
Table 4-18 Variables associated with EDV/BSA at the end of the study.   







95% confidence interval P-value 
Age (years) 0.041 -0.115 0.196 0.606 
Male gender 3.645 0.161 7.128 0.041 
STEMI -0.636 -3.997 2.724 0.707 
Infarct territory 1.188 -0.509 2.885 0.167 
ESV/BSA ml/m2 V1 0.731 0.605 0.856 0.000 
LT4 vs placebo 2.438 -0.579 5.456 0.112 
Table 4-19 Variables associated with ESV/BSA at the end of the study.  







4.2.4 The effect of levothyroxine on cardiac parameters assessed by gadolinium 
enhancement 
 
Overall 30 patients in the LT4 group and 30 patients in the placebo group received gadolinium.  
The main measurements were infarct/g, left ventricular mass/g (LVM/g) and % infarct.  There 
was no significant difference in infarct/g at visit 2 between both LT4 and placebo groups with 
median values of 5.6 (1.31-15.2) vs 7.03 (1.03-13.3), p=0.82 using the Mann-Whitney test 
(median and IQR) (Table 4-20).  The median % infarct at V2 was 5.8 (2.05-12.9) vs 8.4 (1.03-
14.8), p=0.81.  Multiple linear regression analysis was used to correct for each independent 
variable.  The % infarct at V2 was used as the dependent variable whereas the independent 
variables were age, gender, type of MI, infarct territory, % infarct at V1 and allocation to 
LT4/placebo.  The only significant predictor of % infarct at V2 was % infarct at V1, p<0.001 
(Table 4-21).  Allocation to LT4/placebo was a non-significant predictor, p=0.976 with the beta 
coefficient showing a difference of only 0.02% in infarct size between both groups.  Table 4-22 
shows the adjusted difference (95% confidence interval) for each infarct size measurement 
between both groups with the results being non-significant. 
 
 
 LT4 (n=30) Placebo (n=30) P value 
Infarct/g V1 
 
7.97 (2.54-20.3) 8.96 (1.94-16.1) 0.92 
LVM/g V1 
 
106.4 (±33.4) 102.1 (±22.9) 0.56 
% infarct V1 
 
7.77 (2.65-14.7) 8.49 (1.7-16.2) 0.96 
Infarct/g V6 
 
5.6 (1.31-15.2) 7.03 (1.03-13.3) 0.82 
LVM/g V6 
 
99.2 (±29.9) 94.0 (±18.2) 0.60 
% infarct V6 
 
5.8 (2.05-12.9) 8.4 (1.03-14.8) 0.81 
Table 4-20  A comparison of gadolinium enhancement in both the LT4 and placebo groups.   
Values are shown as mean (±SD) and median (IQR). 










95% confidence interval P-value 
Age 0.022 -0.050 0.094 0.543 
Male gender 0.921 -0.739 2.582 0.271 
STEMI -0.018 -1.753 1.718 0.984 
Infarct territory -0.465 -1.261 0.331 0.246 
% infarct V1 0.808 0.742 0.874 0.000 
LT4/placebo -0.020 -1.377 1.336 0.976 
Table 4-21  Variables associated with the % infarct at V2 using multiple regression.  The only 
positive predictor was % infarct at V1, p<0.001.  Allocation to LT4/placebo was non-
significant with p=0.976. 
 
 







Baseline                      V6 Baseline                      V6 
  
  Infarct size (n= 30) (n=30) 
 
  
Infarct gms 7.9 (2.5-20.3) 5.6 (1.3-15.2) 8.9 (1.9-16.1) 7.0 (1.0-13.3) 0.23 (-1.31-1.77) 0.77 
LVM gms  106.4 (±33.4) 99.2 (+- 29.9) 102.1 (±22.9) 94.0 (+- 18.2) 1.97 (-4.43-8.37) 0.54 








Table 4-22  Infarct size data compared between both groups using multiple regression.  








The current RCT demonstrates no improvement in LV function in SCH patients treated with 
LT4 post AMI.  The findings from the ThyrAMI study are important as: 
I. This is the first RCT investigating the use of thyroxine in patients with SCH post AMI 
to assess an improvement in LV function.   
II. Participants were on all recommended secondary prevention therapy and were chosen 
based on a strict eligibility criteria to minimise confounding variables. 
III. We need to investigate further therapies to improve cardiovascular outcomes in patients 
with low TH levels post AMI, and this study should give investigators the confidence 
in the safety profile of using thyroid replacement therapy. 
In this double-blind, randomised, placebo-controlled trial, treatment with LT4, albeit a low 
dose, for 52 weeks appeared safe but did not improve LV function in SCH patients presenting 
with AMI.  The findings show there is no benefit of treating SCH patients with thyroxine post 
AMI and suggest further studies are needed to investigate alternative TH treatments in patients 
with a low TH state.   
SCH, particularly when serum TSH is greater than 7 mU/L, is associated with a higher risk of 
developing cardiovascular disease and heart failure (Rodondi et al., 2010; Kannan et al., 2018).  
The presence of SCH in patients admitted with an acute cardiac event is associated with an up 
to 3.6-fold increase in cardiac mortality and a 2.3-fold increase in mortality (Iervasi et al., 2007; 
Molinaro et al., 2012).  There is some evidence that thyroid hormone administration may be 
beneficial in ameliorating cardiac disease.  In animal models of AMI, administration of thyroid 
hormone augments myocardial remodelling and improves LV function (Pingitore et al., 2012).  
Individuals with SCH aged 65 years or older treated with LT4 have a 72% reduction in heart 
failure events (Rodondi et al., 2008).  Several other smaller trials have shown that treatment of 
SCH with LT4 improves LV function (Biondi et al., 1999; Monzani et al., 2001; Ripoli et al., 
2005).  Thus, SCH following AMI is an important marker for poor outcome, and one that is 
suitable for a cost-effective intervention, if evidence of efficacy can be shown. However, it 
remains unknown if the relationship between SCH with poor prognosis in cardiac patients is 
causal or whether a raised serum TSH is a biomarker of the disease severity. To our knowledge, 
this is the first trial to have prospectively and systematically studied the effects of treatment of 
SCH with LT4 on LVEF compared with placebo, in addition to optimal medical treatment in 
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AMI patients. Our results demonstrate that treatment of SCH in AMI patients does not improve 
LV function and suggest that raised serum TSH may simply be a biomarker of worse prognosis.  
Although LT4 treatment did not result in a significant improvement in LV function, there was 
a trend towards an improvement in LV volumes with a reduction in both EDV and ESV with 
treatment.  Studies have demonstrated that a decrease in LVEF with subsequent increases in 
cardiac volumes represent adverse cardiac remodelling which is associated with worse cardiac 
outcomes (Konstam et al., 2011).  The present study therefore demonstrates a potential benefit 
of LT4 treatment in ameliorating pathological cardiac remodelling despite no improvement in 
LVEF. 
One of the strengths of our study is we utilised robust imaging techniques to evaluate cardiac 
function. MRI is considered as the reference-standard technique to assess cardiac mass, 
volumes and function.  Only one previous trial utilised MRI in SCH individuals to assess 
cardiac function, and, in this non-randomised trial, LT4 treatment in women with no previous 
cardiac history improved LVEF (Ripoli et al., 2005).  The study also addresses an important 
uncertainty and previous concern regarding the potential safety profile of using TH 
replacement therapy in a post MI setting.  In the study, TH replacement therapy was safe with 
a low risk of potential adverse affects in such a setting.  This is shown by no SAE within the 
study group being related to levothyroxine as well as no patients developing a sinus tachycardia 
or any tacharrhythmias such as atrial fibrillation.  The findings from this study support three 
previous studies which have used intravenous triiodothyronine in patients undergoing 
cardiovascular surgery to show no major adverse side effects such as arrhythmias (Klemperer 
et al., 1995; Klemperer et al., 1996; Mullis-Jansson et al., 1999).  Therefore the findings from 
the present study sets more clarity on the safety profile of TH for future studies involving 
patients with cardiovascular disease, in particular AMI. 
Despite the current negative findings, an increase in mortality in patients with a low TH state 
after AMI is a testament to the need for ongoing studies to reduce vascular event rates in this 
specific group, to levels seen in euthyroid patients.  Some of the reasons which may explain 
the current findings may be due to the potential limitations in the study.  Firstly, it can be argued 
that patients recruited to the study did not have a low enough thyroid function to warrant 
treatment in the first place.   Patients with a milder form of SCH with at least one TSH value 
below 10.0 mU/L were recruited. This group constitutes to the majority of SCH patients and 
where the greatest uncertainty with regards to efficacy of treatment prevails. The results of the 
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present study support those guidelines which recommend treatment only if the serum TSH level 
is more than 10 mU/L (Pearce et al., 2013).  Second, the time window between coronary 
occlusion and initiation of LT4 therapy may have been prolonged (median of 17 days). This 
was considered necessary as we only wanted to recruit patients with sustained SCH in this trial. 
Third, due to the unknown safety profile of LT4 in this group of patients, LT4 was initiated at 
a small dose (25 mcg daily) and titrated over several weeks. The median dose of LT4 at the 
end of the study (50 mcg daily) is lower than the starting doses used in other trials that have 
demonstrated benefit of treatment on endothelial function and lipid profiles (Monzani et al., 
2004; Razvi et al., 2007). This may have reduced the therapeutic efficacy of LT4 on cardiac 
remodelling and ventricular function, but, serum TSH levels in the LT4 group were within the 
target range (0.4 – 2.5 mU/L) and FT4 levels were higher at the end of the trial compared to 
baseline as well as the placebo group.  Fourth, nearly 40% of patients recruited in this trial had 
evidence of preserved LV function and mean LVEF in both groups suggested only mild 
impairment.  It is interesting that the pre-specified subgroup analysis in patients with LVEF 
<55% suggests that levothyroxine may be associated with some benefit. Future research will 
be required to evaluate efficacy in this group of patients. 
Finally, the type of thyroid hormone used may have been ineffective.  Experimental data has 
shown that in a post MI setting, a decrease in D1 and D2 activity and an increase in the D3 
activity leads to a decreased conversion of T4 to T3 and T3 downregulation (Olivares et al., 
2007).  In a large clinical study by Peeters eta al, increased D3 activity and low TH levels in 
pathological states was shown to occur locally within the heart and at the systemic level 
(Peeters et al., 2003).  Therefore the bioavailability of cardiac T3 could have been low in the 
study leading to the reduced cardiac effects and subsequent benefit of TH replacement.  Owing 
to the impaired conversion of T4 to T3 in pathological states, T4 might not be the most suitable 
first line therapy in such conditions.  These findings suggest further studies are needed to 
investigate alternative thyroid hormone treatments in patients with a low thyroid hormone state.  
In one recent open label by Iervasi et al, 37 patients post AMI with low T3 were investigated 
in which 19 patients received a T3 analogue called sodium liothyronine, which was given orally 
in liquid form.  The 19 patients were compared with 18 untreated patients.  The results showed 
no difference in LVEF, volumes or LGE enhancement between both groups at 6 months using 
CMR.  This was only a pilot study with the initial study being powered to recruit more than 
100 patients to detect a significant difference (Pingitore et al., 2019).   
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Although it can be argued the study may have been underpowered, patients treated with LT4 
only had a 0.76% higher EF compared to the placebo group.  Even with a higher recruitment 
number, such a difference may have been statistically significant but would not have had any 
clinical significance as such a percentage increase is not associated with any clinical benefit.  
It is highly likely that recruiting more patients would not have changed the effect size of LT4 
from the one observed (0.76%) although it may have reduced the uncertainty around this value. 
In summary, among AMI patients with SCH, LT4 treatment was shown to be safe but did not 
improve LVEF.  A role for LT4 or other thyroid hormone treatments in more severe forms of 



















4.3  The effect of levothyroxine on thrombus area, viscoelastography and clot kinetics, 
platelet reactivity and endothelial function 
 
4.3.1 The effect of levothyroxine on thrombus area 
 
In total, 32 patients in the LT4 group and 32 patients in the placebo group completed the 
Badimon chamber experiments before and after treatment.  All patients were on aspirin and a 
second antiplatelet in the form of a P2Y12 inhibitor which included either clopidogrel, 
ticagrelor and prasugrel.   
At V1, there was no significant difference in the median (IQR) thrombus area, in µ2 per mm, 
between both the LT4 and placebo groups with values of 9906 (7206-13628) vs.  placebo 9388 
(7595-16631) p=0.75, 95% CI of the difference between the two groups was -2286 - 4186.  At 
V2, there was no significant difference in the median thrombus area between both groups with 
values of 9668 (6712-13364) vs. placebo 9413 (7813-13621) p=0.82, 95% CI of the difference 
between the two groups being -2007 - 2542 (Figure 4-9).  In view of the skewed nature of the 
data, values were log transformed for statistical analysis.  In summary, although the thrombus 
burden decreased between visits 1 and 2 in the LT4 group, there was no difference in the 
thrombus area between both the LT4 and placebo groups. 
Both groups were compared to see whether patients in the LT4 group may have had a lower 
thrombus burden depending on the specific P2Y12 inhibitor.  The results showed that 
irrespective of the antiplatelet, there was still no significant difference in median thrombus area 






Figure 4-9  Individual plots for thrombus area in the LT4 and placebo groups before and after 







































































Table 4-23  A comparison of median thrombus area between both the LT4 and placebo groups 
determined by the type of P2Y12 antiplatelet, at the end of the study visit (V6).  For each 
antiplatelet, there was no significant difference in thrombus area between the two groups. 




Figure 4-10 A difference in median total thrombus area between patients on LT4 and placebo 
after treatment (V6) determined by the specific P2Y12 antiplatelet.  Overall, for each P2Y12 
antiplatelet, there was no significant difference in thrombus burden when comparing both 















































Multiple linear regression analysis was used to ascertain the relationship between thrombus 
area at visit 2 and allocation to either LT4 or placebo. Thrombus area at visit 2 was the 
dependent variable whereas the various independent variables included gender, age, type of 
AMI, smoking status, type of P2Y12 as the second antiplatelet, total mean thrombus area at 
visit 1 and finally allocation to either LT4 or placebo.  Allocation to LT4 was not a significant 
predictor (p=0.56) with the adjusted difference (95% confidence interval) thrombus area being 
710 µ2 per mm (-1748 - 3170) higher in the LT4 group compared to placebo as shown from 
the beta coefficient.  The only positive predictors of an increased mean thrombus area at V2 





95% confidence interval P-value 
Age -40.771 -189.670 108.127 0.585 
Male ender 885.368 -2130.906 3901.642 0.558 
STEMI -101.281 -3371.220 3168.658 0.951 
Smokers 2057.114 -542.120 3572.108 0.009 
Mean V1 µ2/mm -0.039 -0.217 0.140 0.665 
P2Y12 inhibitor -601.867 -2467.478 1263.744 0.520 
LT4 vs placebo 710.984 -1748.330 3170.299 0.564 
 
Table 4-24  Variables associated with mean thrombus area after treatment.  Type of P2Y12 













Sensitivity analysis assessed the interaction between allocation code and each of the variables 
of sex, age, type of AMI, baseline thrombus area, and baseline serum TSH, and suggested that 
the result obtained was robust, and not due to differences in relevant baseline characteristics.  
For each interaction variable, allocation to LT4 did not result in a significant improvement in 
thrombus area (Table 4-25). 
 
 
Variable LT4            Placebo 
(n=32)            (n=32) 
 Thrombus area at 52 weeks 




  Male 
  Female 
 
27                     24 
 
5                  8 
 
86.2 (-567 - 739) 




Age groups, years 
  Below median ( 62.7) 
  Above median (> 62.7) 
 
16                   20 
 
16                   12 
 
-10.2 (-1274 - 1254) 
140 (-817 - 1098) 
 
0.84 
Type of AMI 
  STEMI 
  NSTEMI 
 
21                      20 
11                      12 
 




Baseline thrombus area, 
µ2 per mm 
  Below median ( 9491) 
  Above median (> 9491) 
 
 
18                      15 
 
14                     17 
 
 
-49.4 (-988 - 1086) 
 





Baseline serum TSH, 
mU/L 
  Below median ( 5.7) 
  Above median (> 5.7) 
 
 
14                    17 
 
18                    15 
 
 
-2058 (-5421 - 1305) 
 





Table 4-25  Effect of LT4 treatment compared with Placebo on thrombus area according to 
prespecified subgroups. 







4.3.2 The effect of levothyroxine on platelet reactivity 
 
Platelet reactivity was assessed using VerifyNow in 32 patients taking LT4 and 32 patients 
taking placebo to measure the effects of aspirin and P2Y12 inhibitors on platelet inhibition.  
On treatment platelet hyperactivity to aspirin, ARU, was not statistically different between both 
the groups at the study start (ARU, mean±SD: LT4 436±85.4 vs. placebo 412±72.3, p=0.19) 
and end of the study (ARU, mean±SD: LT4 452±85.1 vs. placebo 441±79.4, p=0.57) (Figure 
4-11).  9 patients in the LT4 group and 8 patients in the placebo group were hyporesponders to 
aspirin using a cutoff value of 495 (p=0.77).  On treatment platelet hyperactivity index to 
P2Y12 inhibition, PRUz, showed no statistical significance between LT4 and placebo patients 
at the study start with a median (IQR) of 50 (13-88.5) vs. placebo 39 (12-60), p=0.54 and the 
study end 74 (25-114) vs. placebo 54 (26-106), p=0.63 (Figure 4-12).  In view of the data being 
non-normally distributed for both groups, the data was log transformed prior to analysis.  
Percentage platelet inhibition as calculated by using the manufacturer’s formula for P2Y12 was 
66% in LT4 group and 65% in placebo group (p=0.92).  Using a PRUz cut off ≥ 240 units, no 
patients in either group were “hyporesponders” to P2Y12 inhibition.  PRUz values did not 
correlate with thrombus area from the Badimon chamber (rho -0.02, p=0.91) (Figure 4-13).  
There was also no correlation between thrombus area and ARU values (rho 0.18, p=0.14) 
(Figure 4-14). 
 
Both groups were compared to see whether patients in the LT4 group may have had a higher 
platelet inhibition dependent on the specific P2Y12 inhibitor.  The results showed that 
irrespective of the antiplatelet, there was still no significant difference in on treatment platelet 
reactivity to P2Y12 inhibition, PRUz, between both the LT4 and placebo groups at the end of 


















Figure 4-11 Mean ARU in the LT4 and placebo groups at both study visits.  ARU represents 















































Figure 4-12  PRUz values for patients in the LT4 and placebo groups before and after treatment.  
Baseline and post treatment values in both groups were not statistically different.  Solid lines 













































Figure 4-13  Correlation between thrombus area and VerifyNow® PRUz values in both groups 






Figure 4-14  Correlation between thrombus area and VerifyNow® ARU values in both groups 


























































Figure 4-15  A difference in median PRUz between patients on LT4 and placebo at 52 weeks 
after treatment determined by the specific P2Y12 antiplatelet agent.  The solid bars represent 

















Multiple regression was used to ascertain the relationship between on treatment platelet 
reactivity to aspirin and P2Y12 inhibition at visit 2, as measured by ARU and PRUz, and 
allocation to either LT4 or placebo.  ARU and PRUz at visit 2 were used as the dependent 
variable in separate analyses whereas the various independent variables included gender, age, 
type of AMI, smoking status, ARU or PRUz at visit 1 and finally allocation to either LT4 and 
placebo (allocation code).  For on treatment platelet reactivity to P2Y12 inhibition, the type of 
P2Y12 inhibitor was also used as an independent variable. 
For on treatment platelet reactivity to aspirin, ARU, allocation to LT4/placebo was a non-
significant predictor (p=0.719) with the adjusted difference (95% confidence interval) of 7.3 
ARU units (-47.4-32.9) lower in the LT4 group (Table 4-26).  For on treatment platelet 
reactivity to P2Y12 inhibition, PRUz, allocation to LT4/placebo was a non-significant 
predictor with p=0.395 and a beta coefficient showing a difference of 9.9 (-13.2-33) PRUz 
units (Table 4-27). The only positive predictors of platelet inhibition were PRUz at V1 



























95% confidence interval P-value 
Age (years) 1.319 -.921 3.559 0.244 
Male gender -47.304 -95.776 1.168 0.056 
STEMI 7.505 -40.388 55.398 0.755 
Smokers -2.615 -27.286 22.056 0.833 
ARU V1 0.139 -0.120 0.398 0.288 
LT4 vs placebo -7.265 -47.390 32.861 0.719 
Table 4-26 Variables associated with on treatment platelet reactivity to aspirin inhibition after 







95% confidence interval P-value 
Age (years) 0.197 -1.082 1.477 0.759 
Male gender -19.798 -47.738 8.142 0.162 
STEMI -11.594 -42.591 19.403 0.457 
Smokers -11.369 -25.436 2.699 0.111 
P2Y12 inhibitor -25.034 -41.185 -8.884 0.003 
PRUz V1 0.619 0.390 0.848 0.000 
LT4 vs placebo 9.890 -13.210 32.991 0.395 











4.3.3 The effect of levothyroxine on viscoelastography and clot kinetics 
 
Standard TEG parameters (e.g. R, K, MA to kaolin and CI) were compared in both groups.  
The maximum amplitude to kaolin (MA-CK) and clot index (CI), both a measure of clot 
strength, significantly decreased in both the LT4 and placebo groups after 1 year of treatment 
(Table 4-28).  However when the MA-CK and CI parameters were compared between both 
groups after 1 year, there was no significant difference (Table 4-29).  At baseline the MA-CK 
was 67.8±5.4 vs. 66.7±4.9 in the placebo group, p=0.68 whereas after 1 year of treatment the 
MA-CK was 61.5±5.4 vs. 58.9±12.4 in the placebo group, p=0.24.  After 1 year of treatment, 
there were no significant differences in the other TEG parameters between both groups (Table 
4-29).  The % of clot lysis at 30 minutes did not significantly decrease in each group between 
both visits and furthermore there was no significant difference in clot lysis between both groups 
at the end of the study. 
Platelet mapping studies showed no significant reduction of maximum viscoelastic strength of 
thrombus after treatment with a P2Y12 inhibitor, in both the LT4 group and placebo groups, 
as measured by maximum amplitude (MA-ADP, in mm) upon stimulation by 10μl of ADP 
(30±14.2 vs. 26.1±11.4, p=0.07 in LT4 and 29.8±16.9 vs. 26±15.9, p=0.17 in placebo) (Table 
4-28).  Response to aspirin improved significantly in both group of patients with a reduction in 
maximum amplitude of the thrombus (MA-AA, in mm) upon stimulation with 10μl of 
arachidonic acid (21.7±16.4 vs. 13.5±12.2, p=0.002 in LT4 and 18.9±13.8 vs. 13.4±11.8, 
p=0.0014 in placebo).  However when the MA-ADP and MA-AA were compared between 















LT4 n= 32 
 
Placebo n= 32 
 Baseline 1 year 
after 
therapy 






5.5±1.2 5.6±1.0 0.73 5.2±1.5 5.4±1.7 0.55 
 
K, min 





67.8±5.4 61.5±5.4 <0.001 66.7±4.9 58.9±12.4 0.001 
Clot Lysis  
30min, % 



































69.8±18.7 65.3±18.7 0.13 63.4±18.3 64.3±17.1 0.76 
Table 4-28  Standard TEG measurements with citrated kaolin in both LT4 and placebo groups 
at baseline and after therapy.  Within each group, values were compared using the paired t-test. 
Values are shown as mean (±SD) or median (IQR). 
*Non-normally distributed data, analysed after log-transformation with Student t-testing. 
MA – Maximum amplitude; AA – Arachidonic acid; ADP - Adenosine diphosphate. 
R: Time taken till initial fibrin formation. 
K: Time taken to reach a fixed level of clot strength. 
MA-CK: Maximum viscoelastic strength of the thrombus by kaolin. 
MA-AA: Maximum viscoelastic strength of the thrombus by arachidonic acid. 







 LT4 (n=32) Placebo (n=32) P value 
R, min 5.6±1.0 5.4±1.7 0.51 
K, min 1.4±0.3 1.2±0.9 0.37 
Maximum Amplitude, min 61.5±5.4 58.9±12.4 0.24 
Clot Lysis 30min, % 97.1±3.4 95.7±4.4 0.14 
Clot Index * 0.65 (-0.18-1.9) 0.7 (-0.5-1.7) 0.99 
MA –AA, mm * 
 
9.1 (6-14.4) 9 (4.8-18.1) 0.97 
MA-ADP, mm 26.1±11.4 26±10.6 0.97 
% platelet inhibition to AA 88.1±18.4 86.5±19.2 0.72 
% platelet inhibition to ADP 65.3±18.7 64.3±17.3 0.83 
Table 4-29  A direct comparison of TEG and platelet mapping parameters between both LT4 
and placebo groups after treatment. 
Values are shown as mean (±SD) or median (IQR). 



















Figure 4-16  A comparison of mean TEG and Platelet Mapping platelet aggregation indices 
after treatment. Maximum amplitude of thrombus upon stimulation with Kaolin (MA-CK), 
arachidonic acid (MA-AA) and ADP (MA-ADP) was not significantly different in both LT4 
















The correlation between VerifyNow assay and TEG Platelet mapping was assessed in the 
cohort of patients with both groups combined. There was no correlation between ARU and 
PRUz indices of VerifyNow and maximum amplitude of the thrombus formed in TEG upon 
stimulation by kaolin (rho 0.119, p=0.321 for ARU and rho -0.022, p=0.856 for PRUz) (Table 
4-30).  However, there was a significant positive correlation seen between ARU and maximum 
amplitude of the thrombus formed in TEG upon stimulation by AA (0.357, p=0.002) (Figure 
4-17).  Interestingly, ARU also correlated with the maximum amplitude of thrombus formation 
by ADP (0.305, p=0.010).  PRUz (which measured P2Y12 response) correlated positively with 
maximum amplitude of thrombus formation in TEG upon stimulation by ADP (0.524, 
P<0.001) as well as upon stimulation by AA (0.255, p=0.032).  In summary, these results 
demonstrate that both ARU and PRUz did not predict total clot strength on stimulation by 
kaolin but were a good marker for assessing clot strength on stimulation by AA and ADP.  
Therefore VerifyNow is a good alternative to TEG, as a point of care test, to assess platelet 

























Rho, (2-tailed p value)  
 
ARU PRUz 
R, min 0.069 -0.074 
 
 (0.562) (0.540) 
K 0.046 0.176 
 (0.699) (0.141) 
MA for kaolin, mm 0.119 -0.022 
 (0.321) 0.856 
CI 0.035 0.010 
 (0.775) 0.934 
MA for ADP, mm 0.305 0.524 
 *(0.010) *(<0.001) 
MA for AA, mm 0.357 0.255 
 *(0.002) *(0.032) 
Table 4-30 Correlations between VerifyNow and thromboelastography in the whole cohort of 
















Figure 4-17 Correlation between VeifyNow indices and TEG Platelet Mapping indices at the 
end of the study.  There was a significant correlation between MA-AA and ARU (0.357, 

















































Multiple regression was used to ascertain the relationship between MA to kaolin, considered 
the most important parameter in TEG, and allocation to either LT4 or placebo. MA to kaolin 
at visit 2 were used as the dependent variable in whereas the various independent variables 
included gender, age, type of AMI, smoking status, MA at visit 1 and finally allocation to either 
LT4 and placebo (Table 4-31).  The analysis showed that allocation to LT4/placebo was a non-
significant predictor with p=0.312 and a beta coefficient showing the mean MA to be only 2.36 





95% confidence interval P-value 
Male gender 2.894 -2.820 8.608 0.315 
Age (years) -0.130 -0.395 0.135 0.332 
STEMI -4.790 -10.509 0.928 0.099 
Smokers -1.615 -4.438 1.207 0.257 
MA(mm) V1 0.305 -0.187 0.796 0.220 
LT4 vs placebo -2.369 -7.011 2.274 0.312 



















4.3.4 The effect of levothyroxine on endothelial function 
 
Endothelial function was assessed with EndoPAT which measured the reactive hyperaemia 
index (RHI).  An increase in RHI corresponded with an improvement in endothelial function.  
32 patients in the LT4 group and 39 patients in the placebo group underwent EndoPAT.  At 
baseline, the RHI in the LT4 group was 1.86±0.44 vs. 1.86±0.73 in the placebo group, p=0.995.  
After 1 year of treatment, the RHI in the LT4 group was 2.06±0.69 vs. 1.96±0.61 in the placebo 
group, p=0.51.  Although the RHI increased more in the LT4 group, this did not reach statistical 
significance.  Multiple regression was used to correct for each baseline variable with the 
dependent variable being the RHI at the end of the study whereas the independent variables 
included: age, gender, type of AMI, smoking status, RHI at the study start and finally allocation 
to LT4/placebo (Table 4-32).  Allocation to LT4 was not a significant predictor (p=0.41) with 
the adjusted difference (95% confidence interval) RHI being only 0.119 (-0.17-0.4) higher in 
the LT4 group compared to placebo as shown from the beta coefficient.  Gender and RHI at 
V1 were the only positive predictors of RHI at visit 2, with females having a higher RHI than 





95% confidence interval P-value 
Age 0.002 -0.014 0.017 0.841 
Male gender -0.577 -0.946 -0.208 0.003 
Type of AMI -0.198 -0.509 0.112 0.206 
Smokers 0.081 -0.094 0.257 0.358 
RHI V1 0.400 0.171 0.630 0.001 
LT4/placebo 0.119 -0.165 0.403 0.405 











4.3.5 Summary of results 
 






 Baseline                      V6 Baseline                      V6   
Badimon 
Chamber 
(n=32) (n=32)     
Mean thrombus 
area 





      
VerifyNow (n=32) (n=32)     
ARU 436 (±85.4)   452±85.1 411 (±72.3) 441±79.4 -7.3 (-47.3-32.9) 0.72 
PRU 59.8 (±52.1)   72.9 (±52.3) 47.1 (±46) 76.1±63.8 9.9 (-13.2-33) 0.39 
       
  TEG (n= 32) (n=32) 
 
  
MA-CK 67.8±5.4   61.5±5.4 66.7±4.9 58.9±12.4 -2.4 (-7-2.3) 0.31 
Clot index 1.7±1.6   0.7±1.3 1.9±1.7  0.7±1.6 0.65 (-0.63-0.76) 0.85 
MA-AA 21.7±16.4   13.5±12.2 18.9±13.8   13.4±11.8 0.85 (-4.3-5.9) 0.74 
MA-ADP 30±14.2  26.1±11.4 29.8±16.9   26±15.9 -0.1 (-5.1-4.9) 0.97 
EndoPAT (n=32) (n=39) 
 
  
RHI 1.86±0.44 2.06±0.69 1.86±0.73 1.96±0.61 0.12 (-0.17-0.4) 0.40 
       
Table 4-33 Summary of the effect of LT4 on platelet dependent thrombosis, platelet reactivity, 


















This study shows that treating mild SCH patients post AMI does not affect thrombus burden, 
viscoelastic properties of clot formation and lysis, platelet reactivity or endothelial function.  
Therefore poorer outcomes in SCH patients with cardiovascular disease are unlikely to be 
attributed to platelet reactivity or an increase in the coagulation cascade.  A recent study using 
the Badimon chamber at our institution showed thrombus area in patients with SCH 7-10 days 
post non-ST elevation myocardial infarction to be larger than in euthyroid patients despite the 
use of dual antiplatelets in the form of aspirin and clopidogrel (Viswanathan et al., 2014a).  In 
the current study all patients were on dual antiplatelet therapy and secondary preventive therapy 
post AMI, and there was no difference in median thrombus area between the LT4 and placebo 
groups after 1 year.  An important difference in the current study was the use of different P2Y12 
inhibitors, with not all patients taking clopidogrel as the second antiplatelet in addition to 
aspirin.  As per updated ACS guidelines, the different P2Y12 inhibitors included ticagrelor and 
prasugrel as the second antiplatelet.  The Plato study showed ticagrelor reduces the rate of death 
from vascular causes and AMI compared to clopidogrel whereas in the TRITON-TIMI study 
prasugrel therapy compared to clopidogrel reduced the rate of ischaemic events including stent 
thrombosis (Wiviott et al., 2007; Wallentin et al., 2009).  Therefore the use of more potent 
antiplatelet therapies and optimal secondary prevention measures post AMI may be an 
explanation for the negative findings and a reason for why LT4 may not further affect thrombus 
burden. 
Previous small studies have demonstrated TH deficiency to not only affect the coagulation 
pathway but to also inhibit the fibrinolytic pathway.  Such studies have shown increased VII 
activity, increased factor VII activity:factor VII antigen ratio, increased levels of fibrinogen 
and decreased antithrombin III activity in subjects with SCH (Muller et al., 2001; Canturk et 
al., 2003; Guldiken et al., 2005).  From these studies, TH may activate the fibrinolytic pathway 
leading to increased thrombus breakdown.  Although individual clotting factors were not 
measured as in these studies, the use of TEG in this study measured the rate and strength of 
clot formation induced by thrombin which activates platelets and the coagulation cascade.  By 
assessing thrombus formation continuously over a period of time, TEG reflects whole blood 
thrombosis by showing the interaction between platelets leading to platelet aggregation; and 
the interaction of platelets with fibrin and the coagulation cascade.  This involved measuring 
each cycle of clot formation and the susceptibility of the clot to autolyse. The current study 
demonstrated no effect of LT4 on the time taken to form a stabilised thrombus, as well as no 
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effect on the maximum tensile strength of the thrombus.  Furthermore there was no effect of 
LT4 on clot autolysis suggesting no difference in fibrinolysis between both groups.  The likely 
reason for differences between previous studies and the current study includes differences in 
patient risk profile and baseline characteristics.  Firstly, the current study was performed in 
patients post AMI in whom thrombotic risk was being targeted and treated by means of 
antiplatelet medications to reduce further cardiovascular events whereas subjects in previous 
studies had no history of cardiovascular disease.  The current patients were on dual antiplatelet 
therapy whereas subjects in previous studies were not even on a single antiplatelet agent in the 
form of aspirin.  Thirdly, increases in individual clotting factors in SCH patients likely make 
no difference to thrombus formation as we know clot formation is dependent on multiple 
factors including the interaction of the clotting cascade, platelets and fibrin.  Therefore even if 
patients with SCH have increased clotting factors as shown in previous studies, the use of 
antiplatelets in platelet inhibition reduces the interaction of platelets with the coagulation 
cascade preventing an increase in thrombus burden and clot kinetics. 
The current study also shows no effect of LT4 on improving endothelial function in SCH as 
previous studies have shown.  A RCT by Nagasaki et al showed restoring euthyroidism with 
LT4 in SCH subjects significantly decreased brachial-ankle pulse wave velocity, a measure of 
arterial stiffness (Nagasaki et al., 2009).  Two RCTs showed LT4 treatment to improve 
endothelial function in SCH patients (Taddei et al., 2003; Razvi et al., 2007).  The RCT by 
Razvi et al showed LT4 to reduce LDL levels, improve  quality of life and improve endothelial 
function as measured by FMD in SCH patients (Razvi et al., 2007).  These studies were 
performed in stable SCH patients in whom many subjects had no other cardiovascular risk 
factors and were not on medications which improved endothelial function.  In the current study, 
all patients were on an ace-inhibitor, a beta blocker and the maximum dose of atorvastatin post 
AMI. A number of clinical and experimental studies have shown an improvement in 
endothelial function with the use of statins and ace-inhibitors in patients with CAD (Dupuis et 
al., 1999; Schiffrin et al., 2000; Prasad et al., 2001).  Ace inhibitors inhibit the production of 
angiotensin which is a potent vasoconstrictor and increases the production of bradykinin 
leading to increase NO production whereas statins increase the production of NO synthase.  
Therefore subjects being on optimal doses of secondary preventive medications may have 
resulted in minimal improvements in endothelial function with thyroxine therapy despite 
previous studies showing significant improvements.  Furthermore, it is likely that the dose of 
thyroxine in our study may have been suboptimal although serum TSH levels in the LT4 group, 
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at the end of the study, were within the target range (0.4 – 2.5 mU/L).  Razvi et al used a starting 
dose of 100mcg from the start whereas in the current study, the initial dose was 25mcg and the 
median dose by visit 5 (6 months post randomisation) was 50mcg.  Additionally, patients in 
the study may not have had a low enough thyroid function to warrant treatment in the first place 
with the median TSH being below 6.0 mU/L in both the LT4 and placebo groups.   
In summary, the present study shows no effect of LT4 therapy on the different mechanisms 
which are associated with increased cardiovascular disease, although these results are not 



















4.4  Thyroid dysfunction and patient reported outcomes 
4.4.1 Results 
 
Patient reported outcomes were assessed using the Centre for epidemiologic studies depression 
scale (CES-D), Minnesota living with heart failure questionnaire (MLWHF), and the Short 
form mental and physical score (SF12-M and SF12-P).  The CES depression score did not 
significantly improve in both groups between the start and end of the study (Table 4-34).  When 
both groups were directly compared at both study visits, the CES-D score was not significantly 
different at V1 with median scores (IQR) of 9 (4-16) vs. 8 (2.5-15), p=0.67, and V6 with median 
scores of 10 (2-18) vs. 5 (2-14), p=0.16, in the LT4 and placebo groups respectively (Table 
4-35).  Overall the median scores of the participants in both groups suggested a low risk of 
clinical depression (using the accepted clinical cut-off score of 16.0).   
The Minnesota scores showed a significant decrease in quality of life (QOL) scores in both 
groups between the start and end of the study but there was no significant difference in the 
median (IQR) scores between both groups at V1 of  27 (12.3-40) vs. 23 (11.5-37.5), p=0.64, 
and V6 scores of 13 (7-24) vs. 15 (6-30), p=0.58, in the LT4 and placebo groups respectively.  
These results demonstrated that the median self-rated scores of trial participants at baseline in 
both groups were suggestive of moderate QOL from heart failure but improved to being rated 
as ‘good’ over the subsequent 52 weeks.  
The mean (± s.d) SF12 scores showed a minimal increase in the mental scores in both groups 
by the end of study whereas the mean physical scores significantly increased in both groups.  
There was no significant difference in both SF12 scores between both groups at V6 with scores 
of 50.4 (±11.7) vs. 52.8 (7.9), p=0.27, for SF12-M and 46 (±10.1) vs. 45.6 (±10.6), p=0.86, for 
SF12-P in the LT4 and placebo groups respectively.  The mean mental score of approximately 
50 suggests that the average participant in this trial rated their mental health as being good or 
very good whereas for physical health the mean score of approximately 40 suggests that the 
average participant in this trial scored their physical health as being good or very good. 
These results show that heart failure QOL improved whereas physical health increased in both 
groups despite no significant differences when both groups were directly compared.  
Furthermore, mood and mental status did not improve in each group due to low symptom scores 
at the study start.  The results overall showed that LT4 treatment did not make any significant 
difference to patient reported outcomes and QOL post AMI when compared to placebo. 
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Multiple regression was used to ascertain the relationship between each individual score at the 
end of study and allocation to either LT4 or placebo. For each questionnaire, the end of the 
study score was the dependent variable whereas the various independent variables included 
gender, age, type of AMI, the score at visit 1 and allocation to either LT4 or placebo.  For all 
4 questionnaires, allocation to LT4 was a non-significant predictor for each questionnaire score 
at visit 2 (CES-D p=0.05, Minnesota p=0.28, SF-12 physical 0.95, SF-12 mental 0.96) (Table 





























LT4 n= 46 
 
Placebo n= 49 
 Baseline 1 year 
after 
therapy 






9 (4-16) 10 (2-18) 0.99 8 (2.5-15) 5 (2-14) 0.08 

























Table 4-34  A comparison of patient reported outcomes in both groups at visit 1 and visit 6. 
Variables are shown as mean (±SD) and median (IQR). 
 *Non-normally distributed data, analysed after log-transformation with Paired t-test. 
CESD: scores range from 0 to 60, with higher scores indicating greater depressive symptoms.  
MLWHF: scores range from 0 to 105, with higher scores indicating increase in symptoms of 
heart failure.  SF12 Mental: scores range from 41 to 61, with higher scores indicate perceived 
better mental health.  SF12 Physical: scores range from 20 to 56, with higher scores 
























 LT4 (n=46) Placebo (n=49) P value 
CES depression V1* 9 (4-16) 8 (2.5-15) 0.67 
MLWHF V1* 27 (12.3-40) 23 (11.5-37.5) 0.64 
SF-12 mental V1 49.6 (±10.5) 51.6 (±10.8) 0.41 
SF-12 physical V1 39.9 (±10.6) 38.5 (±10.9) 0.56 
CES depression V6* 10 (2-18) 5 (2-14) 0.16 
MLWHF V6* 13 (6.8-24.3) 15 (6-30) 0.58 
SF-12 mental V6 50.4 (±11.7) 52.8 (7.9) 0.27 
SF-12 physical V6 46 (±10.1) 45.6 (±10.6) 0.86 
Table 4-35  A comparison of patient reported outcomes between both groups at visit 1 and visit 
6. 
Variables are shown as mean (±SD) and median (IQR). 






















Figure 4-18 Box plot of CES-D scores in both LT4 and placebo groups at visits 1 and 6.   
The box represents the 25th to 75th centile.  The transverse line with numbers inside the box 
represents the median and "whiskers" above and below the box show the locations of the 
minimum and maximum. 
 
 






Figure 4-20 A comparison of the mental and physical scores between LT4 and placebo groups 











































































95% confidence interval P-value 
Age -0.061 -0.228 0.106 0.470 
Gender 0.038 -3.821 3.896 0.985 
Type of MI 0.960 -2.493 4.412 0.582 
CES-D V1 0.626 0.447 0.805 0.000 
LT4 vs placebo 3.130 -0.005 6.265 0.050 
Table 4-36 Multiple regression to assess the relationship between the allocation to LT4/placebo 







95% confidence interval P-value 
Age -0.287 -0.657 0.083 0.126 
Gender 3.277 -4.864 11.417 0.425 
Type of MI -1.072 -8.626 6.483 0.778 
Minnesota V1 0.517 0.320 0.715 0.000 
LT4 vs placebo -3.741 -10.560 3.078 0.278 
Table 4-37  Multiple regression to assess the relationship between the allocation to 













Table 4-38  Multiple regression to assess the relationship between the allocation to LT4/placebo 






95% confidence interval P-value 
Age 0.052 -0.209 0.312 0.693 
Gender 2.252 -3.109 7.612 0.405 
Type of MI 0.775 -4.298 5.848 0.761 
SF-12 Mental V2 0.489 0.254 0.724 0.000 
LT4 vs placebo 0.134 -4.551 4.818 0.955 
Table 4-39  Multiple regression to assess the relationship between the allocation to LT4/placebo 













95% confidence interval P-value 
Age -0.076 -0.320 0.169 0.539 
Gender 3.853 -1.397 9.103 0.148 
Type of MI 1.033 -3.816 5.882 0.672 
SF-12 physical V1 0.357 0.130 0.584 0.003 














 Baseline                      V6 Baseline                      V6   
 (n=45) (n=45)   
CESD 9 (4-16) 10.0 (2.0-18.0) 8 (2.5-15) 5.0 (2.0-14.0) 3.13 (-0.005-6.27) 0.05 
MLWHF 27 (12.3-40) 13.0 (6.8-24.3) 23 (11.5-37.5) 15.0 (6.0-30) -3.74 (-10.6-3.08) 0.28 
SF12 Physical 39.9 (±10.6) 46.0 (+- 10.1) 38.5 (±10.9) 45.6 (+- 10.6) -0.14 (-4.54-4.23) 0.95 
SF12 Mental 49.6 (±10.5) 50.4 (+- 11.7) 51.6 (±10.8) 52.8 (+- 7.9) 0.13 (-4.6-4.8) 0.95 
     
    Table 4-40 Summary of results to show patient reported outcomes. 
Patient reported outcomes were compared using linear regression adjusting for age, sex, type 

























In the present study, LT4 therapy in SCH patients post AMI was not associated with improved 
patient reported outcomes and quality of life after 1 year of treatment.  Furthermore, although 
the heart failure related QOL did improve in both groups after 1 year, there was no significant 
difference between both groups respectively.  This is the first study to report such outcomes in 
SCH patients post AMI.   
The current study does not support the use of LT4 therapy in improving QOL in SCH patients 
post AMI.  These findings support a recent meta-analysis and systematic review of 21 
randomised controlled studies which showed no improvement in quality of life or thyroid 
reported symptoms in patients with SCH treated with LT4 therapy (Feller et al., 2018).  This 
meta-analysis be Feller et al included 2 of the latest randomised studies recently published 
which are the largest studies to date assessing LT4 treatment and quality of life (Stott et al., 
2017; Mooijaart et al., 2019).  However, the largest contribution to the meta-analysis was from 
the TRUST Study which recruited older asymptomatic individuals treated with low dose LT4 
therapy (Stott et al., 2017).  Therefore the analysis may not be applicable to younger or 
symptomatic patients.  The current results are also consistent with a Cochrane review of 22 
studies showing no benefit of LT4 treatment on quality of life, physical and mental scores and 
daily living scores (Reyes Domingo et al., 2019).  The results of the present study support 
current European and US guidelines which do not advocate the treatment of patients with SCH 
unless they have persistent symptoms or have TSH levels above 10 mU/L irrespective of age 
(Garber et al., 2012; Pearce et al., 2013).  However the European Thyroid Association does 
recommend a trial of LT4 therapy in younger symptomatic patients irrespective of their TSH 
levels (Pearce et al., 2013). 
Despite the negative findings in the current study, there are limitations which should be 
considered.  Firstly, the median TSH of all participants in the LT4 group was 5.75 mU/L, 
indicating mild SCH, and this combined with the low burden of symptoms at the start of the 
study and a low median dose of LT4 use may be a reason as to why LT4 treatment did not 
make a significant difference in the interventional group.  In the meta-analysis by Feller et al, 
the mean TSH levels were below 7 mU/L in half of the studies included in the analysis.  When 
the RCTs from the meta-analysis are assessed separately, we find that in studies with 
participants with a mean TSH above 7 mU/L or the use of high dose LT4 therapy, there was a 
significant improvement in symptoms with LT4 treatment (Meier et al., 2001; Razvi et al., 
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2007; Aghili et al., 2012).  In the Basel Thyroid Study by Meier et al, the mean TSH levels 
prior to treatment was 11.7 and administering a mean LT4 dose of 85.5mcg/day resulted in 
improvement in hypothyroid symptoms after 48 weeks (Meier et al., 2001).  In the study by 
Aghili et al, the mean TSH level was 8.25 and administering LT4 for 3 months resulted in a 
significant improvement in cognitive scores (Aghili et al., 2012).  In the study by Razvi et al, 
although the mean TSH was 6.6, LT4 treatment at a higher dose of 100mcg lead to a significant 
improvement in tiredness (Razvi et al., 2007).  Therefore a subgroup of patients with higher 
TSH levels and a higher burden of symptoms may benefit from treatment irrespective of the 
current data.  Furthermore subjects with SCH enrolled to the present study as well as previous 
studies are likely to be of low symptom burden from their SCH, as patients with more severe 
symptoms are likely to be prescribed treatment and therefore be unrepresented in clinical trials.  
No study to date has recruited patients with only severe symptoms secondary to SCH and seven 
studies (1263 adults) in the meta-analysis by Feller et al recruited patients with only mild-
moderate symptoms. 
TSH levels increase with age meaning some older patients enrolled to the present study may 
not have had true SCH, resulting in no improvement in symptoms to treatment, although 
international guidelines do not define SCH according to age and TSH cutoff values.  Vadiveloo 
et al demonstrated that using age specific TSH reference ranges in patients above 70 would 
prevent the overestimation and unnecessary treatment of SCH (Vadiveloo et al., 2013).  This 
is further supported by studies which have shown no benefit of LT4 therapy on QOL in patients 
above the age of 70 (Stott et al., 2017; Mooijaart et al., 2019).  In the TRUST Study, the mean 
age of participants was 74.4 and LT4 treatment provided no symptomatic benefit to participants 
with a mean TSH of 6.4 at the start of the study (Stott et al., 2017).  In another recent study by 
Mooijaart et al, LT4 treatment in patients above the age of 80 with a mean TSH of 6.4 resulted 
in no significant improvement in quality of life (Mooijaart et al., 2019).  Furthermore, in a 
secondary analysis of the TRUST Study which analysed 638 persons with the highest symptom 
burden, LT4 treatment failed to improve QOL or symptoms of tiredness (de Montmollin et al., 
2020).  The findings of these two studies support the current European and US guidelines in 
not initiating treatment to SCH patients above the age of 80 and adopting a more conservative 
approach (Garber et al., 2012; Pearce et al., 2013).   
Meyerovitch et al found that TSH levels fluctuate and returned to normal in 62% of healthy 
subjects with a TSH between 5.5 and 10 mIU/L who were followed up over 5 years 
(Meyerovitch et al., 2007).  Transient illness, environmental and stress factors are likely to 
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explain this variation.  Other than in the TRUST Study and the studies by Mooijaart et al and 
Razvi et al which recruited subjects with a TSH measured on atleast two occasions to diagnose 
SCH, other studies assessing QOL in SCH patients have not stated whether subjects had repeat 
thyroid testing, to suggest true SCH, prior to commencing treatment with  LT4 therapy.  
Finally, the type of symptoms linked to hypothyroidism and SCH are very non-specific and the 
probability of diagnosing SCH based on one of these symptoms is 10% (Bekkering et al., 
2019).  The Colorado Study showed that 20-25% of patients with normal thyroid function 
report atleast one of these symptoms (Canaris et al., 2000).  Therefore in the current study, it 
is difficult to ascertain an improvement in symptiology and QOL with LT4 treatment when 
such symptoms were only mild prior to therapy, and not necessarily related to the thyroid 
dysfunction but rather to recovery post AMI. 
In summary, LT4 treatment did not improve patient reported outcomes and QOL in SCH 
patients post AMI, but there may be a selective group of patients who may still benefit 
depending the severity of their SCH as well as symptom burden irrespective of TSH levels.  It 
is essential for clinicians to decide whether specific symptoms impacting on QOL are likely 














4.5 The association of thyroid dysfunction with mortality  
 
4.5.1 Subclinical hypothyroidism and mortality 
The relationship between thyroid parameters and all-cause mortality was evaluated using Cox 
proportional hazards multivariable analysis. Survival times were calculated from the date of 
the AMI till the date of death or date of being known to be alive. The median (IQR) follow up 
period was 42 (37-49) months.  We used restricted cubic splines to account for nonlinearity of 
the associations, but no evidence of nonlinearity was observed. All analyses were adjusted for 
relevant variables such as gender, age, smoking status (current, ex- or non- smoker), body mass 
index (BMI), type of AMI (STEMI or NSTEMI), serum creatinine, history of ischemic heart 
disease (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), cerebrovascular disease 
(yes/no), atrial fibrillation (yes/no) and hypothyroidism (yes/no), standardised troponin and 
CRP.  
312 SCH patients were compared with 1437 euthyroid patients.  During the follow up period, 
there were 43 (13.8%) deaths in the SCH group whereas the number of deaths in the euthyroid 
group were 156 (10.9%), with p=0.167 using the Chi-squared test.  Using Cox proportional 
hazards multivariable analysis, patients in the SCH group had a similar all cause mortality with 
an adjusted hazard ratio (95% CI) of 1.05 (0.73-1.50), p=0.814.  Figure 4-21 demonstrates the 
cumulative survival curves for both the SCH and euthyroid groups. 
As observed in chapter 4.1.2, the diagnosis of SCH and the proportion of patients who 
normalised their thyroid function was independently and significantly associated with time of 
sampling.  All-cause mortality in the SCH participants was not different across the various time 
periods (p for interaction between SCH and time-period = 0.34).  When time-period specific 
TSH ranges were utilised (Table 4-41), the prevalence of SCH reduced dramatically (n=45; 
2.5%) and the prevalence of SCH was similar across all time-periods when time-period specific 
TSH reference intervals were utilised (p=0.79).  In contrast to the findings of the SCH group 
identified using a uniform TSH reference interval, mortality was significantly higher in SCH 
patients that were categorised using a time-period specific reference interval with HR of 2.07 
(1.05-4.10), p=0.036 (Figure 4-22). The number of deaths in the SCH group were 9 (20%) 
compared to 189 (10.9%) in the euthyroid group. Figure 4-22 shows a steep drop in the survival 
curve in the SCH group, compared to the euthyroid group, representing a higher mortality from 
the study start.  This is followed by further divergence of the curves throughout the follow up.  
Table 4-42 shows other predictors of long-term mortality when SCH and euthyroid patients 
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were compared using the Cox proportional hazard model, with SCH diagnosed using time-
period specific TSH reference intervals.   
 
 
Figure 4-21  Hazard plot of all-cause mortality demonstrating cumulative survival when 
comparing SCH patients with euthyroid using a uniform TSH reference range.  There was no 















 00:01 – 06:00 06:01 – 12:00 12:01 – 18:00 18:01 – 00:00 
Median TSH 
(2.5th – 97.5th centile) 
2.62 
(0.59 – 9.26) 
1.94 
(0.57 – 8.21) 
1.80 
(0.37 – 6.38) 
2.09 
(0.52 – 8.23) 
Mean FT4  
(2.5th – 97.5th centile) 
16.3 
(11.6 – 24.7) 
16.1 
(11.1 – 22.6) 
15.9 
(11.4 – 23.2) 
16.3 
(11.3 – 25.5) 
Mean FT3 
(2.5th – 97.5th centile) 
4.9 
(3.0 – 7.0) 
4.8  
(3.3 – 6.6) 
4.7  
(3.3 – 6.2) 
4.8 
(3.1 – 6.6) 
Euthyroid n (%) 323 (96.7) 506 (95.1) 518 (95.6) 373 (94.9) 
SCH n (%) 8 (2.4) 13 (2.4) 14 (2.4) 10 (2.5) 
SHyper n (%) 3 (0.9) 13 (2.4) 11 (2.0) 10 (2.5) 
Table 4-41  Reference ranges for TSH, FT4 and FT3, and prevalence of thyroid status 
calculated according to the time of sampling. 
 
 
Figure 4-22 Hazard plot of all-cause mortality, comparing SCH patients with euthyroid, when 




Variable HR (95% CI) P-value 
Female gender 0.85 (0.61-1.20) 0.37 
Age (per year increase) 1.09 (1.07-1.12) <0.001* 
BMI (per unit increase) 0.97 (0.94-1.01) 0.16 
Smoking 
         Never smoked 
         Current smokers 






Type of MI 





SCH 2.07 (1.05-4.10) 0.036* 
TPOAb (per unit increase) 1.01 (0.99-1.02) 0.29 
Creatinine (per µmol/dL increase) 1.04 (1.02-1.06) <0.001* 
Ischaemic heart disease 1.19 (0.86-1.65) 0.29 
Diabetes mellitus 1.93 (1.38-2.70) <0.001* 
Hypertension 1.01 (0.73-1.39) 0.97 
Hypercholesterolaemia 0.74 (0.51-1.06) 0.11 
Cerebrovascular disease 1.13 (0.68-1.86) 0.64 
Peripheral vascular disease 2.02 (1.20-3.40) 0.009* 
Standardised troponin (per unit 
increase) 
1.24 (1.03-1.49) 0.022* 
CRP (per mg/L increase) 1.01 (1.005-1.013) <0.001* 
 
Table 4-42 Predictors of long-term mortality in SCH and euthyroid patients using the Cox 
proportional hazard model, with SCH diagnosed using time-period specific TSH reference 
intervals.  BMI – body mass index, MI – myocardial infarction, NSTEMI - Non-ST elevation 
myocardial infarction, SCH- subclinical hypothyroidism, TPOAb – TPO antibodies, CRP – 




4.5.2 LT3 and mortality 
When the Cox proportional hazard model was used in the whole patient cohort of the ThyrAMI 
1 Study, T3 levels at baseline significantly predicted subsequent mortality with an increase in 
T3 levels associated with a reduction in mortality; adjusted hazard ratio (95% CI) of 0.63 (0.50-
0.77), p<0.001 (Table 4-43).  Other variables associated with increased mortality included: age 
1.08 (1.06-1.10), current smoking status 1.83 (1.19-2.81), NSTEMI 1.73 (1.16-2.58), creatinine 
1.01 (1.01-1.02), PVD 3.13 (1.95-5.02), diabetes mellitus 1.64 (1.18-2.3), standardised 
troponin 1.29 (1.07-1.54) and CRP 1.01 (1.00-1.01). Baseline serum TSH or FT4 were not 
































Variable HR (95% CI) P-value 
Female gender 0.92 (0.66-1.28) 0.61 
Age (per year increase) 1.08 (1.06-1.10) <0.001* 
BMI (per unit increase) 0.98 (0.95-1.02) 0.43 
Smoking 
         Never smoked 
         Current smokers 








Type of MI 





TSH (per mU/L increase) 1.01 (0.98-1.05) 0.32 
FT4 (per pmol/L increase) 1.06 (0.97-1.13) 0.08 
FT3 (per pmol/L increase) 0.63 (0.50-0.77) <0.001* 
Creatinine (per µmol/dL increase) 1.01 (1.01-1.02) <0.001* 
Ischaemic heart disease 1.17 (0.85-1.62) 0.34 
Diabetes mellitus 1.64 (1.18-2.3) 0.003* 
Hypertension 1.01 (0.74-1.38) 0.97 
Hypercholestrolaemia 0.78 (0.53-1.12) 0.18 
Cerbrovascular disease 0.98 (0.60-1.60) 0.94 
Peripheral vascular disease 3.13 (1.95-5.02) <0.001* 
LT4 use 1.48 (0.83-2.62) 0.18 
Standardised troponin (per unit 
increase) 
1.29 (1.07-1.54) 0.007* 
CRP (per mg/L increase) 1.01 (1.00-1.01) 0.01* 
 
Table 4-43  Predictors of long-term mortality in all the patients in the ThyrAMI 1 study using 
the Cox proportional hazard model.  BMI – body mass index, MI – myocardial infarction, 
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NSTEMI - Non-ST elevation myocardial infarction, TSH – thyrotropin, FT4 – free thyroxine 
4, FT3 – free triiodothyronine, LT4 – levothyroxine, CRP – C-reactive protein. 
*p<0.05 indicating statistical significance. 
 
 
T3 levels were inversely associated with increased mortality in a linear manner as a continuous 
variable (Table 4-43 and Figure 4-23).  Further analysis was conducted by comparing mortality 
in patients with a normal and low T3, using a T3 cut-off value of 3.5. 1263 patients in the 
normal T3 group and 63 patients in the low T3 group were compared. During a follow up 
period of 55 months, there were 147 deaths (11.1%) in total.   In the normal T3 group there 
were 125 (9.89%) deaths whereas the number of deaths in the LT3 group was 22 (34.9%), with 
a p<0.001 using the Chi-squared test.  Using Cox proportional hazards multivariable analysis, 
patients in the low T3 group had a higher all-cause mortality with an adjusted hazard ratio (95% 
CI) of 2.15 (1.30-3.55), p=0.002.  Figure 4-24 demonstrates the cumulative survival curves for 






Figure 4-23 Relationship of T3 with all-cause mortality in the ThyrAMI-1 cohort. 
Adjusted for age, gender, BMI, smoking status, type of acute myocardial infarction (STEMI or 
NSTEMI), TSH, T4, T3, creatinine, ischemic heart disease, diabetes mellitus, hypertension, 
hypercholesterolaemia, cerebrovascular disease, peripheral vascular disease, atrial fibrillation, 






     Number at risk  
   Normal T3: 1263           1218               1194              1172              1147               1138                                                                
        Low T3: 63      50                   46                  42                  42                   41 
 
 
Figure 4-24 Kaplan–Meier curves demonstrating cumulative survival in the low T3 and normal 















4.5.3 Relationship between thyroid function parameters and CRP at baseline 
There was a significant negative linear relationship between serum T3 levels and CRP with 
p<0.0001 (Figure 4-25).  However, there was no significant relationship between serum T4 or 
TSH levels with CRP.  Higher CRP levels at baseline were significantly associated with higher 
risk of subsequent mortality using Cox proportional hazards multivariable analysis (Table 
4-43) with an adjusted hazard ratio of 1.01 (1.00 – 1.01), p=0.01.  As CRP may not just be a 
confounder but also be a mediator in the relationship between T3 and mortality, an additional 
Cox proportional hazards multivariable analysis in which the separate variables of T3 and CRP 
were replaced by the combination groups of FT3 and CRP were performed (Figure 4-26). The 
same covariates for the multivariable models, as per previous analyses, were selected.  This 
demonstrated that compared to patients in the high FT3 and low CRP group, all other groups 
had higher adjusted mortality risk (p for trend <0.001).  Patients in the low T3 and high CRP 
group had more than 3-fold risk of subsequent mortality with HR 3.2 (1.62-6.82) (Figure 4-26).  
Even patients in the low T3 and low CRP group had a nearly 2-fold risk of subsequent mortality 
with HR 1.97 (1.03-4.23). Interestingly, patients in the group in whom both the T3 and CRP 
levels were high had a similar risk of subsequent death  as the high FT3 and low CRP group, 
suggesting that the increased risk of an amplified inflammatory response may be mitigated by 






















Figure 4-25 Relationship of T3 with CRP. 
Adjusted for age, sex, body mass index, smoking status, type of acute myocardial infarction 
(STEMI or NSTEMI), ischemic heart disease, type 2 diabetes mellitus, hypertension, 
cerebrovascular disease, peripheral vascular disease, atrial fibrillation, hypothyroidism, serum 


























Figure 4-26  T3 and CRP levels and risk of mortality. 
Adjusted for age, sex, body mass index, smoking status, type of acute myocardial infarction 
(STEMI or NSTEMI), ischemic heart disease, type 2 diabetes mellitus, hypertension, 
cerebrovascular disease, peripheral vascular disease, atrial fibrillation, hypothyroidism, serum 





































Low FT3 & Low
CRP (n=188)




































This study has demonstrated that SCH diagnosed with TSH levels higher than the time-period 
specific reference range, rather than diagnosed using a uniform TSH reference range as per 
current practice, and low serum T3 levels are associated with increased mortality in patients 
with AMI.  Furthermore, the predictive role of T3 was more pronounced in AMI patients with 
an elevated CRP which is a marker of inflammation.   
The results of this study support previous studies which have demonstrated worse mortality 
outcomes in patients with SCH and low T3 who have cardiovascular disease.  Iervasi and 
colleagues found cardiac patients with SCH (6.7% of the total cohort) and low circulating T3 
levels (29.2%) to have a higher risk of cardiovascular and all-cause mortality than euthyroid 
individuals within a large cohort of patients admitted with cardiac events (Iervasi et al., 2007).  
However, patients with acute MI were excluded.  Other studies have also demonstrated worse 
outcomes in patients with SCH and acute cardiovascular disease (McQuade et al., 2011; 
Molinaro et al., 2012; Seo et al., 2018).  In another study, Iervasi et al investigated 573 patients 
admitted with acute cardiac events of which 173 patients with low T3 were compared with 400 
patients with normal T3.  Patients presented with various cardiac conditions including AMI, 
heart failure, arrhythmias and cardiomyoapthies with the number of cumulative and cardiac 
deaths being significantly higher in the low T3 group during a 1 year follow up period (Iervasi 
et al., 2003).  Zhang et al demonstrated similar results in 501 patients of which 171 patients 
had a low T3 (Zhang et al., 2012). A further interventional study showed a low T3 in up to 
20% of 641 consecutive  patients below the age of 75 admitted with a STEMI whom were 
shown to have a lower survival rate despite percutaneous coronary intervention, further 
supporting the role of TH in myocardial recovery (Lazzeri et al., 2012).   
Clinical data strongly suggest that  inflammation has a role in the progression of atherosclerosis 
with studies demonstrating elevated biomarkers of inflammation such as CRP and IL-6 to be 
associated with increased cardiovascular events (Ridker et al., 1997; Ridker et al., 2000).  
Treatment with canakinumab, a monoclonal antibody which reduces IL-6 by inhibiting 
interleukin 1β, reduces recurrent cardiovascular events (Ridker et al., 2017).  However, there 
is paucity of data on the relation between low FT3, inflammation and subsequent mortality 
after acute AMI.   Our findings however demonstrate that a combination of low T3 levels and 
elevated CRP augment mortality risk compared to either biomarker alone.  Patients with low 
FT3 and high CRP had a more than three-fold subsequent risk of mortality compared to those 
with high T3 and low CRP.  The present study not only confirms that low T3 levels are 
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associated with higher mortality but importantly this association may in part be via the 
inflammatory process.    It is unknown if inflammation is one of the mechanisms by which low 
T3 levels and subsequent mortality are linked or whether T3 and CRP levels are independently 
related to mortality.  Evidence supporting the former view include previous experimental 
studies showing the association between deiodinase enzymes, markers of inflammation and TH 
levels.  Markers of inflammation such as IL-1 and IL-6 have been shown to decrease TH 
experimentally by inhibiting D1 activity and competing for receptor coactivators leading to 
decrease conversion of T4 to T3 (Yu and Koenig, 2000).  The hypoxia and the inflammatory 
response reduce deiodinase activity in the cardiomyocyte, resulting in a decrease of 
intracellular T3 bioavailability (Gereben et al., 2008).  This relative lack of T3 is further 
compounded by an increase in D3 deiodinase expression, leading to degradation of T3 into 
inactive iodothyronines (Simonides et al., 2008).  On the contrary, T3 and CRP levels could be 
linked independently as shown from the present data in which patients with low T3 and low 
CRP levels still had a nearly 2-fold increase in mortality. 
A consensus amongst clinicians and scientists is the low T3 encountered post AMI is likely 
due to the stress response of the myocardial insult, and hence a biomarker of disease severity, 
rather than an exacerbating factor which could influence injury.  However, as seen in chapter 
4.1, there was no association between low TH levels and troponin on multiple regression 
analysis.  Therefore the low TH levels post AMI could be maladaptive irrespective of troponin 
levels.  A subsequent reduction in bioavailable thyroid hormone in the acutely affected tissue 
has been considered a protective mechanism by reducing metabolic demand (Simonides et al., 
2008).  However Rajabi et al have suggested the low T3 in the injured myocardium could be a 
benefit in conserving energy after an MI, by changing myocyte expression, however this is also 
considered to be a maladaptive state in the long term if not reversed which has poor prognostic 
benefits (Rajabi et al., 2007).  It is therefore plausible that the post-AMI reduction in circulating 
T3 is maladaptive with T3 therapy having a potential role in improving outcomes.   
The protective effect of TH observed in AMI experimentally include improved LV function, 
reduced apoptosis, induced angiogenesis and mitochondrial preservation (Jabbar et al., 2017).  
TH has also been shown to limit the extent of infarct size and apoptosis in the border area of 
the infarcted tissue experimentally leading to an improvement in LV function (Chen et al., 
2008; Kalofoutis et al., 2010).  This limitation of infarct extension is through the activation of 
the cellular pro-survival pathways PI3K/Akt and PKC and suppression of the p38 MAPK 
pathway shown experimentally in rodent models of AMI treated with T3 (Kuzman et al., 2005; 
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Pantos et al., 2009a).  In a randomized controlled trial of T3 therapy in chromic heart failure 
subjects, oral liothyronine administration for 6 weeks was associated with a reduction in CRP 
levels further supporting the potential benefit of T3 replacement in inflammation (Amin et al., 
2015).  In other clinical studies T3 therapy has been shown to improve left ventricular function 
in patients with heart failure (Pingitore et al., 2008; Amin et al., 2015) and those undergoing 
surgical revascularization (Klemperer et al., 1995; Sirlak et al., 2004; Ranasinghe et al., 2006).  
In a recent trial of T3 in a small number of AMI patients has demonstrated safety (Pingitore et 
al., 2019).   
In summary, patients diagnosed with SCH on time specific reference ranges have a higher 
mortality than when a uniform TSH reference range is used, as per current practice.  This 
demonstrates TSH reference ranges should take time of sampling into account when diagnosing 
SCH to prevent a potential over diagnosis.  The present data also advances the literature and 
shows low T3 and elevated CRP levels to augment mortality risk compared to either biomarker 
alone.  This identifies a group of individuals who may potentially benefit from T3 therapy - 
AMI patients with low serum FT3 and high CRP.  The ideal dose, safety and efficacy of T3 













5 Chapter: Conclusion 
5.1 General discussion 
This study demonstrated a high prevalence of thyroid dysfunction in patients admitted with 
AMI with SCH being observed in 1 in 6 patients. Other forms of thyroid dysfunction including 
LT3 and SHyper had a lower prevalence.  Older individuals, females, those with higher TPOAb 
levels or higher creatinine concentrations and patients who had their thyroid function samples 
obtained in the early hours of the morning had a higher risk of being classed as having SCH. 
The results of this analysis have shown the diagnosis of subclinical thyroid disease and 
subsequent rates of normalisation of serum TSH levels in patients with AMI are significantly 
influenced by the time of sampling.  Furthermore, SCH patients diagnosed when time-specific 
reference ranges are applied, and patients with LT3 had an increased mortality compared to 
those who were euthyroid.  The interventional trial of LT4 therapy in those with sustained SCH 
demonstrated no improvement in markers of LV function and, similarly, secondary endpoints 
such as thrombus area, viscoelastography and clot kinetics, platelet reactivity, endothelial 
function and patient reported outcomes, showed no significant difference with treatment. 
Therefore the results of this study suggest the higher observed mortality risk in AMI patients 
with mild SCH may not be attenuated by LT4 treatment and that rather a raised serum TSH 
may simply be a biomarker of worse prognosis. 
Previous observational studies have assessed the prevalence of SCH in patients with AMI 
(Ertugrul et al., 2011; Molinaro et al., 2012; Zahler et al., 2019) and this study adds to this by 
identifying risk factors for the common thyroid dysfunction states which may be useful for 
clinicians managing patients with AMI .  The prospective nature of this study meant data could 
be collected in a uniform manner and therefore assessed other important variables such as TPO 
antibodies and time of sampling on the prevalence of thyroid dysfunction and the rates of 
normalisation. The time of blood sampling from participants was a strong predictor of SCH 
with samples taken between 00:01 and 06:00 followed by samples between 18:01 and 24:00 
being the strongest predictors of SCH.  However, patients who had SCH diagnosed between 
12:01 and 18:00 were more likely to remain in SCH on repeat testing with only 28% of patients 
normalising their TSH compared to 50% of patients who were initially diagnosed with SCH 
between 00:01 and 06:00.  The present data suggests the time of sampling should be considered 
when devising the reference range for TSH to avoid the inappropriate classification and 
treatment of individuals with thyroid dysfunction.  This is further supported by the mortality 
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data which found patients diagnosed with SCH solely based on the time-specific reference 
ranges to have higher mortality than when SCH was diagnosed using a uniform TSH reference 
range as per current practice.   The current study therefore supports previous observational 
studies which have shown SCH to be associated with worse outcomes including mortality in 
patients with cardiovascular disease (Iervasi et al., 2007; Rodondi et al., 2010; McQuade et al., 
2011; Molinaro et al., 2012; Rhee et al., 2017; Seo et al., 2018).   
The prevalence of LT3 syndrome in this study was 1.3% and such patients had an increased 
mortality. This prevalence is lower than previous observational studies demonstrating a 
prevalence between 20-30% in patients with acute cardiac events including AMI (Iervasi et al., 
2003; Iervasi et al., 2007; Lazzeri et al., 2012; Molinaro et al., 2012; Zhang et al., 2012).  
However, these studies included patients with cardiac diseases other than AMI (Iervasi et al., 
2007; Molinaro et al., 2012), whereas one study did not include patients with AMI (Iervasi et 
al., 2003).  A meta-analysis using a strict diagnostic criteria showed the pooled prevalence of 
LT3 syndrome to be 17.6% in patients with acute cardiovascular events (Wang et al., 2017).  
These studies also demonstrated an increased long-term mortality in LT3 patients which is 
supported by the meta-analysis by Wang et al.  A likely explanation for the low prevalence of 
LT3 in the current study may be due to all thyroid function tests being performed on admission 
to hospital, and no later than 24 hours post hospital admission.  Furthermore, thyroid function 
was evaluated prior to coronary angiography, whereas in previous studies thyroid tests were 
performed beyond 1 week of admission.  Therefore the impact from non-thyroidal illness and 
coronary angiographic dyes may likely explain the higher prevalence in previous studies as 
contrast media doubles the risk of thyroid dysfunction (Rhee et al., 2012).  In addition, the 
inclusion of patients with chronic heart diseases may have increased the prevalence of LT3 in 
these studies. 
There was no significant association between FT3 and troponin levels.  There was also no 
association between SCH and troponin levels meaning the increased mortality in SCH and LT3 
may not be related to troponin levels or potential infarct size.   This may explain that low TH 
levels post AMI are not due to the stress response of the myocardial insult but rather may be 
an exacerbating factor which could influence myocardial injury and hence mortality.  Elevated 
inflammatory markers also augmented the increased mortality observed in LT3 patients with 
the presence of LT3 and an elevated CRP resulting in a three-fold increase in mortality 
compared to a two-fold increase in patients with a low FT3 and CRP.  However, despite the 
current study and previous studies demonstrating adverse outcomes in patients with LT3 and 
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SCH post AMI, we cannot be sure of a casual association between the two.  Therefore clinical 
studies involving T3 replacement are necessary to identify this link.  The current data advances 
the literature and identifies a group of individuals who may potentially benefit from T3 therapy 
- AMI patients with low serum FT3 and high CRP levels. 
The RCT showed no benefit of LT4 therapy on improving LV function.  However, nearly 40% 
of patients recruited to the trial had evidence of preserved LV function and the effect of 
treatment in patients with worse LVEF remains unknown.  It is interesting that the pre-specified 
subgroup analysis in patients with LVEF <55% suggested that LT4 may be associated with 
improvement in LVEF.  There may be a treatment benefit in this specific group of patients with 
previous studies relating to SCH patients with heart failure demonstrating higher 
hospitalisation rates and worse outcomes compared to euthyroid patients with heart failure 
(Iacoviello et al., 2008; Rodondi et al., 2008; Silva-Tinoco et al., 2011).  Furthermore, other 
markers of LV contractility (such as global longitudinal strain) may offer greater prognostic 
information (Park et al., 2018a).  It is interesting that LT4 treatment showed a trend towards a 
reduction in LV diastolic and systolic volumes suggesting that irrespective of no significant 
improvement in LV function, TH treatment may ameliorate pathological cardiac remodelling. 
Previous studies have demonstrated LT4 therapy to improve cardiac and vascular function 
(Biondi et al., 1999; Monzani et al., 2001; Taddei et al., 2003; Ripoli et al., 2005; Razvi et al., 
2007).  This study showed no benefit of LT4 treatment on surrogate markers of vascular 
function such as endothelial dysfunction, thrombus burden and clot kinetics.  Therefore any 
future trial that does show a benefit of LT4 therapy in reducing the cardiovascular events in 
SCH patients could be by alternative means other than ameliorating common cardiovascular 
risk factors.   
 
5.2 Strengths and limitations  
 
The strengths of this study include its study design in being a double-blinded RCT, being well 
powered to detect a significant difference between both groups and participants being on all 
recommended secondary prevention therapy and chosen based on a strict eligibility criteria to 
minimise confounding variables.  Another strength was that cardiac MRI, considered as the 
reference-standard technique, was utilised to assess cardiac volumes and function (Pohost et 
al., 2003).   Despite the negative findings, a greater risk of mortality in patients with SCH after 
AMI highlights the need for on-going studies to reduce vascular event rates to levels seen in 
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euthyroid patients. One of the reasons for the discrepancy detected in the previous 
observational studies of poor prognosis in individuals with SCH and the lack of efficacy of 
LT4 shown in this trial could be because many observational studies diagnosed SCH based on 
a single blood test.  In this trial, only patients with sustained subclinical hypothyroidism were 
recruited and all baseline thyroid function were assessed prior to coronary angiography. In 
addition, patients with mild subclinical hypothyroidism (at least one TSH value below 10.0 
mU/L) were recruited, as this group constitutes the majority of subclinical hypothyroidism 
patients and where the greatest uncertainty of treatment efficacy prevails (Bekkering et al., 
2019). It remains unknown if targeting treatment in individuals with more severe disease (TSH 
>10.0 mU/L) may or may not be beneficial. 
There are limitations to the study: a potential delay in the initiation of LT4 treatment, a median 
dose of 50mcg at the end of the study being lower than in other trials demonstrating a benefit 
on surrogate markers of vascular function, and the bioavailability of cardiac T3 potentially 
being low due to impaired conversion of T4 to T3 from changes in the activating and 
inactivating thyroid hormone enzymes (deiodinases).  Furthermore, nearly 40% of patients 
recruited in this trial had evidence of preserved LV function and the effect of treatment in 
patients with worse LVEF remains unknown. Additional research might be useful to evaluate 
efficacy in this group of patients. Individuals with chronic persistent subclinical 
hypothyroidism may be a different population to the population studied here and it is not 
possible to exclude whether levothyroxine might improve LV function in this population 
outside the situation of a recent acute myocardial infarction.  Finally, the TSH reference range 
used to diagnose SCH is not applicable to everyone with large studies such as the TRUST 
Study and a follow up study of over 400,000 patients demonstrating a large number of 
individuals diagnosed with SCH normalised their thyroid function during follow up 
(Meyerovitch et al., 2007; Stott et al., 2017).  In the present study, the median TSH decreased 
from 5.7 (4.7-7.3) to 3.2 (2.7-4.2) at the end of the study in the placebo group indicating some 
patients normalised their TSH over the course of the study and may not have had true SCH 
despite the strict eligibility criteria. 
 
5.3 Future directions 
 
This study shows that treatment of SCH in AMI patients is not associated with an improvement 
in cardiac function or surrogate markers of vascular function. Further studies are needed to 
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investigate the worse outcomes observed in these patients which will help clarify whether SCH 
has a direct casual cause or is just a biomarker of a worse prognosis.  One specific approach 
could include having stricter inclusion criteria to diagnose SCH based on time or age specific 
reference ranges rather than utilising a uniform TSH reference range as per current practice.  
An alternative approach would be to recruit patients with more severe SCH (with a TSH>10 
mIU/L) as this group has been associated with worse mortality outcomes (Rodondi et al., 
2010), and the development of heart failure (Rodondi et al., 2008; Nanchen et al., 2012).  This 
could set more clarity on treating such patients as per current guidelines where current evidence 
is lacking (Pearce et al., 2013).   
Further studies assessing LV function should assess SCH patients with an impaired LV 
function; as a preliminary analysis in the current study demonstrated a trend towards 
improvement in this group of patients.  Additionally, the use of T3 could be an alternative to 
LT4 treatment in future studies investigating both SCH and LT3 syndrome which bypasses the 
activating thyroid hormone enzymes (deiodinases) used to convert T4 to T3, resulting in a 
higher therapeutic effect of TH treatment.  An open-label trial of oral T3 in 37 patients with 
STEMI and low serum T3 levels demonstrated 6 months of oral T3 therapy to be safe although 
there was no improvement in LV function and scar size as measured by CMR (Pingitore et al., 
2019).  In other clinical studies T3 therapy has been shown to improve left ventricular function 
in patients with heart failure (Pingitore et al., 2008; Amin et al., 2015) and those undergoing 
surgical revascularization (Klemperer et al., 1995; Sirlak et al., 2004; Ranasinghe et al., 2006).   
Further studies should assess the effect of T3 replacement on markers of inflammation in 
patients with AMI.  This is important as the worse outcomes in patients with cardiovascular 
disease and inflammation, as shown in previous studies (Ridker et al., 1997; Ridker et al., 
2017), could be mediated via low TH levels.  Finally, irrespective of effects on cardiac function 
and surrogate markers vascular function, large RCTs should also be conducted to assess the 
role of TH replacement therapy on long term patient outcomes post AMI with such studies 
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